Document:

Assignment Agreement

 Exhibit 10.4 
 Confidential Materials omitted and filed separately with the Securities and Exchange Commission. Asterisks denote omissions. 
 ASSIGNMENT AGREEMENT 
 This Assignment
Agreement (hereinafter referred to as “Agreement”) is made and entered into as of the 9th day of February, 1994, by and between RESEARCH DEVELOPMENT FOUNDATION (hereinafter referred to as “RDF”), a Nevada nonprofit corporation having its office at 402 North Division Street, Carson
City, Nevada, 89703; 
 AND 
 DEPOTECH CORPORATION (hereinafter referred to as “DepoTech”), a California corporation, having an office at 11025 North Torrey Pines Road, Suite 100, La Jolla, California, 92037. 

WITNESSETH: 
 WHEREAS, RDF is a nonprofit organization exempt from taxation under Section 501 (c)(3) of the Internal Revenue Code of 1986; 

WHEREAS, RDF is the owner of certain inventions, discoveries, and know-how comprising certain Proprietary Property (as
hereinafter defined) described in Exhibit 1 hereto; 
 WHEREAS, RDF is the owner of all the right, title and
interest in and to said Proprietary Property and has determined that assignment thereof to Licensee is the only practicable manner in which the Proprietary Property can be utilized to benefit the public; 

 WHEREAS, RDF has filed and intends to file for patents and/or other
protection therefor in the countries listed in Exhibit 2 hereto (hereinafter referred to as “worldwide”) as provided herein; and 
 WHEREAS, DepoTech desires to obtain the exclusive worldwide rights to use, make, produce and sell methods, processes, or products of RDF’s Proprietary Property; 

NOW, THEREFORE, in consideration of the above premises and the covenants herein, the parties agree as follows:

 ARTICLE I 
 Definitions 
 As used in this Agreement, the following
terms shall have the following respective meanings: 
 1.1 The term “Proprietary Property” shall mean
and include developments, patent rights, copyrights, as well as all patent applications, techniques, methods, processes, apparatus, products, data, trade secrets, confidential information, improvements thereto, modifications thereof, and Know-How,
whether patentable or not, related to the technology described in Exhibit 1 hereto; 
 1.2 The term “Patent
Rights” or “Rights in Patents” shall mean any pending United States patent application, any pending foreign patent application, and/or any patent now or hereafter owned or controlled by, or assigned to, RDF and any divisions,
continuations and continuations-in-part based thereon, any reissues, patents of addition or importation, or other extensions thereof, and includes any pending patent applications and patents issuing thereon during the term of this Agreement which
cover improvements and modifications related to the foregoing technology. 

  
 - 2 -

 1.3 The term “Know-How” shall mean all information, data,
specifications, techniques, software, methods of manufacture, and clinical, as well as diagnostic, information relating to RDF’s Proprietary Property which is known to RDF, which RDF is free to disseminate without accounting to others and which
is not in the public domain (as defined in Article XIII, paragraphs [a]-[d]). 
 1.4 The term “Assigned
Proprietary Property” shall mean and include the Proprietary Property, including the Patent Rights, Rights in Patents and Know-How, all of which are assigned hereunder to DepoTech. 

1.5 The term “Assigned Applications” shall mean patent application rights included within Proprietary Property,
and any division, continuation, extension or confirmation rights with respect to the filings thereof in the United States of America and foreign countries. 
 1.6 The term “Assigned Patents” shall mean, both individually and collectively, the United States of America and Foreign Patents included within Proprietary Property and any division, reissue,
continuation or extension thereof. 
 1.7 The term “Product” shall mean a product or portion of a
product that where made, used or sold “embodies an invention there claimed, or which is specifically intended to be used to practice a method or process there claimed, in an Assigned Patent (or a patent application if the resulting Letters
Patent would constitute an “Assigned Patent” hereunder) and which is manufactured and sold by or for DepoTech (or its licensees). 
 1.8 The term “Improvements” shall mean any improvement and/or modification of the Assigned Proprietary Property that comes within the claims of the Assigned Patents. 

1.9 The term “Subsidiaries” shall mean any present or future companies organized under the laws of any nation
with respect to which (i) at least fifty percent (50%) in value or (ii)

  
 - 3 -

 
at least fifty percent (50%) of the total combined voting power of all classes of shares entitled to vote is directly or indirectly under the control of DepoTech. The term
“DepoTech” wherever used herein shall include any Subsidiaries of DepoTech. 
 1.10 The term
“Gross Revenues” shall mean charges actually collected by DepoTech from sales, rental, lease, licensing, maintenance, or production of a Product or from licensing or the use of Assigned Proprietary Property to a third party, less:

  

	 	(a)	 Usual trade and/or cash discounts actually allowed and taken; 

 

	 	(b)	 Forwarding expenses, freight, special packaging charges, postage and duties actually paid or allowed and taxes imposed directly on the seller with
respect to such sales and other transactions; 

  

	 	(c)	 Credits for goods returned; and 

  

	 	(d)	 Government-related retroactive price reductions or rebates. 

No other allowance or deduction shall be made by whatever name known. Notwithstanding the foregoing, Gross Revenues shall
not include payments and fees relating to research, development and/or regulatory approval contracts or the like. 
 1.11 The terms “commercialize” and “commercialization” shall mean the sale, licensing, or other use by DepoTech of the right to use the method and process or to manufacture and
distribute for sale to the public the Assigned Proprietary Property under such circumstances as may be permitted by applicable international, federal, and state laws and regulations. 

ARTICLE II 

Assignment 
 2.1 RDF hereby assigns to DepoTech all right, title, and interest in the Assigned Proprietary Property such that DepoTech shall have the exclusive rights to produce, have

  
 - 4 -

 
produced, to make, have made, to manufacture, have manufactured for it, to use and/or to sell, rent or lease the apparatus, products, techniques, methods, processes, advances, developments, and
inventions employing the Assigned Proprietary Property throughout the world. Except as provided herein, no other, further, or different property or rights are hereby assigned or granted, either expressly or by implication. 

2.2 DepoTech shall give to RDF written notice of licenses to others, and RDF shall be a third party beneficiary of each
such license. 

  
 - 5 -

 ARTICLE III 
 Improvements, Patents and Publication 
 3.1 DepoTech
agrees, at DepoTech’s expense, to timely file patent applications relating to the Proprietary Property in the territories listed on Exhibit 2 hereto (except to the extent such applications have previously been filed by RDF). 

3.2 DepoTech further agrees to use its best efforts to prosecute such patent applications and to maintain any patents
issued thereon. Notwithstanding the foregoing sentence, in the event that DepoTech reasonably determines that prosecution or maintenance of a patent in a particular territory is not economically viable, DepoTech shall promptly notify RDF of
DepoTech’s intention to abandon such patent application or patent. Upon receipt of such notice, RDF, in its sole discretion, may elect to assume responsibility (and to pay associated fees and expenses) with respect to a patent application or
patent which DepoTech intends to abandon. If RDF elects to assume responsibility for a patent application or patent which DepoTech intends to abandon, DepoTech shall assign such patent application or patent to RDF. RDF may, in its sole discretion,
abandon any patent application or patent for which it has previously assumed responsibility and will not be liable to DepoTech in any way for such abandonment. 
 3.3 Consistent with the definitions contained in Article I, RDF agrees to make available promptly to DepoTech during the term of this Agreement any Improvements now or hereafter found, owned, or
controlled by RDF, and to submit to DepoTech all available Know-How pertaining thereto. Such Improvements in or to the Assigned Proprietary Property and the corresponding rights throughout the world in patents or copyrights shall be included in the
Assigned Proprietary Property which is assigned to DepoTech pursuant to Article II upon the same terms and conditions set forth in this Agreement. 

  
 - 6 -

 3.4 DepoTech shall reasonably, promptly submit to RDF during the term of
this Agreement all available information and Know-How on any Improvements, whether patentable, copyrightable or not, now or hereafter found, discovered, invented, owned, or controlled by DepoTech. 

3.5 Any Improvements, whether patentable, copyrightable or not, now or hereafter made and conceived by agents or
employees of DepoTech, either independently or jointly with others, shall to the extent of DepoTech’s rights therein be considered as part of the Assigned Proprietary Property. The world-wide rights in the corresponding patents, patent
applications, copyrights and/or Know-How shall be the property of DepoTech subject to all the terms and conditions of this Agreement. RDF shall reimburse DepoTech for the salaries, costs and expenses DepoTech incurs directly (excluding indirect
overhead) in conceiving, developing and reducing to practice Improvements included in the Assigned Proprietary Property that are subject to this Section wherein ownership is vested in DepoTech. Said reimbursement shall be effectuated by DepoTech
retaining [**] percent ([**]%) of the royalties and payments resulting from such Improvements due and payable to RDF pursuant to Article IV. The total amount to be reimbursed hereunderfor all Improvements subject to this Section shall not exceed
the amount of $[**]. 
 3.6 If patentable or otherwise protectable Improvements are now or hereafter made
and conceived by agents or employees of DepoTech or RDF, either independently or jointly with others, and DepoTech, at its sole discretion, considers it desirable to obtain patent, copyright, or other protection thereon, RDF agrees to cooperate
fully and to do all proper things necessary or desirable to obtain and maintain patent, copyright or other protection therefor throughout the world, all at DepoTech’s expense. 

  
 - 7 -

 3.7 Notwithstanding the provisions in Section 3.6 above, if DepoTech
fails to file an application for patent or other protection therefor within six (6) months after receipt of a written request from RDF to do so, DepoTech shall be deemed to have consented to RDF obtaining and maintaining the necessary
protection therefor at RDF’s expense, in which event all right, title and interest in such Improvements shall be the property of RDF, subject to: (i) DepoTech’s right to open negotiations with RDF for a license back to DepoTech of
such Improvements, and (ii) a right of first refusal on the part of DepoTech. The right of first refusal provided by this Section is exercisable as follows: if a license of all or a part of RDF’s interest in Improvements acquired under
this Section is to be offered to any party not under the exclusive control of RDF (hereafter, a “third party”), or if RDF receives an offer from a third party for a license of such Improvements by RDF, then RDF shall notify DepoTech in
writing of its intent to make or consider the offer and of the terms of the offer. 

  
 - 8 -

 DepoTech shall then have a period of ninety (90) days from its receipt of the notice to
respond thereto with an offer of terms for the license of the Improvements to DepoTech, which offer will be considered with good business judgment by RDF. Any competing offer made by or to RDF prior to the expiration of the ninety (90) day
period will not be available for acceptance until (a) the expiration of the ninety (90) day period, and (b) RDF’s consideration of, and response to, any offer made by DepoTech. The filing and prosecuting of the United States
patent applications by DepoTech or RDF, at DepoTech’s expense, shall in no case go beyond an appeal to and a decision by the United States Patent and Trademark Board of Appeals or the highest administrative patent authority in any other
territory, unless DepoTech specifically agrees to further proceedings in writing. RDF may pursue further proceedings at its expense without the written authorization of DepoTech. 

3.8 If either DepoTech or RDF files patent applications or otherwise obtains patent rights or copyrights which relate to
the Assigned Proprietary Property, such patent application, patent rights or copyrights shall be included in the Assigned Proprietary Property, and DepoTech shall have exclusive worldwide rights thereto under the terms and conditions as set forth in
this Agreement. 

  
 - 9 -

 ARTICLE IV 
 Royalties 
 4.1 As consideration for granting of the
assignment herein by RDF, DepoTech shall pay RDF during the term of this Agreement an earned royalty of [**] percent ([**]%) on Gross Revenues. 
 4.2 Only one royalty shall be payable on a Product, regardless of the number of Assigned Applications and Assigned Patents of the Assigned Proprietary Property under which such Product has been
manufactured, used or sold. In those cases where a Product is sold as a part of an article which includes additional materials or components, the production of which does not use the inventions, processes or methods of the Assigned Proprietary
Property, the Gross Revenues shall be based on the sales price at which DepoTech would sell the Product or services with respect to Product independently of such other materials or components in an arm’s length transaction. 

4.3 Royalty payments, as provided in Section 4.1 of this Agreement, to be paid hereunder, shall be paid for a period
extending from the first commercial revenue actually collected by DepoTech for the life of the last to expire of the patents or patent applications, of the Assigned Proprietary Property. Royalty payments shall cease for any patent which has been
declared invalid by a final determination or judgment, or if this Agreement is terminated as hereinafter specified and provided. 
 4.4 DepoTech will pay to RDF [**] percent ([**]%) of the royalties or other consideration received from licensees with respect to the license of the Assigned Proprietary Property or the amount of royalty
DepoTech would have owed pursuant to Section 4.1 had it engaged in the same conduct as said licensees, whichever is greater. 

  
 - 10 -

 4.5 Wherever this Agreement provides that DepoTech may deduct expenses,
payments or other amounts from royalties payable to RDF, (a) such deduction shall be applied only against royalties received from the territory with respect to which such deduction arose, and (b) such deduction shall be prorated over such
time as is necessary to assure that the royalties payable to RDF from such territory in any period shall not be reduced by more than [**] percent ([**]%). 
 ARTICLE V 
 Payment and Reports 

5.1 DepoTech shall notify RDF, in writing, within thirty (30) days of the date of the first commercial making, use,
sale, or production employing the Assigned Proprietary Property. 
 5.2 DepoTech agrees that beginning with the
date of the first commercial making, use, sale, or production of the Assigned Proprietary Property, RDF shall receive within sixty (60) days after the end of each of the first three fiscal quarters and within ninety (90) days after the
fiscal year end: 
  

	 	(a)	 Payment of earned royalties; and 

  

	 	(b)	 A report showing the information and basis on which the earned royalties have been calculated. 

  
 - 11 -

 5.3 All royalties payable by DepoTech shall be paid in U.S. Dollars.
Conversion from currencies other than U.S. Dollars shall be at the rate of exchange used by DepoTech for its general accounting purposes, consistent with generally accepted accounting principles. 

5.4 Until such time as royalties become payable pursuant to this Agreement, DepoTech agrees to make an annual report to
RDF each April covering DepoTech’s progress during the previous calendar year with respect to research, development and commercialization of the Assigned Proprietary Property. 

5.5 DepoTech also agrees to make a written report to RDF within ninety (90) days after the termination of this
Agreement, stating in such report the royalties payable hereunder, the basis therefor, and the reason not previously reported and paid to RDF. DepoTech shall also continue to make annual reports pursuant to the provisions of this Agreement covering
sales, uses, or production and the applicable earned royalties hereunderfor Assigned Proprietary Property and Products produced, during the term of this Agreement, but not sold or used until after termination thereof, until such time as all such
reportable sales, uses, making, or production shall have terminated. Concurrent with the submittal of each post-termination report, DepoTech shall pay RDF all applicable royalties. 

5.6 DepoTech shall keep full, true, clear and accurate records and books of account with respect to the Assigned
Proprietary Property subject to royalty. Said records and books of account shall be kept by DepoTech at the usual places where their like records and books are kept and shall be retained for a period of five (5) years following the end of the
calendar year to which they pertain. RDF shall have the right through its designated representatives to examine and audit, at a reasonable time, all such records and books of account and such other records and accounts as may under recognized
accounting practices contain information bearing upon the 

  
 - 12 -

 
amount of royalty payable to it under this Agreement. Prompt adjustment shall be made by the proper party to compensate for any errors or omissions disclosed by such examination or audit. Neither
such right to examine and audit nor the right to receive such adjustment shall be affected by any statement to the contrary appearing on checks or otherwise, unless such statements appear in a letter, signed by the party having such right and
delivered to the other party, expressly waiving such right. Notwithstanding the foregoing, RDF may require DepoTech to furnish any other information reasonably requested to enable RDF to evaluate DepoTech’s performance under this Agreement.
Information obtained by RDF or its designated representative, pursuant to this paragraph 5.6, shall be treated as confidential and not disclosed to third parties, except to the extent necessary to enforce this Agreement or to prepare accounting and
financial records and reports of RDF. 
 5.7 Royalty payments provided for in this Agreement shall, when
overdue, bear interest at the then existing prime rate at Citibank of New York plus [**] percent ([**]%) per annum until paid, but in no event shall such interest exceed the usury limit as it exists from time to time in the State of Nevada.

  
 - 13 -

 ARTICLE VI 
 Effort to Commercialize 
 6.1 DepoTech shall undertake to
use its best efforts with regard to commercialization of the Assigned Proprietary Property. DepoTech shall be considered to have utilized its best efforts if it pays to RDF within ninety (90) days after calendar year end the amounts specified
below. Such payments shall begin with the calendar year in which occurs the date (the “Beginning Date”) of the earlier of (a) FDA approval of the Product, or (b) the first commercial sale by DepoTech or a licensee of the Product:

  

	 	(a)	 For calendar year of Beginning Date, at least $[**]. 

 

	 	(b)	 For first calendar year after Beginning Date, at least $[**]. 

 

	 	(c)	 For second calendar year after Beginning Date, at least $[**]. 

 

	 	(d)	 For each succeeding calendar year, at least $[**]. 

The amounts paid may be earned royalties, payments attributable to licensing, or advances to be credited against future
royalties payable by DepoTech to RDF. 
 6.2 In the event DepoTech shall fail to meet the requirements for
commercialization set forth in Section 6.1 of this Article, RDF, in its sole discretion, may either convert this Agreement into a non-exclusive license agreement or terminate this Agreement pursuant to the provisions of Article IX. 

  
 - 14 -

 ARTICLE VII 
 Protection of Patents 
 7.1 DepoTech agrees where
economically justified and within reasonable limits to protect the patent and/or Know-How of the Assigned Proprietary Property from infringement or misappropriation by third parties and to prosecute such infringers or defendants, but the decision to
undertake such protection shall be in the sole discretion of DepoTech. DepoTech shall be entitled to deduct all its non-reimbursed expenses, including costs and legal fees incurred in bringing and prosecuting such infringement or misappropriation
action, from royalties due RDF after commencement of such infringement or misappropriation action. In the event DepoTech desires to settle or compromise such suit or action in a manner that adversely impacts RDF or the Assigned Proprietary Property,
DepoTech shall not so settle or compromise such suit or action without the written consent of RDF. In the event that DepoTech shall recover profits and/or damages from said infringer or defendant, DepoTech agrees to turn over to RDF [**] percent
([**]%) of any amounts paid to it by said infringer or defendant after deducting any of its expenses, including costs and legal fees incurred in such litigation, which DepoTech has not previously deducted from royalties payable to RDF. 

7.2 RDF and DepoTech shall each give immediate written notice to the other of any infringement of a patent or
misappropriation of Know-How of the Assigned Proprietary Property by any third party as may come to its knowledge. Notwithstanding Section 7.1, if DepoTech has not within six (6) months from the date on which it is notified or otherwise
becomes aware of an infringement or misappropriation either terminated such infringement or initiated legal action against the infringer or defendant, it shall, upon written request of RDF, grant to RDF the right to prosecute an action against the
infringer or defendant. DepoTech agrees, in the event that RDF 

  
 - 15 -

 
cannot prosecute such infringement or misappropriation in its own name, to sign and give to RDF, as soon as practicable, all necessary documents in order for RDF to prosecute in the name of
DepoTech, such infringement or misappropriation. In the event RDF shall recover profits and/or damages from said infringer or defendant, RDF agrees to turn over to DepoTech [**] percent ([**]%) of any amounts paid to it by said infringer or
defendant after deducting any of its expenses, including costs and legal fees, incurred in such litigation. 

7.3 DepoTech shall promptly advise RDF in writing of any notice or claim of any infringement and of the commencement
against it of any suit or action for infringement of a third party patent made or brought against DepoTech and based upon the use hereunder by DepoTech of the Assigned Proprietary Property. RDF shall have the right either to: 

 

	 	(a)	 Request that DepoTech enter into negotiations with such third party to obtain rights under the third party patent; or 

 

	 	(b)	 Request that DepoTech defend such suit or action at DepoTech’s expense. 

7.4 DepoTech is neither obligated to enter into negotiations with such third party to obtain rights under the third party
patent nor obligated to defend such suit or action. If DepoTech, at its sole discretion, elects to enter into negotiations with such third party to obtain rights under the third party patent, or if DepoTech, at its sole discretion, elects to
undertake at its own expense the defense of any such suit or action to the extent that the alleged infringement is based upon such use hereunder of the Assigned Proprietary Property, RDF shall render DepoTech all reasonable assistance that may be
required by DepoTech in the negotiations or in the defense of such suit or action. DepoTech has the primary right to control the defense of any such suit or action by counsel of its own choice, and RDF shall have the right, at its own expense, to be
represented in any such suit or action in respect of which RDF is a defendant by 

  
 - 16 -

 
counsel of its own choice, subject to DepoTech’s right of control. Notwithstanding the foregoing, if DepoTech has not within ninety (90) days (or such lesser period of time as is
necessary to avoid entry of a default judgment against DepoTech or RDF) from the date of receipt of a request from RDF under Section 7.3 either entered into negotiations with such third party to obtain rights under the third party patent or
initiated legal action to defend such suit, it shall, upon written request of RDF, grant to RDF the right to enter such negotiations or defend such suit. DepoTech shall be entitled to deduct all its expenses, including costs and legal fees, incurred
in entering into such negotiations or defending such suit from royalties due RDF after commencement of such action. In the event DepoTech desires to settle or compromise any such suit or action in a manner that adversely impacts RDF or the Assigned
Proprietary Property, DepoTech shall not settle or compromise any such suit or action without the written consent of RDF, which consent shall not be unreasonably withheld. 

7.5 In negotiating with such third party to obtain rights under such third party patents, and if, in obtaining such
rights, DepoTech is required to make any payment to such third party, DepoTech shall be entitled to deduct such payment from the royalty payable to RDF. 
 ARTICLE VIII 
 Disclaimer of Liability and/or Warranty 

8.1 Notwithstanding provisions in Article VII of this Agreement, nothing in this Agreement shall be construed as:

  

	 	(a)	 a warranty or representation by RDF as to the validity or scope of any Assigned Proprietary Property; or 

 

	 	(b)	 a warranty or representation that anything sold, used, produced or otherwise disposed of under any assignment or license granted in this Agreement
is or will be free from infringement of patents, copyrights, and/or trademarks of third parties; or 

  
 - 17 -

  

	 	(c)	 an express or implied warranty of merchantability or fitness for a particular purpose. 

8.2 RDF shall exercise reasonable care in verifying the accuracy of information provided under this Agreement, but RDF
shall not be liable for any damages arising out of or resulting from any information made available hereunder or of the use thereof, nor shall it be liable to DepoTech for consequential damages under any circumstances. 

8.3 RDF shall have no responsibility for the ability of DepoTech to use such information, the quality or performance of
any process or any product produced by DepoTech with the aid of such information or with respect to claims of third parties arising from DepoTech’s use of such information. 

8.4 DepoTech shall assume all responsibility and liability for the sale, use, production, and/or commercialization of the
Assigned Proprietary Property, including, but not limited to, the safety, effectiveness, and reliability of the process and/or products produced pursuant to this Agreement. DepoTech further agrees to defend, indemnify, and hold RDF, its trustees,
directors, officers, employees, agents, representatives, successors, assigns and affiliated entities, harmless from and against any and all liability, demands, damages, expenses and losses for death, personal injury, illness, or property damage,
including the cost of defense against same, which may be asserted, or any claims which may arise from the sale, use, production, commercialization, or other disposition of the Assigned Proprietary Property. DepoTech acknowledges that the Assigned
Proprietary Property hereby is experimental and agrees to take all reasonable precautions to prevent death, personal injury, illness, and property damage. 

  
 - 18 -

 8.5 DepoTech agrees to purchase and/or maintain insurance coverage
sufficient, taking into account its other assets, to establish the ability of DepoTech to honor the indemnity made in Section 8.4 and shall name RDF as an additional named insured on such policy. 

ARTICLE IX 

Term and Termination 
 9.1 The term of this Agreement shall be for the life of the last to expire of the patents or patent applications of the Assigned Proprietary Property, whichever is later, unless sooner terminated as
herein provided. 
 9.2 If DepoTech shall determine that it intends to declare itself insolvent or file for
bankruptcy or reorganization, it shall give ten (10) days’ written notice to RDF. Notwithstanding the above, if DepoTech shall become bankrupt or insolvent; if the business or any assets or property of DepoTech shall be placed in the hands
of a receiver, assignee or trustee, whether by the voluntary act of DepoTech or otherwise; if DepoTech institutes or suffers to be instituted any procedure in bankruptcy court for reorganization or rearrangement of its financial affairs; or if
DepoTech makes a general assignment for the benefit of creditors, this Agreement shall immediately terminate, and DepoTech shall reassign to RDF all right, title, and interest in the Assigned Proprietary Property, unless such bankruptcy, insolvency,
receivership or assignment for the benefit of creditors shall have been cured within thirty (30) days of such event occurring. Upon occurrence of any of the foregoing events, DepoTech shall give immediate written notice thereof to RDF.

  
 - 19 -

 9.3 Upon any material breach or material default under this Agreement by
DepoTech, RDF may give written notice thereof to DepoTech, and DepoTech shall have ninety (90) days after such notice to cure such breach or default. If such breach or default is not so cured, RDF may then in its sole discretion and option
(a) convert this Agreement into a non-exclusive license agreement, or (b) terminate this Agreement whereupon DepoTech shall reassign to RDF the Assigned Proprietary Property or (c) seek such other relief as may be provided by law in
such circumstances by giving written notice thereof to DepoTech. 
 9.4 If DepoTech contests or assists another
in contesting the validity of any of the patents assigned hereunder in a court of competent jurisdiction, RDF shall have the right to terminate this Agreement, whereupon DepoTech shall reassign to RDF the Assigned Proprietary Property. 

9.5 Upon termination of this Agreement by reason of any breach or default of DepoTech, DepoTech agrees to discontinue the
commercialization of the Assigned Proprietary Property, except for the sale of goods on hand. 
 9.6 Upon
termination hereof for any reason, the licenses to third parties by DepoTech under the terms and conditions herein set forth shall remain in effect in accordance with the terms thereof, and DepoTech shall assign such Agreements to RDF. 

  
 - 20 -

 ARTICLE X 
 Representations and Warranties 
 10.1 RDF represents and
warrants that it owns the Assigned Proprietary Property and has the legal power and authority to extend the rights granted to DepoTech pursuant to this Agreement and has not assigned, licensed, pledged or compromised the Assigned Proprietary
Property or made any commitments or offers inconsistent with or in derogation of the rights created by this Agreement. 
 10.2 RDF represents and warrants that it has no knowledge of any information likely to have a material effect on the validity or enforceability of any Assigned Patent or any claim thereof which was not
disclosed to the Patent Office at the time that the Patent Applications for the technology set forth on Exhibit 1 hereto were filed or during the pendency of said applications. 

10.3 DepoTech represents and warrants that it has full power and authority to enter into this Agreement and to carry out
the transactions contemplated hereby. 
 10.4 DepoTech represents and warrants that it has no knowledge of any
third party patent that would present a question of infringement with respect to Products. 
 ARTICLE XI 

Agency/Partnership 
 11.1 Neither party shall be deemed to be an agent of the other party as a result of any transaction under or related to this Agreement, and shall not in any way pledge the other party’s credit or
incur any obligations on behalf of the other party. 

  
 - 21 -

 11.2 This Agreement shall not constitute either a partnership or a joint
venture, and neither party may be bound by the other to any contract, arrangement or understanding except as specifically stated herein. 
 11.3 Except as required by state or federal law, and subject to an exception for private and confidential discussions between DepoTech and potential corporate partners or licensees, DepoTech (including
any affiliate or licensee of DepoTech) shall not, without prior written consent obtained from RDF, use for purposes of sales, advertising, marketing, marking of goods, promotion to investors, press releases or other publicity, etc.: (i) the
name of (or any other information which would identify) RDF or any corporation which is controlled by the same persons who control RDF (“controlled corporation”); (ii) the names of trustees, directors, officers, or employees of RDF or
a controlled corporation; or (iii) any trademarks (or adaptations thereof) of RDF or a controlled corporation. 
 ARTICLE
XII 
 Marking 
 DepoTech agrees to apply or have applied to all articles where practical and to all containers containing products manufactured by it under this Agreement such patent notices as may be required by the
laws of the territories where manufactured or as may reasonably be requested by RDF. 

  
 - 22 -

 ARTICLE XIII 
 Nondisclosure of Confidential Information 
 13.1 All
Proprietary Property and confidential scientific and technical information communicated by either party to the other under this Agreement, including information contained in patent applications, shall be kept confidential by each party, who shall
not disclose it to anyone without first receiving the written consent of the other party to do so. Notwithstanding the foregoing, each party shall be relieved of the confidentiality obligations herein and not be prevented by this Agreement from
utilizing any information received by it from the other party if: 
  

	 	(a)	 The information was previously known to such party, but not including what was previously known to the inventors of the Proprietary Property;

  

	 	(b)	 The information is or becomes generally available to the public through no fault of such party, including as a result of publications and/or laying
open to inspection of any patent applications that RDF may file corresponding to such U.S. or foreign patent applications; 

  

	 	(c)	 The information is acquired in good faith in the future by such party from a third party who is not under an obligation of confidence to the other
party in respect to such information; 

  

	 	(d)	 The disclosure of such information is essential for the commercial exploitation of the Proprietary Property under this Agreement.

  
 - 23 -

 13.2 The agreement of DepoTech to maintain the Proprietary Property as
confidential shall survive termination of this Agreement, regardless of the reason for its termination. 
 ARTICLE XIV

 Miscellaneous 
 14.1 The captions herein are for convenience only and shall not be deemed to limit or otherwise affect the construction hereof. 

14.2 All written notices, payments, reports and the like required or permitted hereunder shall be deemed to be given when
mailed, postage prepaid, by registered or certified mail, if to RDF to: 
 Research Development Foundation

 c/o Andrew MacKenzie, Esq. 

402 North Division Street 
 Carson City, Nevada 89703 
 Attn: C. W. Wellen,
President 
 cc: James F. Weiler, Esq. 

and if to DepoTech to: 
 DepoTech Corporation 
 11025 North Torrey Pines Road 

Suite 100 
 La Jolla, California 92037 
 Attn: Edward L.
Erickson, President 
 or to such other person or by such other means as to which the parties may from time to time agree.

 14.3 This Agreement, in whole or in part, shall not be assignable by either party without prior written
consent of the other (unless to a successor entity to the assigning party by merger, acquisition or other reorganization), which consent will not be unreasonably withheld, and any attempted assignment without such consent shall be void. 

  
 - 24 -

 14.4 The failure of either party to enforce at any time any of the
provisions of this Agreement, or any rights in respect thereto, or to exercise any election herein provided, shall in no way be considered to be a waiver of such provisions, rights, or elections, or in any way to affect the validity of this
Agreement. The exercise by either party of any of its rights herein or any of its elections under the terms or covenants herein shall not preclude either party from exercising the same or any other rights it may have under this Agreement,
irrespective of any previous action or proceeding taken by either party hereunder. 
 14.5 This Agreement shall
be governed and construed in accordance with the laws of the State of Nevada, U.S.A. 
 14.6 If any provision of
this Agreement is judicially determined to be void or unenforceable, such provision shall be construed to be severable from the other provisions of this Agreement which shall retain full force and effect. 

14.7 The parties hereto agree promptly to execute, forward, or otherwise provide all documents and material necessary or
desirable to effectuate this Agreement. 
 14.8 The terms and conditions herein contained constitute the entire
agreement between the parties and shall supersede all previous communications, either oral or written, between the parties hereto with respect to the subject matter hereof. No agreement or understanding bearing on the same shall be binding upon
either party hereto unless it shall be in writing and signed by the duly authorized officer or representative of each of the parties and shall expressly refer to this Agreement. 

  
 - 25 -

 14.9 This Agreement shall be binding on and shall inure to the benefit of
the parties hereto, and their respective successors and assigns. 
 14.10 Mention is made that by an agreement
between the parties dated August 3, 1993, providing for the assignment of the Proprietary Property to DepoTech from RDF, DepoTech agreed to reimburse RDF for costs and expenses incurred to the date of the assignment in obtaining and maintaining
patent protection for the Proprietary Property (approximately $[**]) reduced by costs and expenses incurred to the date of the assignment by DepoTech in connection with the patenting of the Proprietary Property (approximately $[**]). In lieu of a
cash payment for such reimbursement, DepoTech agreed to give RDF a credit note for such amount which can be applied at the option of RDF against: 
 (a) the “Exercise Price” to be paid by RDF upon exercise of warrants to purchase DepoTech shares pursuant to the Warrant Agreement between the parties dated August 14, 1990; or 

(b) royalties earned and payable on Improvements which would otherwise be credited to DepoTech under Section 3.5 of
this Agreement; provided that, at any time after three (3) years from the date of this Agreement, RDF, at its option, may require that DepoTech elect to either: (i) pay off the remaining balance of the credit note in cash, or
(ii) assign the Proprietary Property back to RDF (subject to an exclusive license back to DepoTech). 
 IN
WITNESS WHEREOF, the parties hereto have caused this Agreement to be duly executed in multiple originals by their duly authorized representatives. 
  

			
	RESEARCH DEVELOPMENT FOUNDATION
		
	By:	 	 /s/ Andrew MacKenzie

	Name:	 	 Andrew MacKenzie

	Title:	 	 Vice President

  
 - 26 -

  

			
	DEPOTECH CORPORATION
		
	By:	 	 /s/ Edward L. Erickson, President

		 	Edward L. Erickson, President

  
 - 27 -

 EXHIBIT 1 
 Proprietary Property 
 The technology of “[**],”
“[**],” “[**],” and “[**],” including without limitation U.S. patent application Nos. [**]; and [**]; [**]; U.S. Patent No. [**], respectively, and all divisional, continuation, continuation-in-part, renewal, extension
and reissue applications; all foreign counterpart applications and patents; and all U.S. and foreign Patens issuing on said applications. 

  
 - 28 -

 EXHIBIT 2 
 Proprietary Property 
 “[**]” 

List of Countries 
  

			
		  	 Australia
 Canada

Denmark
 EPC *

Finland
 Ireland

Israel
 Japan

Korea
 New Zealand

Norway
 Portugal

South Africa
 Taiwan

U.S.A.

  

	*	 European patent application (EPC) designating as contracting states: 

Austria, Belgium, France, West Germany, Greece, Italy, Luxembourg, Netherlands, Spain, Sweden, Switzerland, United Kingdom 

“[**]” 

List of Countries 
  

			
		  	 Australia
 Canada

EPC *
 Finland

Ireland
 Israel

Japan
 Korea

Kuwait
 New Zealand

Norway
 Peoples Republic of China

Portugal
 Russian Federation

Saudi Arabia
 South Africa

Taiwan
 U.S.A.

 

	*	 European patent application (EPC) designating as contracting states: 

Austria, Belgium, Denmark, France, Germany, Greece, Italy, Liechtenstein, Luxembourg, Netherlands, Spain, Sweden, Switzerland, United
Kingdom 

 DATED 15 April 2004 

(1) SKYEPHARMA, INC, 
 (2) SkyePharma PLC, ( solely in connection with issue of shares) 
 and 

(2) RESEARCH DEVELOPMENT FOUNDATION 
  

 
 AMENDMENT
AGREEMENT 
  
  

 AMENDMENT AGREEMENT 
 THIS AGREEMENT is made and entered into effective the 15th day of April 2004 (the “Effective Date”) 
 BETWEEN: 
  

	(1)	SKYEPHARMA INC, (formerly known as Depotech Corporation) a company incorporated in California whose principal place of business is 10450 Sciences Center Drive,
San Diego, California 92121 USA (“Skye”); and 

  

	(2)	solely with respect to Article 3, SKYEPHARMA PLC, a corporation organised and existing under the laws of United Kingdom, having offices located at 105 Piccadilly,
London WIV 9FN (Parent); and 

  

	(3)	RESEARCH DEVELOPMENT FOUNDATION a Nevada nonprofit corporation having its office at 402 North Division Street, Carson City, Nevada, 89703 (“RDF”).

 Whereas: 
  

	(A)	 Skye (then trading as Depotech) and RDF are the parties to the Assignment Agreement dated 9th February 1994 (“the “1994 Agreement”) and the Letter Agreement dated 10th December 1997 hereinafter collectively called the
(“Assignment Agreement”); 

  

	(B)	The parties wish to clarify and revise the terms of the Assignment Agreement; 

 THE PARTIES HEREBY AGREE as follows: 
 Article 1. Interpretation 

In this Agreement, except as otherwise provided below, words and phrases shall bear the same meaning as in the Assignment Agreement, except that the
following words and phrases shall have the following meanings: 
 1.1 “Gross Revenues” shall mean charges actually collected by Skye
from sales, rental, lease, licensing, maintenance, or production of a Product or from licensing or the use of Proprietary Property by Skye or a third party, less: 
  

	(a)	usual trade and/or cash discounts actually allowed and taken; 

  
 3 

  

	(b)	forwarding expenses, freight, special packaging charges, postage and duties actually paid or allowed and taxes imposed directly on the seller with respect to such sales
and other transactions; 

  

	c)	credits for goods returned; and 

  

	(d)	government-related retroactive price reductions or rebates. 

 No other allowance or deduction shall be made by whatever name known. Notwithstanding the foregoing, Gross Revenues shall not include payments and fees as defined in Article 1.5 “Other
Consideration”. 
 1.2 “Current Agreements” shall mean: 
 a) those Agreements specified in Appendix 1 
 b) the agreements entered into prior to the date of
this Agreement in relation to the Proprietary Property between Skye and GeneMedix, Astralis, Kirin Brewing Company, Pfizer, Amgen and Chugai and the feasibility agreements between Skye and Cognetix, Zealand and Eyetech. 

1.3 “Future Agreements” shall mean all agreements entered into from the date of this Agreement by Skye that provide a license to (or other
marketing arrangement) a third party to allow such third party to exploit the Proprietary Property’. 
 1.4 “Proprietary
Property” shall mean Skye’s multivesicular liposome DepoFoam technology which consists of [**], [**] [**] composed of [**] (the “DepoFoam Technology”). Such DepoFoam Technology shall include (a) the Assigned Proprietary
Property or Improvements as defined under the 1994 Agreement, and/or (b) existing and future patent or proprietary rights of Skye in DepoFoam Technology whether or not covered by or subject to the Assignment Agreement. For purposes of
Skye’s payment, reporting, and indemnification obligations to RDF under the terms of the Assignment Agreement, as hereby amended, the parties agree that: (a) the scope of all relevant terms impacting such obligations contained in the
Assignment Agreement (e.g., the definitions of Products, Assigned Proprietary Property, Assigned Applications, Assigned Patents, Improvements, etc.) shall be deemed to include all of. the DepoFoam Technology, and (b) the term of the Assignment
Agreement and Skye’s payment, reporting, and indemnification obligations to RDF thereunder, as 

  
 4 

 
herein amended, are hereby extended for so long as Skye receives payments with respect to any of the DepoFoam Technology. For the avoidance of doubt the Proprietary Property shall exclude
Skye’s proprietary technology known as [**], which consists of [**]. 
 1.5 “Other Consideration” shall mean all compensation and
consideration actually collected by Skye or its affiliates (other than royalties or any other form of payment based on Gross Revenues as defined in Article 1.1) from a Licensee or marketing partner from the licensing or use of the Proprietary
Property, Products or Improvements, whether in the form of signing fee, milestone payment, or other payment, less: 
  

	 	(a)	research and development costs directly related to the Products incurred by Skye to date 

 

	 	(b)	cost incurred to date by Skye in respect of regulatory approvals (including without limitation filing fees) 

 

	 	(c)	payments made by Skye to third parties in respect of the Proprietary Property, Products or Improvements. Such payments shall include but not be limited to payments made
for the acquisition or re-acquisition of rights to the Proprietary Property, Products or Improvements. 

  

	 	(d)	payment made to Skye for the issue of SkyePharma equity, other than payments for equity at a price over and above the average of the daily closing share price of
SkyePharma PLC common shares as quoted in the London edition of the Financial Times for the 20 days prior to the date of issue of such common shares. 

 Article 2. Payments 
 Following good faith negotiations between the parties,
the parties have agreed that 
  

	2.1	SkyePharma will pay to RDF [**]% of Gross Revenues on all Current and Future Agreements 

 

	2.2	RDF hereby waives its rights to any and all payments specified in Article 4.4 of the 1994 Agreement, on all Current and Future Agreements except as set out in Article
2.3 and 2.4 of this Agreement 

  
 5 

  

	2.3	In respect of Current Agreements it is agreed that the allowed deductions under Article 1.5 a) b) c) and d) shall be as shown in Appendix 1. For the avoidance of doubt
the following examples are given: 

  

	 	a)	For the MundiPharma Agreement, if milestones received by Skye under the Mundipharma Distribution Agreement total $[**], allowable deductions pursuant to Article 1.5
will be $[**] and therefore Other Consideration will be $[**] of which RDF will be due [**]%. 

  

	 	b)	For Nippon Shinyaku, if milestones received by Skye under the Supply and Distribution Agreement are $[**], there will be no allowable deductions and therefore Other
Consideration will be $[**] of which RDF will be due [**]%. 

  

	 	c)	For Endo and Medeus Pharmaceuticals, if milestones received by Skye under the Endo Development and Marketing Strategic Alliance Agreement and Medeus Strategic Marketing
Agreement are $[**], allowable deductions will be $[**] and therefore Other Consideration will be $[**] of which RDF will be due [**]%. 

  

	 	d)	For Enzon, if milestones received by Skyepharma under the Supply and Distribution Agreement are $[**], allowable deductions will be $[**] and therefore Other
Consideration will be $[**] of which RDF will be due [**]%. 

  

	 	e)	No Other Consideration is expected to be received pursuant to the agreements listed in Article 1.2 (b) and therefore, assuming none is received, no monies will be
due to RDF pursuant to these agreements. 

  

	 	f)	For all Current Agreements listed in Article 1.2 (a) if all $[**] contracted milestones are received, allowable deductions will be $[**] and therefore Other
Consideration will be $[**] of which RDF will be due [**]%. 

  

	2.4	In respect of Future Agreements Skye will pay to RDF [**]% of “Other Consideration”. For the purposes of such calculation for Future Agreements, the
deductions under Article 1.5 of this Agreement will not apply and the only allowable deduction will be for payments of research and development costs by a partner which directly relate to a Product and are paid over to a Contract Research
Organisation or other such clinical trial organisation 

  
 6 

 Article 3. Shares 
 Within 30 days of the Effective Date of this Agreement, Parent will allot and issue to RDF, credited as fully paid, [**] ordinary shares (the “Shares”) of [**] each of parent (representing [**]
ADR’s) based on a price of $[**] per ADR, equivalent in value to $[**]. In the event that the price of the Parent’s ADRs exceeds as of the day prior to the Effective Date of this Agreement $[**] per ADR or is less than $[**] per ADR, both
as quoted in the daily price activity report provided to Parent by the Bank of New York then in such event the number of issuable Shares shall be recomputed using instead of the price of $[**] per ADR the average of the daily closing share price of
Parent’s ADRs as quoted in the daily price activity report provided to Parent by the Bank of New York for the 10 days prior to the Effective Date of this Agreement. The issued Shares will bear the legend shown in Appendix II to this Agreement.
RDF hereby gives the following Reps and Warranties to Parent in respect to the issued Shares: 
  

	3.1	Selling Restrictions. RDF is acquiring the Shares for its own account for investment purposes only and not with a view to or for distributing or reselling such
Shares or any part thereof or interest therein. RDF agrees that if in future it decides to sell or otherwise transfer the Shares, it will do so only in accordance with the terms of this Agreement and (A)(1) to a person whom RDF and any person acting
on its behalf reasonably believe is a qualified institutional buyer within the meaning of Rule 144A under the U.S. Securities Act of 1933, as amended (the “Securities Act”) purchasing for its own account or for the account of a qualified
institutional buyer in a transaction meeting the requirements of Rule 144A, (2) in an offshore transaction in accordance with Rule 903 or Rule 904 of Regulation S under the Securities Act, (3) pursuant to an exemption from registration
under the Securities Act provided by Rule 144 thereunder (if available), or (4) pursuant to sales registered under the Securities Act, and (B) in each case, in accordance with all applicable securities laws of the states of the United
States. 

  

	3.2	Institutional Accredited Investor. RDF is an institution which is an “accredited investor” as that term is defined in Rule 501(a)(3) of Regulation D
under the Securities Act (an “Institutional Accredited Investor”) and is acquiring the shares for its own account. 

  

	3.3	Financial Knowledge, Sophistication and Experience. RDF, either alone or together with its representatives, has such knowledge, sophistication and experience in
business and financial matters as to be capable of evaluating the merits and risks of the prospective investment in the shares, and has so evaluated the merits and risks of such investment. 

  
 7 

  

	3.4	Ability of RDF to Bear Risk of Investment. RDF is aware that the purchase of the shares involves substantial risk and RDF is able to bear the economic risk of an
investment in the shares and is able to afford a complete loss of such investment. 

  

	3.5	Access to Information. RDF acknowledges receipt of Parent’s Annual Report on Form 20-F for the year ended December 31,2002, which was filed with the
U.S. Securities and Exchange Commission (the “SEC”) on June 27, 2003, and all of Parent’s Reports on Form 6-K furnished to the SEC after such date and further acknowledges that it has been afforded (1) the opportunity to ask
such questions as it has deemed necessary of, and to receive answers from, representatives of Parent; (2) access to information (other than material non-public information) about Parent and the Parent’s financial condition, results of
operations, business, properties, management and prospects that RDF deemed necessary to enable it to evaluate its investment in the shares; and (3) the opportunity to obtain such additional information (other than material non-public
information) which Parent possesses or can acquire without unreasonable effort or expense that RDF deemed necessary to make an informed investment decision with respect to the shares. 

 

	3.6	Reliance. RDF understands and acknowledges that (1) the shares are being offered and sold to it without registration under the Securities Act and
(2) the availability of such exemption depends in part on, and that Parent will rely upon the accuracy and truthfulness of, the foregoing representations and RDF hereby consents to such reliance. 

Article 4. Entire Agreement Modification and Waiver 
  

	4.1	This Agreement (including the Appendices and attachments hereto) together with the Assignment Agreement (including the Appendices and attachments thereto) set out and
constitute the entire understanding, warranties and agreement of the parties. The parties acknowledge that no reliance is placed on any prior agreement, representation or understanding whether written or oral relating to its subject matter. In the
event of any conflict between the terms of this Agreement and the terms of the Assignment Agreement, the terms hereof shall control. 

  
 8 

  

	4.2	No amendment or waiver of this Agreement or of any right herein shall be deemed effective unless made in writing and agreed to in writing by a duly authorised officer
of each of the parties. 

  

	4.3	Without RDF’s prior written consent, Skye shall not amend any of the Current Agreements in any manner which would adversely affect the amount of consideration to
be received by RDF. 

 Article 5. Governing Law and Jurisdiction 
 This Agreement is governed by and shall be construed in all respects with the laws of the State of Nevada, U.S.A. applicable to contracts made in such State without regard to conflicts of law doctrines,
and the parties agree that jurisdiction and venue for any dispute regarding this Agreement will be in such State. 
 IN WITNESS whereof the duly
authorised representative of the parties have executed this Agreement effective as of the day and year first above written. 
  

			
	Signed by:
	
	 /s/ [Illegible]

	
	duly authorised for and on behalf of
	
	SkyePharma Inc
		
	Title:	 	 DIRECTOR

		
	Date:	 	 15 APRIL 2004

	
	Signed by:
	
	 /s/ [Illegible]

	
	duly authorised for and on-behalf of
	
	Research Development Foundation
		
	Title:	 	 President

		
	Date:	 	 April 15, 2004

  
 9 

 Appendix I 

Current Agreements 
 Appendix II 
 Legend for Parent’s Restricted Shares Issuable to RDF

 THE SHARES REPRESENTED HEREBY HAVE NOT BEEN AND WILL NOT BE REGISTERED UNDER THE UNITED STATES
SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR WITH ANY SECURITIES REGULATORY AUTHORITY OF ANY STATE OR OTHER JURISDICTION OF THE UNITED STATES AND MAY NOT BE OFFERED, SOLD, PLEDGED OR OTHERWISE TRANSFERRED EXCEPT
(1) TO A PERSON WHOM THE SELLER AND ANY PERSON ACTING ON ITS BEHALF REASONABLY BELIEVE IS A QUALIFIED INSTITUTIONAL BUYER WITHIN THE MEANING OF RULE 144A UNDER THE SECURITIES ACT PURCHASING FOR ITS OWN ACCOUNT OR FOR THE ACCOUNT OF A QUALIFIED
INSTITUTIONAL BUYER IN A TRANSACTION MEETING THE REQUIREMENTS OF RULE 144A, (2) IN AN OFFSHORE TRANSACTION IN ACCORDANCE WITH RULE 903 OR RULE 904 OF REGULATION S UNDER THE SECURITIES ACT, OR (3) PURSUANT TO AN EXEMPTION FROM REGISTRATION
UNDER THE SECURITIES ACT PROVIDED BY RULE 144 THEREUNDER (IF AVAILABLE), IN EACH CASE IN ACCORDANCE WITH ANY APPLICABLE SECURITIES LAWS OF ANY STATE OR OTHER JURISDICTION OF THE UNITED STATES. NO REPRESENTATION CAN BE MADE AS TO THE AVAILABILITY OF
THE EXEMPTION PROVIDED BY RULE 144 UNDER THE SECURITIES ACT FOR RESALES OF THE ORDINARY SHARES REPRESENTED HEREBY. NOTWITHSTANDING ANYTHING TO THE CONTRARY IN THE FOREGOING, THE SHARES MAY NOT BE DEPOSITED INTO ANY UNRESTRICTED DEPOSITORY RECEIPT
FACILITY IN RESPECT OF ORDINARY SHARES ESTABLISHED 

  
 10 

 
OR MAINTAINED BY A DEPOSITORY BANK UNLESS SUCH SHARES MAY BE RESOLD PURSUANT TO RULE 144(K). EACH HOLDER REPRESENTS THAT IT UNDERSTANDS AND AGREES TO THE FOREGOING RESTRICTIONS. 

  
 11 

 APPENDIX I – Current Agreements 

 

					
	 KEY FINANCIAL TERMS
	  	MILESTONES
TO BE
RECEIVED (1)	 	ALLOWABLE
DEDUCTIONS
(2)
			
	 Pharmis Biofarmaceutica Supply and Distribution Agreement (dated August 2003)
	  		 	
			
	 Approval for Solid Tumour
	  	$[**]	 	
	 MundiPharma Distribution Agreement (30th June 2003)
	  		 	
			
	 On top 5 markets if ex-company price is €[**] per vials or greater - $[**]
	  	$[**]	 	
	 On EMEA approval - $[**]
	  	$[**]	 	
	 On EMEA approval in top 5 markets if ex-company price is €[**]
	  		 	
	 Per vial or greater - $[**]
	  	$[**]	 	
			
	 Elan Acquisition Agreement (12th March 2003)
	  		 	
			
	 Return of rights to DepoCyt from Elan
	  		 	
	 - Completion of enrolment for Phase IV - $[**]
	  		 	$[**]
	 - EMEA Approval for Neoplastic Meningitis - $[**]
	  		 	$[**]
		  	 	 	 
			
	 MundiPharma Total
	  	$[**]	 	$[**]
		  	 	 	 

  
 1 

  

					
	 KEY FINANCIAL TERMS
	  	MILESTONES
TO BE
RECEIVED	 	ALLOWABLE
DEDUCTIONS
			
	 Nippon Shinyaku Supply and Distribution Agreement (29th June 2001)
	  		 	
			
	 Submission of NDA for Japan $[**]
	  	$[**]	 	
	 Supply of first product $[**]
	  	$[**]	 	
	 Net Sales of $[**] per year - $[**]
	  	$[**]	 	
	 Net Sales of $[**] per year - $[**]
	  	$[**]	 	
	 Net Sales of $[**] per year - $[**]
	  	$[**]	 	
			
	 Enzon Supply and Distribution Agreement (31st December 2002)
	  		 	
			
	 On sales reaching - $[**] - $[**]
	  	$[**]	 	
	 On sales reaching - $[**] - $[**]
	  	$[**]	 	
	 US Registration for neoplastic inication - before Dec 2006 - $[**]
	  	$[**]	 	
	 - before Dec 2007 - $[**]
	  		 	
	 -afterDec 2007 -$[**]
	  		 	
			
	 Research and Development expenses
	  		 	$[**]
		  	 	 	 
			
	 Enzon Total
	  	$[**]	 	$[**]
		  	 	 	 
			
	 Endo Pharmaceuticals Inc Development and Marketing Strategic Alliance Agreement (31 December 2002)
	  		 	
			
	 FDA Approval
	  	$[**]	 	
	 First time annual Net Sales $[**]
	  	$[**]	 	
	 First time annual Net Sales $[**]
	  	$[**]	 	
		  	 	 	
	 Total Endo
	  	$[**]	 	
		  	 	 	

  
 2 

  

									
	 KEY FINANCIAL TERMS
	  	MILESTONES
TO BE
RECEIVED	 	 	ALLOWABLE
DEDUCTIONS	 
			
	 Medeus Pharma Ltd Strategic Marketing Agreement
	  				 			
			
	 Signing
	  	 	$[**]	  	 			
	
1st Marketing Authorisation
	  	 	$[**]	  	 			
	
2nd country launched
	  	 	$[**]	  	 			
	 Annual sales €[**]
	  	 	$[**]	  	 			
	 Annual sales €[**]
	  	 	$[**]	  	 			
	 Annual sales €[**]
	  	 	$[**]	  	 			
	 Annual sales €[**]
	  	 	$[**]	  	 			
	 Annual sales €[**]
	  	 	$[**]	  	 			
	 Annual sales €[**]
	  	 	$[**]	  	 			
	 Annual sales €[**]
	  	 	$[**]	  	 			
	 Annual sales €[**]
	  	 	$[**]	  	 			
	 Annual sales €[**]
	  	 	$[**]	  	 			
		  	 	 	 	 			
			
	 Total Medeus
	  	 	$[**]	  	 			
		  	 	 	 	 			
			
	 Historical Research and Development expenses
	  				 	 	$[**]	  
	 Future Research and Development commitment under Medeus Contract
	  				 	 	$[**]	  
		  				 	 	 	 
			
	 Total DepoMorphine
	  	 	$[**]	  	 	 	$[**]	  
		  	 	 	 	 	 	 	 
			
	 Total All Products
	  	 	$[**]	  	 	 	$[**]	  
		  	 	 	 	 	 	 	 

  

	(1)	 As summarized in Appendix A to the memorandum from Thomas Brorby dated 10 March, 2004, less the $[**] milestone in respect of FDA filing of
DepoMorphine which was received from Endo in 2003 plus $[**] milestones in Medeus contract announced 7 April ($[**] less $[**] plus $[**] = $[**]). N.B no net impact on draft proposal. 

	(2)	 As summarized in Appendix II to memorandum from Donald Nicholson dated 22 August, 2003 plus $[**] clinical costs committed to under Medeus
contract. 

  
 3Stock Purchase Agreement

 Exhibit 10.5 
 Confidential Materials omitted and filed separately with the Securities and Exchange Commission. Asterisks denote omissions. 
 EXECUTION COPY 
 STOCK PURCHASE AGREEMENT 

by and among 

Blue Acquisition Corp. (“Buyer”), 
 SkyePharma Holding, Inc. (“Seller”), 
 and 

SkyePharma, Inc. (the “Company”) 
 dated as of 
 January 8, 2007 

 EXECUTION COPY 
  

 TABLE OF CONTENTS 

 

							
	 Section
	  	 	  	Page	 
			
	ARTICLE I	  	PURCHASE AND SALE OF THE SHARES	  	 	1	  
			
	 1.1.
	  	Purchase of the Shares from Seller	  	 	1	  
	 1.2.
	  	Further Assurances	  	 	1	  
	 1.3.
	  	Purchase Price	  	 	2	  
	 1.4.
	  	Payment of Base Purchase Price	  	 	2	  
	 1.5.
	  	Post-Closing Adjustments	  	 	2	  
	 1.6.
	  	Escrow Account	  	 	4	  
	 1.7.
	  	Earn-Out	  	 	4	  
	 1.8.
	  	The Closing	  	 	4	  
	 1.9.
	  	Allocation of Payments	  	 	5	  
			
	ARTICLE II	  	REPRESENTATIONS AND WARRANTIES OF SELLER REGARDING THE SHARES	  	 	5	  
			
	 2.1.
	  	Title	  	 	5	  
	 2.2.
	  	Authority	  	 	6	  
	 2.3.
	  	Regulatory Approvals	  	 	6	  
	 2.4.
	  	Circular	  	 	6	  
	 2.5.
	  	Brokers	  	 	6	  
			
	ARTICLE III	  	REPRESENTATIONS AND WARRANTIES OF SELLER REGARDING THE COMPANY	  	 	6	  
			
	 3.1.
	  	Organization, Qualification and Corporate Power	  	 	7	  
	 3.2.
	  	Capitalization	  	 	7	  
	 3.3.
	  	Authorization of Transaction	  	 	7	  
	 3.4.
	  	Noncontravention	  	 	8	  
	 3.5.
	  	Subsidiaries	  	 	8	  
	 3.6.
	  	Financial Statements	  	 	8	  
	 3.7.
	  	Absence of Certain Changes	  	 	9	  
	 3.8.
	  	Undisclosed Liabilities	  	 	9	  
	 3.9.
	  	Taxes	  	 	9	  
	 3.10.
	  	Assets	  	 	11	  
	 3.11.
	  	Owned Real Property	  	 	12	  
	 3.12.
	  	Real Property Leases	  	 	12	  
	 3.13.
	  	Intellectual Property	  	 	12	  
	 3.14.
	  	Inventory	  	 	17	  
	 3.15.
	  	Contracts	  	 	18	  
	 3.16.
	  	Accounts Receivable	  	 	19	  
	 3.17.
	  	Powers of Attorney	  	 	19	  
	 3.18.
	  	Insurance	  	 	19	  
	 3.19.
	  	Litigation	  	 	20	  
	 3.20.
	  	Warranties	  	 	20	  

  
 - i -

 EXECUTION COPY 
  

 TABLE OF CONTENTS 

 

							
	 Section
	  	 	  	Page	 
			
	 3.21.
	  	Employees	  	 	20	  
	 3.22.
	  	Employee Benefits	  	 	21	  
	 3.23.
	  	Environmental Matters	  	 	23	  
	 3.24.
	  	Legal Compliance	  	 	24	  
	 3.25.
	  	Customers and Suppliers	  	 	24	  
	 3.26.
	  	Permits	  	 	24	  
	 3.27.
	  	Certain Business Relationships With Affiliates	  	 	25	  
	 3.28.
	  	Books and Records	  	 	25	  
	 3.29.
	  	Projections	  	 	25	  
	 3.30.
	  	Regulation	  	 	25	  
	 3.31.
	  	Disclosure	  	 	30	  
			
	ARTICLE IV	  	REPRESENTATIONS AND WARRANTIES OF BUYER	  	 	31	  
			
	 4.1.
	  	Organization, Qualification and Corporate Power	  	 	31	  
	 4.2.
	  	Authorization of Transaction	  	 	31	  
	 4.3.
	  	Noncontravention	  	 	31	  
	 4.4.
	  	Brokers’ Fees	  	 	31	  
	 4.5.
	  	Investment Representation	  	 	32	  
	 4.6.
	  	Funding	  	 	32	  
			
	ARTICLE V	  	COVENANTS	  	 	32	  
			
	 5.1.
	  	Closing Efforts	  	 	32	  
	 5.2.
	  	Governmental and Third-Party Notices and Consents	  	 	32	  
	 5.3.
	  	Parent Shareholder Approval	  	 	33	  
	 5.4.
	  	Operation of Business	  	 	33	  
	 5.5.
	  	Access to Information	  	 	35	  
	 5.6.
	  	Notice of Breaches	  	 	36	  
	 5.7.
	  	Exclusivity	  	 	36	  
	 5.8.
	  	Expenses	  	 	36	  
	 5.9.
	  	Transition Services	  	 	37	  
	 5.10.
	  	License Agreement	  	 	37	  
	 5.11.
	  	Assignment; Inter-Company Adjustments and Eliminations	  	 	37	  
	 5.12.
	  	Services Agreement	  	 	37	  
	 5.13.
	  	Change of Company Name	  	 	37	  
	 5.14.
	  	Sharing of Data	  	 	37	  
	 5.15.
	  	Certain Tax Matters	  	 	38	  
	 5.16.
	  	Employee Retention Arrangements	  	 	44	  
			
	ARTICLE VI	  	CONDITIONS TO OBLIGATIONS OF BUYER	  	 	45	  
			
	 6.1.
	  	Parent Shareholder Approval and Other Consents and Approvals	  	 	45	  
	 6.2.
	  	Continued Accuracy of Representations and Warranties of Seller and the Company	  	 	45	  

  
 - ii -

 EXECUTION COPY 
  

 TABLE OF CONTENTS 

 

							
	 Section
	  	 	  	Page	 
			
	 6.3.
	  	Compliance with Covenants and Obligations	  	 	45	  
	 6.4.
	  	Adverse Proceedings	  	 	45	  
	 6.5.
	  	Seller Compliance Certificate	  	 	45	  
	 6.6.
	  	Resignations	  	 	45	  
	 6.7.
	  	Opinion of Counsel	  	 	46	  
	 6.8.
	  	Additional Closing Deliveries	  	 	46	  
	 6.9.
	  	HSR Act	  	 	46	  
	 6.10.
	  	Certain Agreements.	  	 	46	  
	 6.11.
	  	No Material Adverse Effect	  	 	47	  
	 6.12.
	  	Balance Sheet	  	 	47	  
			
	ARTICLE VII	  	CONDITIONS TO OBLIGATIONS OF SELLER	  	 	47	  
			
	 7.1.
	  	Parent Shareholder Approval	  	 	47	  
	 7.2.
	  	Continued Accuracy of Representations and Warranties of Buyer	  	 	47	  
	 7.3.
	  	Compliance with Covenants and Obligations	  	 	48	  
	 7.4.
	  	Adverse Proceedings	  	 	48	  
	 7.5.
	  	Buyer Compliance Certificate	  	 	48	  
	 7.6.
	  	Opinion of Counsel	  	 	48	  
	 7.7.
	  	Additional Closing Deliveries	  	 	48	  
	 7.8.
	  	HSR Act	  	 	48	  
			
	ARTICLE VIII	  	INDEMNIFICATION	  	 	48	  
			
	 8.1.
	  	Indemnification by Seller	  	 	48	  
	 8.2.
	  	Indemnification by Buyer	  	 	49	  
	 8.3.
	  	Indemnification Claims	  	 	50	  
	 8.4.
	  	Survival	  	 	52	  
	 8.5.
	  	Limitations	  	 	53	  
			
	ARTICLE IX	  	CERTAIN POST-CLOSING AGREEMENTS	  	 	55	  
			
	 9.1.
	  	Proprietary Information	  	 	55	  
	 9.2.
	  	No Solicitation of Former Employees	  	 	55	  
	 9.3.
	  	Non-Competition Agreement	  	 	55	  
	 9.4.
	  	Further Assurances	  	 	56	  
			
	ARTICLE X	  	TERMINATION OF AGREEMENT	  	 	57	  
			
	 10.1.
	  	Termination by Lapse of Time	  	 	57	  
	 10.2.
	  	Termination by Agreement of the Parties	  	 	57	  
	 10.3.
	  	Termination by Reason of Breach	  	 	57	  
	 10.4.
	  	Termination For Failure to Obtain Shareholder Approval	  	 	57	  
	 10.5.
	  	Effect of Termination	  	 	58	  
	 10.6.
	  	Election of Remedies; Liquidated Damages	  	 	58	  

  
 - iii -

 EXECUTION COPY 
  

 TABLE OF CONTENTS 

 

							
	 Section
	  	 	  	Page	 
			
	ARTICLE XI	  	DISPUTE RESOLUTION	  	 	59	  
			
	 11.1.
	  	General	  	 	59	  
	 11.2.
	  	Consent of the Parties	  	 	59	  
	 11.3.
	  	Arbitration.	  	 	59	  
			
	ARTICLE XII	  	DEFINITIONS	  	 	60	  
			
	 12.1.
	  	Certain Definitions	  	 	60	  
	 12.2.
	  	Certain Rules of Construction	  	 	71	  
			
	ARTICLE XIII	  	MISCELLANEOUS	  	 	72	  
			
	 13.1.
	  	Press Releases and Announcements	  	 	72	  
	 13.2.
	  	Notices	  	 	72	  
	 13.3.
	  	Successors and Assigns	  	 	73	  
	 13.4.
	  	Entire Agreement; Amendments; Attachments	  	 	73	  
	 13.5.
	  	Severability	  	 	73	  
	 13.6.
	  	No Third Party Beneficiaries	  	 	73	  
	 13.7.
	  	Governing Law	  	 	73	  
	 13.8.
	  	Submission to Jurisdiction	  	 	74	  
	 13.9.
	  	Section Headings	  	 	74	  
	 13.10.
	  	Counterparts and Facsimile Signature	  	 	74	  

  
 - iv -

 EXECUTION COPY 
  

 Exhibits 
  

					
	A	  	-  	  	Form of Parent Guaranty
	B	  	-  	  	Form of Escrow Agreement
	C	  	-  	  	Form of Opinions of Counsel to Parent, Seller and the Company
	D	  	-  	  	Form of Opinion of Buyer’s Counsel
	E	  	-  	  	Paul Capital Term Sheet
	F	  	-  	  	Endo Termination Agreement
	G	  	-  	  	Forms of Assignments
	H	  	-  	  	Form of Transition Services Agreement
	I	  	-  	  	Form of License Agreement

  
 - v -

 EXECUTION COPY 
  

 STOCK PURCHASE AGREEMENT 

This Agreement (the “Agreement”) is made and entered into as of January 8, 2007 by and among Blue Acquisition
Corp., a Delaware corporation (“Buyer”), SkyePharma Holding, Inc. (“Seller”), a Delaware corporation and a wholly owned subsidiary of SkyePharma PLC, a company incorporated under the laws of England and Wales
(“Parent”), and SkyePharma, Inc., a California corporation and wholly owned subsidiary of Seller (the “Company”). 
 Recitals 
 Seller is the direct owner of all issued and outstanding shares
of capital stock of the Company (the “Shares”). Buyer desires to purchase, and Seller desires to sell, the Shares for the consideration set forth below, on the terms and subject to the conditions set forth in this Agreement.

 In order to induce Buyer to enter into this Agreement and consummate the transactions contemplated hereunder, concurrently
herewith, Parent has executed and delivered to Buyer a Parent Guaranty Agreement in the form attached hereto as Exhibit A (the “Parent Guaranty”). 
 In order to induce Seller to enter into this Agreement and consummate the transactions contemplated hereunder, concurrently herewith, Buyer has delivered the Commitment Letters (defined below) naming
Seller as a third party beneficiary thereto. 
 NOW, THEREFORE, in consideration of the premises, and the mutual
representations, warranties, covenants and agreements set forth in this Agreement, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, and intending to be legally bound, Buyer, Seller and the
Company hereby agree as follows: 
 ARTICLE I 
 PURCHASE AND SALE OF THE SHARES 
 1.1. Purchase of the Shares from
Seller. Upon the terms and subject to the conditions set forth in this Agreement, at the Closing, Seller shall sell, transfer, convey, assign and deliver to Buyer, and Buyer shall purchase, acquire and accept from Seller, all of the Shares, free
and clear of all Encumbrances. At the Closing, Seller shall deliver to Buyer certificates evidencing all of the Shares duly endorsed in blank or with stock powers duly executed by Seller. Buyer acknowledges and agrees that in acquiring the Shares,
Buyer is not acquiring any rights, title or interest in, to and under (i) the names “SkyePharma USA, Inc.,” “SkyePharma, Inc.,” “SkyePharma,” “SkyePharma USA,” “Skye, Inc.” “Skye,”
“Skye USA,” variations and derivatives thereof and any other logos or trademarks, trade names or service marks of the Company (collectively, the “Names”) and (ii) the Excluded Assets (as defined below) of the Company
that, pursuant to Section 5.11, are to be transferred from the Company to Seller and/or Affiliates of Seller (other than the Company) prior to the Closing. 
 1.2. Further Assurances. At any time and from time to time after the Closing, at Buyer’s request and without further consideration, Seller shall (and shall cause each of its Affiliates and
each of its Affiliates’ respective directors, officers and employees to) promptly 

  

 EXECUTION COPY 
  

 
execute and deliver such instruments of sale, transfer, conveyance, assignment and confirmation, and take all such other action as Buyer may reasonably request, to transfer, convey and assign to
Buyer, and to confirm Buyer’s title to, all of the Shares, to put Buyer (through the ownership of the Shares) in effective operating control of the assets, properties and business of the Company, to assist Buyer in exercising all rights with
respect thereto, and otherwise to carry out the purpose and intent of this Agreement. 
 1.3. Purchase Price. The Base
Purchase Price to be paid by Buyer to Seller shall be twenty million dollars ($20,000,000), subject to adjustment pursuant to Section 1.5. The Base Purchase Price shall be payable in the manner described in Section 1.4.

 1.4. Payment of Base Purchase Price. At the Closing, Buyer shall (a) pay to Seller the Base Purchase Price, minus
the Escrow Amount, in cash, by wire transfer of immediately available funds to an account designated by Seller, and (b) deliver to the Escrow Agent the Escrow Amount for deposit into the Escrow Fund, such amount and fund to be held in
accordance with the provisions of Sections 1.5 and 5.15 and Article VIII of this Agreement and the Escrow Agreement. 
 1.5. Post-Closing Adjustments. The Base Purchase Price shall be subject to adjustment after the Closing Date as follows: 

(a) Set forth in Column X of the spreadsheet attached in Schedule 1.5(a)(i) is a statement
compiling certain asset and liability accounts of the Company as of November 24, 2006 (the “Target Net Assets Statement”). The Target Net Assets Statement was prepared on the same basis as the Most Recent Net Assets Statement,
with the eliminations and adjustments set forth in Schedule 6.12 and the further eliminations set forth in Schedule 1.5(a)(ii). The Target Net Assets Statement includes a “net assets value” of the Company of $[**] (the
“Net Assets Target”). No later than 5 p.m. Pacific Standard Time on the tenth (10th) business day after the Closing Date, Seller shall deliver to Buyer a compilation of the same asset and liability accounts included in the Target Net Assets Statement, but prepared as of the Closing
Date (the “Draft Closing Net Assets Statement”), which shall be prepared by Seller on the same basis as the Most Recent Net Assets Statement, applied on a basis consistent with the past accounting practices of the Company, with the
eliminations and adjustment set forth in Schedule 6.12 and the further eliminations set forth in Schedule 1.5(a)(ii). Solely for the avoidance of doubt, neither the Draft Closing Net Assets Statement nor the Final Closing Net Assets
Statement will reflect any writedown or fair value adjustment of assets or any provision for liabilities arising from the termination of the Endo Agreement. 
 (b) Buyer shall deliver to Seller, no later than 6 p.m. Pacific Standard Time on the Objection Deadline Date, either a notice indicating that Buyer accepts the Draft Closing Net Assets Statement or a
statement in reasonable detail describing its objections (if any) to the Draft Closing Net Assets Statement and the grounds for such objections (an “Objection Statement”). If Buyer delivers to Seller a notice accepting the Draft
Closing Net Assets Statement, or Buyer does not deliver a timely Objection Statement by 6 p.m. Pacific Standard Time on the Objection Deadline Date, then, effective as of either the date of delivery of such notice of acceptance or as of the close of
business on the Objection Deadline Date, the Draft Closing Net Assets Statement shall be deemed to be the final compilation of the asset and liability accounts included in the Target Net Assets Statement, measured and calculated as of the Closing
Date (the “Final Closing Net Assets Statement”). If Buyer timely objects to the Draft Closing Net Assets Statement, such objections shall be resolved as follows: 

(i) Buyer and Seller shall seek in good faith to resolve such objections. Each Party shall provide the other Parties with reasonable
access to its records, personnel and supporting documentation relating to the Draft Closing Net Assets Statements and the items giving rise to the Objection Statement until such time as the Final Closing Net Assets Statement is determined.

  
 - 2 -

 EXECUTION COPY 
  

 (ii) If Buyer and Seller do not reach a resolution of all objections set forth in
Buyer’s Objection Statement within thirty (30) days after delivery of such Objection Statement, Buyer and Seller shall, within thirty (30) days following the expiration of such 30-day period, engage the Accountant, pursuant to an
engagement agreement executed by Buyer, Seller and the Accountant, to resolve the Unresolved Objections. 
 (iii) Buyer and
Seller shall jointly submit to the Accountant, within ten (10) days after the date of the engagement of the Accountant (as evidenced by the date of the engagement agreement), a copy of the Draft Closing Net Assets Statement, a copy of the
Objection Statement, and a statement setting forth the resolution of any objections agreed to by Buyer and Seller. Each of Buyer and Seller shall submit to the Accountant (with a copy delivered to the other Party on the same day), within thirty
(30) days after the date of the engagement of the Accountant, a memorandum (which may include supporting exhibits) setting forth their respective positions on the Unresolved Objections. Each of Buyer and Seller may (but shall not be required
to) submit to the Accountant (with a copy delivered to the other Party on the same day), within forty five (45) days after the date of the engagement of the Accountant, a memorandum responding to the initial memorandum submitted to the
Accountant by the other Party. Unless requested by the Accountant in writing, neither Party may present any additional information or arguments to the Accountant, either orally or in writing. 

(iv) Within ninety (90) days after the date of its engagement hereunder, the Accountant shall determine whether the objections
raised by Buyer are appropriate and shall issue a ruling which shall include a compilation of the accounts included (or required to be included) in the Draft Closing Net Assets Statement as adjusted pursuant to any resolutions to objections agreed
upon by Buyer and Seller and pursuant to the Accountant’s resolution of the Unresolved Objections. Such statement shall be Final Closing Net Assets Statement. 
 (v) The resolution by the Accountant of the Unresolved Objections shall be conclusive and binding upon Buyer and Seller. Buyer and Seller agree that the procedure set forth in this
Section 1.5(b) for resolving disputes with respect to the Draft Closing Net Assets Statement shall be the sole and exclusive method for resolving any such disputes; provided that this provision shall not prohibit either Party from
instituting litigation to enforce the procedures and deadlines set forth herein or to enforce rulings of the Accountant. 
 (vi)
Buyer and Seller shall share equally the fees and expenses of the Accountant. 

  
 - 3 -

 EXECUTION COPY 
  

 (c) Immediately following the Objection Deadline Date, if a timely Objection Statement
is not delivered, or upon notification by Buyer to Seller that no objection to the Draft Closing Net Assets Statement will be made, or immediately upon final resolution of any dispute in connection with the determination of the Final Closing Net
Assets Statement pursuant to this Section 1.5, the Adjusted Purchase Price shall be determined as follows: 
 (d) If
the “net assets value” as shown on the Final Closing Net Assets Statement is more than [**] dollars ($[**]) less than “net assets value” as shown in the Target Net Assets Statement, the deficiency in excess of such $[**] amount
shall be deducted from the Base Purchase Price to obtain the Adjusted Purchase Price, and shall be paid by Seller to Buyer from the following sources in the following manner and priority: first, by payment in cash to Buyer by the Escrow Agent from
the Escrow Fund, to the extent funds are available in the Escrow Fund, and thereafter, by payment in cash to Buyer by Seller, from funds of Seller, to an account designated by Buyer, in each case by wire transfer of immediately available funds
within two (2) business days after such determination. 
 (e) For purposes of implementing the provisions of
Section 1.5 and Section 8.1(h), each Party shall have reasonable access, upon request, during normal business hours and with reasonable advance notice, to the books, records and personnel of the other Parties to the extent
reasonably relevant to the determination either of the Draft Closing Net Assets Statement and the Final Closing Net Assets Statement and the resolution of any Objection Statement and Unresolved Objections (in the case of Section 1.5) or
the Designated Amounts and the invoices submitted as relating thereto (in the case of Section 8.1(h)). 
 1.6.
Escrow Account. The Escrow Amount shall be delivered to the Escrow Agent for deposit into a fund (the “Escrow Fund”) that shall be held by the Escrow Agent under the terms of the Escrow Agreement for the purpose of securing
the indemnification obligations of Seller pursuant to Article VIII and Section 5.15, any adjustment to the Base Purchase Price pursuant to Section 1.5, and any reimbursement obligation of Parent or Seller with respect
to payments under the Stay Incentive Agreements under Section 5.16. The Escrow Fund shall be held as a trust fund and shall not be subject to any lien, attachment, trustee process or any other judicial process of any creditor of any
Party, and shall be held and disbursed solely for the purposes and in accordance with the terms of the Escrow Agreement. 
 1.7.
Earn-Out. Following the Closing, the Company shall pay to Seller the amounts set forth in Schedule 1.7, minus any amounts determined to be due to Buyer pursuant to Section 1.5 or Section 5.16, or pursuant to
Article VIII or Section 5.15 (only to the extent of the Cap set forth in Section 8.5), and not otherwise paid to Seller before any such amounts on Schedule 1.7 (if any) become payable pursuant to Schedule
1.7. 
 1.8. The Closing. 
 (a) The Closing shall take place at the offices of Wilmer Cutler Pickering Hale and Dorr LLP, 1117 California Avenue, Palo Alto, California commencing at 9:00 a.m. Pacific Standard Time on the date
within two (2) business days after the satisfaction or waiver of all of the conditions to the obligations of the Parties to consummate the transactions contemplated hereby (excluding the delivery at the Closing of any of the documents set forth
in Articles VI and VII), or such other date as may be mutually agreeable to the Parties. The transfer of the Shares by Seller to Buyer shall be deemed to occur at 9:00 a.m. Pacific Standard Time, on the Closing Date. 

  
 - 4 -

 EXECUTION COPY 
  

 (b) At the Closing, the following actions shall take place: 

(i) Seller shall deliver the agreements, consents, certificates, and other instruments and documents required to be delivered to Buyer
pursuant to Article VI, and Buyer shall execute and deliver the agreements, certificates, and other instruments and documents required to be delivered to Seller pursuant to Article VII; 

(ii) Seller shall then deliver to Buyer certificates evidencing all of the Shares duly endorsed in blank or with stock powers duly
executed by Seller; and 
 (iii) Buyer shall then pay the amount set forth in Section 1.4(a), in the manner
prescribed therein. 
 1.9. Allocation of Payments. The Adjusted Purchase Price and the “Milestone
Payments” pursuant to Section 1.7 and Schedule 1.7 shall be paid as consideration for the Shares and the covenants not to compete set forth in Section 9.3(a)(ii) and Section 9.3(a)(iii); the
“DepoBupivacaine Percentage Payments” pursuant to Section 1.7 and Schedule 1.7 shall be paid as consideration for the covenant not to compete set forth in Section 9.3(a)(i); and the “Biologics Products
Percentage Payments” pursuant to Section 1.7 and Schedule 1.7 shall be paid as consideration for the covenant not to compete set forth in Section 9.3(a)(iv). The Adjusted Purchase Price and all such Percentage
Payments shall be allocated among the Shares and such covenants not to compete in accordance with Schedule 1.9. Unless otherwise required by a Final Determination, the Parties shall report the transactions contemplated by this Agreement in a
manner consistent with such allocations. 
 ARTICLE II 

REPRESENTATIONS AND WARRANTIES OF SELLER 
 REGARDING THE SHARES 
 Seller represents and warrants to Buyer that the
statements contained in this Article II are true and correct as of the date of this Agreement and will be true and correct as of the Closing as though made as of the Closing, except to the extent such representations and warranties are
specifically made as of a particular date (in which case such representations and warranties will be true and correct as of such date). 
 2.1. Title. Seller has (and upon consummation of the purchase contemplated hereby, Buyer will acquire from Seller) good and marketable title to the Shares, free and clear of any and all
Encumbrances. Section 2.1 of the Seller Disclosure Schedule sets forth a true and correct description of the Shares and all shares of capital stock and other securities of the Company owned, directly or indirectly through any other
subsidiary or affiliate, by Seller or which Seller has the right to acquire. 

  
 - 5 -

 EXECUTION COPY 
  

 2.2. Authority. Seller has the full right, power and authority to enter into this
Agreement and to transfer, convey and sell to Buyer at the Closing the Shares and otherwise to perform and fulfill its obligations under this Agreement and the Ancillary Agreements to which Seller is a party. Each of this Agreement and the Ancillary
Agreements to which Seller is party (including the Escrow Agreement) has been duly and validly executed and delivered by Seller and constitutes a valid and binding obligation of Seller, enforceable against Seller in accordance with its terms. The
passing of resolutions (i) approving the Agreement by a majority of the shareholders of Parent (on show of hands) or of the number of shares held by the shareholders of Parent (on a duly convened poll), in each case present (on a poll, either
in person or by proxy) and voting and (ii) approving matters related to a placing by at least 75% of the shareholders (on show of hands) or of the number of shares (on a duly convened poll), in each case present (on a poll, either in person or
by proxy) and voting therewith at a validly convened and held EGM shall operate to approve the transactions contemplated by this Agreement and confer authority on the Parent to complete the transactions contemplated by this Agreement in accordance
with the terms of this Agreement and to take all further actions as it may consider expedient for the purposes thereof and is the only approval of Parent’s shareholders required for the consummation of the transactions contemplated by this
Agreement. 
 2.3. Regulatory Approvals. Except as set forth in Section 2.3 of the Seller Disclosure
Schedule, neither Seller nor Parent is a party to, subject to or bound by any agreement or any judgment, order, writ, prohibition, injunction or decree of any court or other governmental body which would prevent the execution or delivery of this
Agreement or any of the Ancillary Agreements by Seller or the transfer, conveyance and sale of the Shares by Seller to Buyer pursuant to the terms hereof. 
 2.4. Circular. The Circular prepared pursuant to Section 5.3 shall not, either at the time posted or at the time of the EGM or at the Closing, contain any untrue statement of a material
fact or omit to state any material fact required to be stated therein or necessary in order to make the statements therein not misleading. 
 2.5. Brokers. Except for the fees payable in the amounts and to the recipients set forth in Section 2.5 of the Seller Disclosure Schedule (which shall be the sole liability, obligation
and responsibility of Parent and Seller and for which neither the Company nor Buyer shall have any liability or obligation), none of Seller, Parent or the Company or any of their Affiliates has any liability or obligation to pay any fees or
commissions to any broker, finder or agent with respect to the transactions contemplated by this Agreement. 
 ARTICLE III

 REPRESENTATIONS AND WARRANTIES OF SELLER 
 REGARDING THE COMPANY 
 Seller hereby represents and warrants to Buyer
that, except as set forth in the Seller Disclosure Schedule, the statements contained in this Article III are true and correct as of the date of this Agreement and will be true and correct as of the Closing as though made as of the
Closing, except to the extent such representations and warranties are specifically made as of a particular date (in which case such representations and warranties will be true and correct as of such date). The Seller Disclosure Schedule shall be
arranged in sections and subsections 

  
 - 6 -

 EXECUTION COPY 
  

 
corresponding to the numbered and lettered sections and subsections contained in Article II and this Article III. The disclosures in any section or subsection of the Seller
Disclosure Schedule shall qualify only the corresponding section or subsection in this Agreement except to the extent that it is clear from a reading of the disclosure that such disclosure is applicable to such other sections or subsections.

 3.1. Organization, Qualification and Corporate Power. The Company is a corporation duly organized, validly existing
and in good standing under the laws of the State of California. The Company is duly qualified to conduct business and is in corporate and tax good standing under the laws of each jurisdiction listed in Section 3.1 of the Seller Disclosure
Schedule, which jurisdictions constitute the only jurisdictions in which the nature of the Company’s businesses or the ownership or leasing of its properties requires such qualification, except where the failure to be so qualified or in
good standing would not be material to the transactions contemplated by this Agreement. The Company has all requisite corporate power and authority to carry on the businesses in which it is engaged and to own and use the properties owned and used by
it. The Company has furnished to Buyer complete and accurate copies of its Certificate of Incorporation and By-laws. The Company is not in default under or in violation of any provision of its Certificate of Incorporation or By-laws. 

3.2. Capitalization. 
 (a) The authorized capital stock of the Company consists of one thousand (1,000) shares of Common Stock, of which one thousand (1,000) shares are issued and outstanding and no shares are held in
the treasury of the Company. All of the issued and outstanding shares of capital stock of the Company have been and on the Closing Date will be duly authorized, validly issued, fully paid, nonassessable and free of all preemptive rights. All of the
issued and outstanding shares of capital stock of the Company were issued in compliance with all applicable federal and state securities laws. 
 (b) There are no outstanding or authorized options, warrants, rights, calls, convertible instruments, agreements or commitments to which the Company is a party or which are binding upon the Company
providing for the issuance, disposition or acquisition of any of its capital stock. There are no outstanding or authorized stock appreciation, phantom stock or similar rights with respect to the Company. There are no agreements, voting trusts,
proxies or understandings with respect to the voting of any shares of capital stock of the Company. 
 3.3. Authorization of
Transaction. Each of Seller and the Company has all requisite power and authority to execute and deliver this Agreement and to perform its obligations under this Agreement and the Ancillary Agreements to which it is a party. The execution and
delivery by Seller and the Company of this Agreement and the Ancillary Agreements to which Seller or the Company is a party and the consummation by Seller and the Company of the transactions contemplated by this Agreement and the Ancillary
Agreements to which Seller or the Company is a party have been duly and validly authorized by all necessary corporate action on the part of Seller and the Company and has been authorized and approved by Parent. This Agreement has been duly and
validly executed and delivered by Seller and the Company and constitutes a valid and binding obligation of Seller and the Company, enforceable against Seller and the Company in accordance with its terms. The passing of a resolution approving the
Agreement by a majority 

  
 - 7 -

 EXECUTION COPY 
  

 
of the shareholders (on show of hands) or of the number of shares (on a duly convened poll), in each case present (on a poll, either in person or by proxy) and voting at a validly convened and
held extraordinary general meeting of the shareholders of Parent, shall operate to approve the transactions contemplated by this Agreement and confer authority on the Parent to complete the transactions contemplated by this Agreement in accordance
with the terms of this Agreement and to take all further actions as it may consider expedient for the purposes thereof and is the only approval of Parent’s shareholders required for the consummation of the transactions contemplated by this
Agreement. 
 3.4. Noncontravention. Except as set forth in Section 3.4 of the Seller Disclosure Schedule,
neither the execution and delivery by Seller and the Company of this Agreement or any of the Ancillary Agreements to which Seller or the Company is a party, nor the consummation by Seller and the Company of the transactions contemplated by this
Agreement or any of the Ancillary Agreements, will (a) conflict with or violate any provision of the Certificate of Incorporation or By-laws or similar organizational documents of Seller, Parent or the Company, (b) require on the part of
Seller, Parent or the Company any notice to or filing with, or any permit, authorization, consent or approval of, any Governmental Entity, (c) conflict with, result in a breach of, constitute (with or without due notice or lapse of time or
both) a default under, result in the acceleration of obligations under, create in any party the right to terminate, modify or cancel, or require any notice, consent or waiver under, any Material Contract (as defined in Section 3.15) or
instrument to which Seller, Parent or the Company is a party or by which Seller, Parent or the Company is bound or to which any of their respective assets is subject, (d) result in the imposition of any Encumbrance upon any assets of Seller,
Parent or the Company or (e) violate any order, writ, injunction, decree, statute, rule or regulation that, to the knowledge of Seller and the Company, is applicable to Seller, Parent or the Company or any of their respective properties or
assets. 
 3.5. Subsidiaries. The Company has no Subsidiaries, whether wholly or partially owned. The Company does not
control directly or indirectly or have any direct or indirect equity participation or similar interest in any corporation, partnership, limited liability company, joint venture, trust or other business association or entity which is not a
Subsidiary. 
 3.6. Financial Statements. 
 (a) Seller has provided the Financial Statements to Buyer. The items included in the Financial Statements were prepared on the same basis as was used in preparing the consolidation schedules of the
Company used in preparing the consolidated financial statements of Parent as at December 31, 2005, which were prepared in accordance with IFRS on a consistent basis. The Financial Statements fairly present the financial condition of the Company
as of the respective dates thereof (except as set forth in Section 3.6(a) of the Seller Disclosure Schedule), and are consistent with the books and records of the Company. 

(b) Each of the Company and, to the extent their books and records relate to or affect the Company, Parent and its subsidiaries
(including Seller) maintain books and records that accurately reflect, in all material respects, its respective assets and liabilities and maintain internal controls over financial reporting that provide assurance that, in all material respects,
(i) transactions are executed with management’s general or specific authorization, (ii) transactions 

  
 - 8 -

 EXECUTION COPY 
  

 
are recorded as necessary to permit preparation of financial statements of the Company and to maintain accountability for the assets of the Company, (iii) access to assets of the Company is
permitted only in accordance with management’s general or specific authorization, (iv) the reporting of assets of the Company is compared with existing assets at regular intervals, and (v) notes and other receivables and inventory are
properly recorded, and proper and adequate procedures are implemented to effect the collection of such notes and receivables on a current and timely basis. 
 (c) The Target Net Assets Statement was, and the Draft Closing Net Assets Statement will be, prepared by Seller on the same basis as the Most Recent Net Assets Statement, with the eliminations and
adjustment set forth in Schedule 6.12 and the further eliminations set forth in Schedule 1.5(a)(ii). 
 3.7.
Absence of Certain Changes. Since the Most Recent Net Assets Statement Date, (a) there has occurred no event or development that, individually or in the aggregate, has had, or could reasonably be expected to have in the future, a Company
Material Adverse Effect, and (b) except as contemplated by this Agreement, the Company has not taken any of the actions set forth in paragraphs (c), (d), (e), (f) or (k) of Section 5.4 (disregarding any time
limitations set forth in such paragraphs). 
 3.8. Undisclosed Liabilities. Except as set forth in Section 3.8 of
the Seller Disclosure Schedule, the Company has (and will, as of the Closing, have) no liability (whether known or unknown, whether absolute or contingent, whether liquidated or unliquidated, whether due or to become due), except (a) as of
the date hereof, liabilities reflected in the Most Recent Net Assets Statement and liabilities incurred in the Ordinary Course of Business since the Most Recent Net Assets Statement Date and (b) as of the Closing, liabilities that will be
reflected in the Final Closing Net Assets Statement. 
 3.9. Taxes. 

(a) Except as set forth on Section 3.9 of the Seller Disclosure Schedule: 

(i) The Company has (A) properly filed on a timely basis all Tax Returns for Income Taxes and all material Tax Returns for Taxes
other than Income Taxes that it was required to file, and all such Tax Returns were true, correct and complete in all material respects, (B) paid on a timely basis all material Taxes that were due and payable, and (C) established on its
Most Recent Net Assets Statement reserves that are adequate for the payment of all unpaid Taxes. 
 (ii) The Company has not
been a member of a group of corporations with which it has filed (or been required to file) consolidated, combined or unitary Tax Returns other than any group the common parent of which is Seller. 

(iii) Seller has (A) properly filed on a timely basis all Tax Returns for Income Taxes that it was required to file with respect to
any Affiliated Period, and all such Tax Returns were true, correct and complete in all material respects, and (B) paid on a timely basis all material Taxes that were due and payable with respect to all Affiliated Periods. 

  
 - 9 -

 EXECUTION COPY 
  

 (iv) Since the Most Recent Net Assets Statement Date, the Company has not incurred any
liability for Taxes other than (x) in the Ordinary Course of its Business, or (y) in connection with the transactions contemplated by this Agreement, including the distribution of the Excluded Assets and the transactions referred to in
Schedule 6.12. 
 (v) The Company is not a party to or bound by any Tax indemnity, Tax sharing, Tax allocation or
similar agreement. 
 (vi) The Company has complied in all material respects with all applicable laws relating to the payment
and withholding of Taxes and has, within the time and manner prescribed by law, paid over to the proper governmental authority all amounts required to be withheld and paid over under all applicable laws. 

(vii) There are no liens for Taxes imposed on the assets of the Company except for (A) liens for Taxes not yet due and payable or
(B) liens for Taxes being contested in good faith in appropriate proceedings and with respect to which adequate reserves have been established on the Most Recent Net Assets Statement in accordance with IFRS. 

(viii) The Company does not have any liability for Taxes of another person as a transferee or successor (or under similar principles) or
pursuant to any contractual obligation. 
 (ix) No examination or audit of any Tax Return of Parent, Seller or the Company is
currently in progress or, to the knowledge of Seller and the Company, threatened or contemplated. 
 (x)
Section 3.9(a)(x) of the Seller Disclosure Schedule sets forth (i) each jurisdiction (other than United States federal) in which the Company files a Tax Return, (ii) to the knowledge of Seller, each jurisdiction (other than
United States federal) in which the Company is required or has been required to file a Tax Return, and (iii) each jurisdiction that has sent written notices requesting information relating to the Company’s nexus with such jurisdiction.

 (xi) The Company has not (i) waived any statute of limitations with respect to Taxes or agreed to extend the period for
assessment or collection of any Taxes which period has not expired, (ii) requested any extension of time within which to file any Tax Return, which Tax Return has not yet been filed, or (iii) executed or filed any power of attorney with
any Taxing Authority that is still outstanding. 
 (xii) There are no adjustments under Section 481 of the Code (or any
similar adjustments under any provision of the Code or corresponding foreign, state or local Tax laws) that are required to be taken into account by the Company in any period ending after the Closing Date by reason of a change in method of
accounting in any taxable period ending on or before the Closing Date. 

  
 - 10 -

 EXECUTION COPY 
  

 (xiii) For the two year period ending on the date hereof, the Company has not been a
“distributing corporation” or a “controlled corporation” in a distribution intended to qualify under Section 355(a) of the Code. 
 (xiv) The Company does not own any interest in any entity that is characterized as a partnership for U.S. federal income Tax purposes. 

(xv) The Company has not entered into a gain recognition agreement under Section 367 of the Code. 

(xvi) The Company will not be required to include any item of income in, or exclude any item of deduction from, taxable income for any
period (or any portion thereof) ending after the Closing Date as a result of any (i) closing agreement as described in Section 7121 of the Code (or any corresponding or similar provision of state, local or foreign Tax law) executed on or
prior to the Closing Date, (ii) installment sale or other open transaction disposition made on or prior to the Closing Date, or (iii) prepaid amount received on or prior to the Closing Date. 

(xvii) The Company has not engaged in any “listed transaction” for purposes of Treasury Regulation sections 1.6011-4(b)(2) or
301.6111-2(b)(2) or any analogous provision of foreign, state or local law. 
 (b) Seller has delivered to Buyer or made
available to Buyer (or will make available upon Buyer’s request): (i) complete and correct copies of all Tax Returns of the Company and any Affiliated Group (but in the case of any such Affiliated Group, only the portions of such Tax
Returns relating solely to the Company), and (ii) complete and correct copies of all private letter rulings, revenue agent reports, information document requests, notices of proposed deficiencies, deficiency notices, protests, closing
agreements and any other similar material documents, in each case, submitted by, received by, or agreed to by the Company and relating to Taxes of the Company for all prior Taxable periods for which the statute of limitations has not expired.

 (c) The aggregate basis in the assets of the Company as of December 31, 2006 for federal Income Tax purposes was not
less than [**] dollars ($[**]). 
 Notwithstanding anything to the contrary contained in this Agreement, except as and to the extent provided in
Section 3.22, this Section 3.9 is the only Section in this Agreement in which representations and warranties relating or attributable to Taxes and/or Tax Returns are made, including for purposes of any other Section in this
Article III and Section 6.2. 
 3.10. Assets. The Company is the true and lawful owner, and has good
title to, all of the assets (tangible or intangible) reflected in the Most Recent Net Assets Statement (other than leasehold interests) or otherwise purported to be owned by the Company, free and clear of all Encumbrances, including the assets
listed or described in Schedule 3.10(a). The Company owns or leases all tangible assets sufficient for the conduct of its businesses as presently conducted. Each such tangible asset is free from material defects, has been maintained in
accordance with normal industry practice, is in good operating condition and repair (subject to normal wear and tear) and is suitable for the purposes for which it presently is used. 

  
 - 11 -

 EXECUTION COPY 
  

 3.11. Owned Real Property. The Company has no direct or indirect ownership
interest in any Owned Real Property. 
 3.12. Real Property Leases. Section 3.12 of the Seller Disclosure
Schedule lists all Leases. The Company has delivered to Buyer complete and accurate copies of the Leases. With respect to each Lease: 
 (a) such Lease is legal, valid, binding, enforceable and in full force and effect as against the Company and, to the knowledge of the Seller and the Company, each other party thereto; 

(b) neither the Company nor, to the knowledge of Seller and the Company, any other party, is in breach or violation of, or default under,
any such Lease, and no event has occurred, is pending or, to the knowledge of Seller and the Company, is threatened, which, after the giving of notice, with lapse of time, or otherwise, would constitute a breach or default by the Company or, to the
knowledge of Seller and the Company, any other party under such Lease; 
 (c) to the knowledge of Seller and the Company, there
are no disputes, oral agreements or forbearance programs in effect as to such Lease; 
 (d) the Company has not assigned,
transferred, conveyed, mortgaged, deeded in trust or encumbered any interest in the leasehold or subleasehold; and 
 (e) to the
knowledge of Seller and the Company, there is no Encumbrance applicable to the real property subject to such Lease which would reasonably be expected to materially impair the current uses or the occupancy by the Company of the property subject
thereto. 
 3.13. Intellectual Property. 
 (a) For purposes of this Agreement (other than for purposes of Section 3.30, in the case of terms separately defined in Section 3.30): 

(i) “Intellectual Property” shall mean, collectively, all U.S. and non-U.S. registered, unregistered and pending
(A) trademarks, trade dress, Product and Product Candidate names, internet domain names, and all registrations and applications therefor (collectively, “Trademarks”), (B) copyrights (including those in computer software),
database rights, and all grants, registrations and applications therefor (collectively, “Copyrights”), (C) patents, and all registrations and applications therefor (collectively, “Patents”),
(D) inventions, invention disclosures, statutory invention registrations, trade secrets and confidential business information, know-how, manufacturing and product processes and techniques, research and development information, financial,
marketing and business data, pricing and cost information, business and marketing plans and customer and supplier lists and information, whether patentable or nonpatentable (collectively, “Trade Secrets”), and (E) other
proprietary rights relating to any of the foregoing. 

  
 - 12 -

 EXECUTION COPY 
  

 (ii) “IP Contracts” shall mean, collectively, all license, assignment,
distribution, collaboration, development or other agreements relating to any Company Intellectual Property, including (A) all licenses, covenants or other agreements pursuant to which the Company or any of its Affiliate has assigned,
transferred, licensed, distributed or otherwise granted any right or access to any Person, or covenanted not to assert any right, with respect to any past, existing or future Company Intellectual Property, and (B) all agreements, contracts,
assignments or other instruments pursuant to which the Company or any of its Affiliate has obtained any right or license, or any joint or sole ownership interest, in or to any item of Company Intellectual Property. 

(iii) “Company Intellectual Property” shall mean all (A) Intellectual Property in which the Company has an
ownership interest or will, pursuant to Section 5.11, acquire an ownership interest (“Company Owned Intellectual Property”), (B) all Intellectual Property in which any Affiliate of Company has an ownership interest
which claims or covers a Product or Product Candidate (or developing, making, using and commercializing any Product or Product Candidate), or is used or is currently intended to be used, in the business of the Company as now conducted or as intended
to be conducted, including in connection with the developing, making, using and commercializing of any Product or Product Candidate, and including all patents and patent applications relating to Biosphere technology or otherwise set forth in
Schedule 5.11 (“Affiliate Owned Intellectual Property”, and together with the Company Owned Intellectual Property, “Group Owned Intellectual Property”), and (C) all Intellectual Property in which a third
party has an ownership interest which claims or covers a Product or Product Candidate (or developing, making, using and commercializing any Product or Product Candidate), or is used or is currently intended to be used, in the business of the Company
as now conducted or as intended to be conducted, including in connection with the developing, making, using and commercializing of any Product or Product Candidate (“Third Party Intellectual Property”). 

(iv) “Company Patents” shall mean (A) all Patents included in the Group Owned Intellectual Property, and
(B) all Patents included in Third Party Intellectual Property which the Company has the right or responsibility to prosecute, maintain and/or enforce pursuant to any IP Contract. 

(v) “Products” shall mean the products of the Company known as DepoCyt, DepoDur, and DepoBupivacaine, but, in each
case, only the form of such products, and the formulation and specification thereof, (1) in existence as of the Closing, or (2) as contemplated by an authorization or approval filed by the Company with a Relevant Regulatory Authority on or
before the Closing, including any supplements thereto, in each case as filed on or before the Closing Date.  
 (vi)
“Product Candidates” shall mean those products currently under pre-clinical research and development by the Company, including all products that are based on or derived from the DepoFoam or Biosphere technologies, but in each case,
only the form of such products, and the formulation and specification thereof, in existence as of the Closing Date. 

  
 - 13 -

 EXECUTION COPY 
  

 (vii) “Product Intellectual Property” shall mean all Company
Intellectual Property included in, covering or used in connection with the Products or Product Candidate, or their therapeutic use or manufacture. 
 (viii) “Registered Intellectual Property” shall mean any and all U.S. and non-U.S. (A) Patents, (B) Trademark, (C) copyright registrations and applications therefor,
(D) internet domain names, and (E) any other Intellectual Property that is the subject matter of an application, certificate, filing, registration or other document issued by, filed with, or recorded by any Governmental Entity. 

(ix) The phrases “intended to be used,” “intended to be conducted,” and “intended to be done” in this
Section 3.13 shall mean and be limited to the intent of the Company’s management prior to Closing as demonstrated by written business plans provided to Buyer prior to Closing. 

(x) As used in this Section 3.13 only, the term “Affiliate” shall mean any affiliate, as defined in Rule 12b-2
under the Securities Exchange Act of 1934, existing on or before the Closing Date. 
 (b) Section 3.13(b) of the Seller
Disclosure Schedule sets forth a complete and accurate list of (i) each item of Registered Intellectual Property that is included in the Group Owned Intellectual Property, in each case, enumerating specifically whether it is Company Owned
Intellectual Property or Affiliate Owned Intellectual Property, and the applicable filing or registration number, title, jurisdiction in which filing was made or from which registration issued, date of filing or issuance, names of all current
applicant(s) and registered owners(s), as applicable, and (ii) each IP Contract, specifically indicating the parties to such IP Contract and, as applicable, each amendment to each original agreement included in each such IP Contract (excluding
IP Contracts of currently available, off the shelf software programs licensed by the Company pursuant to “shrink wrap” licenses, the total fees associated with which are less than [**] dollars ($[**]) in the aggregate). All assignments of
Registered Intellectual Property listed in Section 3.13(b) of the Seller Disclosure Schedule to the Company or to the applicable Affiliate have been, or as of the Closing Date shall be, properly executed and recorded in the name of
Company. 
 (c) Except as set forth in Section 3.13(c)(1) of the Seller Disclosure Schedule which identifies the
joint owners of the Company Owned Intellectual Property, the Company is the sole and exclusive owner of each item of Company Owned Intellectual Property, free and clear of any Encumbrance. Section 3.13(c) of the Seller Disclosure
Schedule sets forth a complete and accurate list of Affiliate Owned Intellectual Property and, in each case, each applicable Affiliate that has an ownership interest therein. Except as set forth in Section 3.13(c)(2) of the Seller
Disclosure Schedule which identifies the joint owners of the Affiliate Owned Intellectual Property, each Affiliate so listed is the sole and exclusive owner of each such item of Affiliate Owned Intellectual Property, free and clear of any
Encumbrance. Except as set forth in Section 3.13(c)(3) of the Seller Disclosure Schedule, the Company or an Affiliate of Company, as applicable, is listed in the records of the appropriate U.S. and/or non-U.S. Governmental Entity as the
sole and exclusive owner of record for each item of Registered Intellectual Property as such owner is listed in Section 3.13(b) of the Seller Disclosure Schedule or as a joint owner for each Company Owned Intellectual Property identified
in Section 3.13 (c) of the Seller Disclosure Schedule. On or before the Closing, the Company will be the sole owner of all Group Owned Intellectual Property. 

  
 - 14 -

 EXECUTION COPY 
  

 (d) Each item of Company Intellectual Property will be owned or available for use by the
Company immediately following the Closing on identical terms and conditions as it was immediately prior to the Closing. Neither Company nor any of its Affiliates is, or will as a result of the consummation of the transactions contemplated by this
Agreement be, in breach in any material respect of any IP Contract. 
 (e) Except for the Trademarks and Patents identified in
Section 3.13(b) of Seller Disclosure Schedule as abandoned, to the knowledge of Company and Seller, no act has been done or omitted to be done by the Company or any of its Affiliates, or by any direct or indirect licensee, distributor or
collaborator of the Company or any Affiliate, or any Person or Governmental Entity with which the Company or any Affiliate is a co-owner of any Group Owned Intellectual Property, which has, had or is reasonably likely to have the effect of
canceling, forfeiting, abandoning or dedicating to the public, or entitling any U.S. or non-U.S. Governmental Entity or any other Person to cancel, forfeit, modify or consider abandoned, any Group Owned Intellectual Property, or give any Person or
Governmental Entity any rights with respect thereto. Neither the Company nor the Seller has any knowledge of any facts or claims which cause or would cause any Group Owned Intellectual Property to be invalid or unenforceable. Neither the Company nor
any Affiliate has received any written notice that any Person or Governmental Entity may bring a claim that would cause any Group Owned Intellectual Property to be invalid or unenforceable. 

(f) With respect to the Company Patents: (i) all necessary registration, maintenance and renewal fees due and owing as of the
Closing Date have been paid on or before the Closing and all necessary documents and certificates have been filed with the relevant Governmental Entities for the purpose of maintaining such Company Patents; (ii) there are no inventorship
challenges or interferences declared or provoked with respect to such Company Patents; (iii) the Company and each applicable Affiliate has complied with their respective required duty of candor and good faith in dealing with the U.S. Patent and
Trademark Office and similar Governmental Entities (collectively, “Patent Offices”) with respect to the Company Patents, including the duty to disclose to the Patent Offices all information required to be disclosed under all
applicable laws and regulations; and (iv) other than through an IP Contract listed in Section 3.13(b) of the Seller Disclosure Schedule, no third party, including any academic organization or Governmental Entity, possesses any
rights or licenses to any Company Patent. 
 (g) The Company owns, free and clear of any Encumbrance, or otherwise has the right
to use through an IP Contract listed in Section 3.13(b) of the Seller Disclosure Schedule, the terms of which have been fully disclosed to Buyer, all Company Intellectual Property (including all Product Intellectual Property), which, in
each case, is either used in or currently intended to be used in, or is reasonably necessary for, the conduct of the business of the Company as now conducted or as intended to be conducted, including in connection with the developing, making, using
and commercializing of all Products or Product Candidates. Except as set forth in Section 3.13(g) of the Seller Disclosure Schedule, the Company Owned 

  
 - 15 -

 EXECUTION COPY 
  

 
Intellectual Property, together with the Third Party Intellectual Property under which Company has rights under an IP Contract listed in Section 3.13(b) of the Seller Disclosure
Schedule, constitutes all Intellectual Property necessary (i) to make, use and sell, as applicable, the Company Products and Product Candidates in the manner so done currently and intended to be done, and (ii) to conduct the business
of the Company in all material respects in the manner currently conducted or intended to be conducted by the Company, including in connection with developing, making, using and commercializing of all Products and Product Candidates. 

(h) To the knowledge of Seller and the Company, neither the Company, nor the business of the Company as previously conducted, as now
conducted or as intended to be conducted, or any other activity, product or service of the Company (including the developing, making, using and commercializing of Products or Product Candidates), is in violation or infringement of, or has violated
or infringed any rights or asserted rights of any other Person or Governmental Entity with respect to any Intellectual Property of such other Person or Governmental Entity. The Company has not (and no Affiliate of the Company has, with respect to
the business of the Company), received any notice alleging any conflict with or violation or infringement of the Intellectual Property rights of any third party by the Company or any Affiliate of the Company. There are no Legal Proceedings pending,
with respect to any such conflict, violation or infringement, nor have any such Legal Proceedings been instituted or asserted in writing against the Company or, with respect to the business of the Company or any Product or Product Candidate, any
Affiliate of the Company, and, to the to the knowledge of Seller and the Company, no Legal Proceedings have been threatened against Company or any Affiliate of Company with respect to business of Company or any Product or Product Candidate, alleging
any violation of any rights or asserted rights of any other Person or Governmental Entity with respect to any Intellectual Property of such other Person or Governmental Entity. To the knowledge of Seller and the Company, there is no valid basis for
any such Legal Proceeding against the Company. 
 (i) Section 3.13(i) of the Seller Disclosure Schedule lists any
and all written complaints, claims and notices, and threats of any of the foregoing (including any notification that a license under any patent is or may be required), received by the Company, or by any Affiliate of the Company alleging
infringement, violation or misappropriation of any third party Intellectual Property and any request or demand for indemnification or defense received by the Company, or by any Affiliate of the Company with respect any alleged infringement,
violation or misappropriation of any third party Intellectual Property from any reseller, distributor, customer, user or any other third party; and the Company and Seller have provided to Buyer copies of all such written complaints, claims, notices,
requests, demands or threats, as well as any legal opinions, studies, market surveys and analyses relating to any such alleged infringement, violation or misappropriation. 
 (j) No Legal Proceedings in which the Company or any Affiliate alleges that any Person or Governmental Entity is infringing upon, or otherwise violating, any Group Owned Intellectual Property, are
pending, and none have been served by, instituted or asserted by the Company or any Affiliate To the knowledge of Seller and the Company, there is no valid basis for any such proceeding or claim. The Company and Seller have provided to Buyer copies
of all correspondence, legal opinions, or written complaints, claims, notices or threats concerning the infringement, violation or misappropriation of any Group Owned Intellectual Property. 

  
 -16 -

 EXECUTION COPY 
  

 (k) The Company has obtained from all individuals who are or have been involved in the
development or invention of any Company Owned Intellectual Property (as employees of the Company, as consultants, as employees of consultants or otherwise) assignments of any and all rights of such individuals with respect thereto, and each
Affiliate owner of Affiliate Owned Intellectual Property has obtained from all individuals who are or have been involved in the development or invention of any Affiliate Owned Intellectual Property (as employees of such Affiliate, as consultants, as
employees of consultants or otherwise) assignments of any and all rights of such individuals with respect thereto. To the knowledge of Company and the Seller, no officer or employee of the Company is subject to any agreement with any other Person or
Governmental Entity which requires such officer or employee to assign any interest in any Intellectual Property developed during such officer’s or employee’s employment with Company to such Person or Governmental Entity. 

(l) The Company and, where applicable, each of its Affiliates, has taken all reasonable actions which are necessary or reasonable in
order to protect the Company Intellectual Property in a manner consistent with prudent commercial practice in the biopharmaceuticals industry. To the knowledge of the Company, Company, and with respect to the business of the Company and Company
Products, each of its Affiliates, has complied in all material respects with all applicable contractual and legal requirements pertaining to information privacy and security. No written complaint relating to an improper use or disclosure of, or a
breach in the security of, any such information has been made or threatened against Company or, with respect to any business of the Company or Company Products, any Affiliate of the Company. There has been no: (i) to the knowledge of the
Company, unauthorized disclosure of any third party proprietary or confidential information in the possession, custody or control of Company, or (ii) material breach of Company’s security procedures as a result of which confidential
information has been disclosed to a third person. The Company, and each applicable Affiliate of the Company, has use commercially reasonable efforts to police the quality of all goods and services sold, distributed or marketed under each of
trademark relating to any Product, and has use commercially reasonable efforts to enforce adequate quality control measures to ensure that no trademarks relating to any Product that it has licensed to others shall be deemed to be abandoned.

 (m) The Company and its Affiliates has not sought, applied for nor received any support, funding, resources or assistance
from any Governmental Entity in connection with the any Company Product or any facilities or equipment used in connection therewith. 
 3.14. Inventory. All inventory of the Company, taken as a whole, whether or not reflected on the Most Recent Net Assets Statement, is usable and saleable in the Ordinary Course of Business, except
for obsolete items and items of below-standard quality, all of which have been written-off or written-down to the estimated net realizable value on the Most Recent Net Assets Statement. All inventories not written-off have been priced at the lower
of cost or market on a first-in, first-out basis. 

  
 - 17 -

 EXECUTION COPY 
  

 3.15. Contracts. 

(a) Section 3.15 of the Seller Disclosure Schedule lists the following agreements (written or oral) to which the Company is a
party or by which any asset or property of the Company is bound (including all amendments thereto and modifications thereof, waivers thereunder, and termination notices and agreements with respect thereto): 

(i) all agreements with Mundipharma, Maruho, Endo Pharmaceuticals, Enzon, and/or Zeneus Pharmaceuticals, any portion of which is (or is
claimed by any person to be) currently in effect; 
 (ii) any agreement (or group of related agreements) for the purchase or
sale of products or for the furnishing or receipt of services (A) which calls for performance over a period of more than one year, or (B) which involves more than the sum of [**] dollars ($[**]), or (C) in which the Company has
granted manufacturing, marketing, sale or distribution rights, “most favored nation” pricing provisions or marketing or distribution rights relating to any product or territory, or (D) in which the Company has agreed to purchase a
minimum quantity of goods or services or has agreed to purchase goods or services exclusively from a certain party; 
 (iii)
any agreement concerning the establishment or operation of a partnership, joint venture or limited liability company; 
 (iv)
any agreement (or group of related agreements) under which it has created, incurred, assumed or guaranteed (or may create, incur, assume or guarantee) indebtedness (including capitalized lease obligations) involving more than [**] dollars ($[**]) or
under which it has imposed (or may impose) an Encumbrance on any of its assets, tangible or intangible; 
 (v) any agreement
for the disposition of any significant portion of the assets or business of the Company (other than sales of products in the Ordinary Course of Business) or any agreement for the acquisition of the assets or business of any other entity (other than
purchases of inventory or components in the Ordinary Course of Business); 
 (vi) any agreement concerning confidentiality or
noncompetition; 
 (vii) any employment, severance or consulting agreement; 

(viii) any agreement involving any current or, to the knowledge of Seller and the Company, former officer, director or stockholder of
the Company or, to the knowledge of Seller and the Company, any Affiliate thereof; 
 (ix) any agreement under which the
consequences of a default or termination would reasonably be expected to have a Company Material Adverse Effect; 
 (x) any
agreement which contains any provisions requiring the Company to indemnify any other party (excluding indemnities contained in agreements for the purchase, sale or license of products entered into in the Ordinary Course of Business); 

  
 - 18 -

 EXECUTION COPY 
  

 (xi) any agreement (or group of related agreements) for the lease of personal property
from or to third parties providing for lease payments in excess of [**] dollars ($[**]) per annum or having a remaining term longer than three (3) months; and 
 (xii) any other agreement (or group of related agreements) either involving more than [**] dollars ($[**]) or not entered into in the Ordinary Course of Business. 

(b) The Company has delivered to Buyer a complete and accurate copy of each agreement required by the terms of Section 3.13 or
3.15 to be listed in Section 3.13 or Section 3.15 of the Seller Disclosure Schedule (each a “Material Contract” and collectively, the “Material Contracts”). With respect to each agreement so
listed: (i) the agreement is legal, valid, binding and enforceable and in full force and effect as against the Company and, to the knowledge of Seller and the Company, each other party thereto; and (ii) neither the Company nor, to the
knowledge of Seller and the Company, any other party, is in breach or violation of, or default under, any such agreement, and no event has occurred, is pending or, to the knowledge of Seller and the Company, is threatened, which, after the giving of
notice, with lapse of time, or otherwise, would constitute a breach or default by the Company or, to the knowledge of Seller and the Company, any other party under such agreement. With respect to the termination of that certain license agreement
with Endo Pharmaceuticals, Inc., the Company has no financial obligations to Endo Pharmaceuticals, Inc. other than as set forth in the Endo Termination Agreement. 
 3.16. Accounts Receivable. All accounts receivable of the Company reflected on the Most Recent Net Assets Statement (other than those paid since such date and other than accounts receivable to be
eliminated pursuant to items “c” and “e” of Schedule 6.12) are valid receivables subject to no setoffs or counterclaims and are, to the knowledge of Seller and the Company, collectible within ninety (90) days after
the date on which it first became due and payable consistent with the past practices of the Company, net of the applicable reserve for bad debts on the Most Recent Net Assets Statement. A complete and accurate list of the accounts receivable
reflected on the Most Recent Net Assets Statement, showing the aging thereof, is included in Section 3.16 of the Seller Disclosure Schedule. All accounts receivable of the Company that have arisen since the Most Recent Net Assets
Statement Date (other than accounts receivable to be eliminated pursuant to items “c” and “e” of Schedule 6.12) are valid receivables subject to no setoffs or counterclaims and are, to the knowledge of Seller and the
Company, collectible within ninety (90) days after the date on which it first became (or becomes) due and payable consistent with the past practices of the Company net of the applicable reserve for bad debts in an amount proportionate to the
reserve shown on the Most Recent Net Assets Statement. The Company has not received any written notice from an account debtor stating that any account receivable in an amount in excess of [**] dollars ($[**]) is subject to any contest, claim or
setoff by such account debtor. 
 3.17. Powers of Attorney. There are no outstanding powers of attorney executed on
behalf of the Company. 
 3.18. Insurance. Section 3.18 of the Seller Disclosure Schedule lists and provides
a summary of the material terms of each insurance policy (including fire, theft, casualty, comprehensive general liability, workers compensation, business interruption, environmental, 

  
 - 19 -

 EXECUTION COPY 
  

 
product liability and automobile insurance policies and bond and surety arrangements) which have been issued and delivered to the Company to which the Company is a party, all of which are in full
force and effect. True and complete copies of each insurance policy held by the Company for the benefit of the Company and so identified in Section 3.18 of the Seller Disclosure Schedule have been provided to Buyer. There is no material
claim pending under any such policy as to which coverage has been denied or, to the knowledge of Seller and the Company, questioned or disputed by the underwriter of such policy. All premiums due and payable under all such policies have been paid,
the Company is not liable for retroactive premiums or similar payments, and the Company is otherwise in compliance in all material respects with the terms of such policies. To the knowledge of Seller and the Company, except as set forth in
Section 3.18 of the Seller Disclosure Schedule, there has been no threatened termination of, or premium increase with respect to, any such policy. 
 3.19. Litigation. Except as set forth in Section 3.19 of the Seller Disclosure Schedule, there is no Legal Proceeding which is pending or has been threatened in writing against the
Company which (a) seeks either damages in excess of [**] dollars ($[**]) or equitable relief or (b) in any manner challenges or seeks to prevent, enjoin, alter or delay the transactions contemplated by this Agreement. Except as set forth
in Section 3.19 of the Seller Disclosure Schedule, there are no judgments, orders or decrees outstanding against the Company, and there are no arbitration awards outstanding against the Company that have not been paid in full.

 3.20. Warranties. No product or service manufactured, sold, leased, licensed or delivered by the Company is subject to
any guaranty, warranty, right of return, right of credit or other indemnity other than (i) the applicable standard terms and conditions of sale of the Company, which are set forth in Section 3.20 of the Seller Disclosure Schedule
and (ii) manufacturers’ warranties for which the Company has no liability. Section 3.20 of the Seller Disclosure Schedule sets forth the aggregate expenses incurred by the Company in fulfilling their obligations under their
guaranty, warranty, right of return and indemnity provisions during each of the fiscal years and the interim period covered by the Financial Statements; and neither Seller nor the Company knows of any reason why such expenses should significantly
increase as a percentage of sales in the future. 
 3.21. Employees. 

(a) Section 3.21 of the Seller Disclosure Schedule contains a list of all employees of the Company whose annual rate of
compensation exceeds [**] dollars ($[**]) per year, along with each such person’s position. Seller has heretofore disclosed to Buyer the current annual rate of compensation of each such person. Each person who is or at any time since
January 1, 2004 or, to the knowledge of Seller and the Company, since March 11, 1999 (inclusive) was or has been) an employee of the Company has entered into a confidentiality/assignment of inventions agreement with the Company, and a copy
of the form of agreement has previously been delivered to Buyer. Section 3.21 of the Seller Disclosure Schedule contains a list of all employees of the Company who are a party to a non-competition agreement with the Company; copies of
such agreements have previously been delivered to Buyer. All of the agreements referenced in the two preceding sentences will continue to be legal, valid, binding and enforceable and in full force and effect against the Company and, to the knowledge
of Seller and the Company, against such employee immediately following the 

  
 - 20 -

 EXECUTION COPY 
  

 
Closing in accordance with the terms thereof as in effect immediately prior to the Closing. Section 3.21 of the Seller Disclosure Schedule contains a list of all employees of the
Company who are not citizens of the United States. To the knowledge of Seller and the Company, no employee or group of employees whose departure could result in a Company Material Adverse Effect has any plans to terminate employment with the
Company. 
 (b) The Company is not a party to or bound by any collective bargaining agreement, nor has any of them experienced
any strikes, grievances, claims of unfair labor practices or other collective bargaining disputes. Neither Seller nor the Company has knowledge of any organizational effort made or threatened, either currently or within the past two years, by or on
behalf of any labor union with respect to employees of the Company. 
 (c) The Company has (and after the Closing will have) no
liability to any employee under any stock, option or similar plan or scheme of Seller. Seller is and will remain solely responsible, and the Company will have no liability or obligation, for the Company’s Stay Incentive Program or any Stay
Incentive Agreement or any other management retention plan, scheme, arrangement or agreement with or in favor of any Company executive or employee. 
 3.22. Employee Benefits. 
 (a) Section 3.22(a) of the Seller
Disclosure Schedule contains a complete and accurate list of all Company Plans. Complete and accurate copies of (i) all Company Plans which have been reduced to writing, (ii) written summaries of all unwritten Company Plans,
(iii) all related trust agreements, insurance contracts and summary plan descriptions, and (iv) all annual reports filed on IRS Form 5500, 5500C or 5500R and (for all funded plans) all plan financial statements for the last three
(3) plan years for each Company Plan, have been delivered to Buyer. 
 (b) Each Company Plan has been administered in all
material respects in accordance with its terms and each of the Company and the ERISA Affiliates has in all material respects met its obligations with respect to each Company Plan and has made all required contributions thereto. The Company, each
ERISA Affiliate and each Company Plan are in compliance in all material respects with the currently applicable provisions of ERISA and the Code and the regulations thereunder (including Section 4980 B of the Code, Subtitle K, Chapter 100 of the
Code and Sections 601 through 608 and Section 701 et seq. of ERISA). All filings and reports as to each Company Plan required to have been submitted to the Internal Revenue Service or to the United States Department of Labor have been duly
submitted. No Company Plan that is qualified under Section 401(a) of the Code has assets that include securities issued by the Company or any ERISA Affiliate. 
 (c) There are no Legal Proceedings (except claims for benefits payable in the normal operation of the Company Plans and proceedings with respect to qualified domestic relations orders) against or
involving any Company Plan or asserting any rights or claims to benefits under any Company Plan that could give rise to any material liability. 

  
 - 21 -

 EXECUTION COPY 
  

 (d) All the Company Plans that are intended to be qualified under Section 401(a) of
the Code have received determination letters, or opinion letters relating to prototype plans upon which the Company is entitled to rely, from the Internal Revenue Service to the effect that such Company Plans are qualified and the plans and the
trusts related thereto are exempt from federal income taxes under Sections 401(a) and 501(a), respectively, of the Code, no such determination letter has been revoked and revocation has not been threatened, and no act or omission has occurred with
respect to any such Company Plan, that would adversely affect its qualification or materially increase its cost. Each Company Plan which is required to satisfy Section 401(k)(3) or Section 401(m)(2) of the Code has been tested for
compliance with, and satisfies the requirements of Section 401(k)(3) and Section 401(m)(2) of the Code for each plan year ending prior to the Closing Date. 
 (e) Neither the Company nor any ERISA Affiliate has ever maintained an Employee Benefit Plan subject to Section 412 of the Code or Title IV of ERISA. 

(f) At no time has the Company or any ERISA Affiliate been obligated to contribute to any “multiemployer plan” (as defined in
Section 4001(a)(3) of ERISA). 
 (g) There are no unfunded obligations under any Company Plan providing benefits after
termination of employment to any employee of the Company (or to any beneficiary of any such employee), including but not limited to retiree health coverage and deferred compensation, but excluding continuation of health coverage required to be
continued under Section 4980B of the Code or other applicable law and insurance conversion privileges under state law. The assets of each Company Plan which is funded are reported at their fair market value on the books and records of such
Company Plan. 
 (h) No act or omission has occurred and no condition exists with respect to any Company Plan that would subject
the Company or any ERISA Affiliate to (i) any material fine, penalty, tax or liability of any kind imposed under ERISA or the Code or (ii) any contractual indemnification or contribution obligation protecting any fiduciary, insurer or
service provider with respect to any Company Plan. 
 (i) No Company Plan is funded by, associated with or related to a
“voluntary employee’s beneficiary association” within the meaning of Section 501(c)(9) of the Code. 
 (j)
Each Company Plan is amendable and terminable unilaterally by the Company at any time without liability or expense to the Company or such Company Plan as a result thereof (other than for benefits accrued through the date of termination or amendment
and reasonable administrative expenses related thereto) and no Company Plan, plan documentation or agreement, summary plan description or other written communication distributed generally to employees by its terms prohibits the Company from amending
or terminating any such Company Plan. 
 (k) The Company has not made any payment, is not obligated to make any payment, and is
not a party to any agreement that could obligate it to make any payment that may be treated as an “excess parachute payment” under Section 280G of the Code (without regard to Sections 280G(b)(4) and 280G(b)(5) of the Code) or that may
be subject to the tax imposed by Section 4999 of the Code. 

  
 - 22 -

 EXECUTION COPY 
  

 (l) Section 3.22(l) of the Seller Disclosure Schedule sets forth the policy
of the Company with respect to accrued vacation, accrued sick time and earned time off and the amount of such liabilities as of the date of this Agreement. 
 (m) Each Company Employee Plan that is a “nonqualified deferred compensation plan” (as defined in Code Section 409A(d)(1) has been operated since January 1, 2005 in good faith
compliance with Code Section 409A and IRS Notice 2005-1. No Company Employee Plan that is a “nonqualified deferred compensation plan” has been materially modified (as determined under Notice 2005-1) after October 3, 2004. No
event has occurred that would be treated by Code Section 409A(b) as a transfer of property for purposes of Code Section 83. No stock option or equity unit option granted under any Company Employee Plan has an exercise price that has been
or may be less than the fair market value of the underlying stock or equity units (as the case may be) as of the date such option was granted or has any feature for the deferral of compensation other than the deferral of recognition of income until
the later of exercise or disposition of such option. 
 3.23. Environmental Matters. 

(a) Except as set forth in Section 3.23(a) of the Seller Disclosure Schedule, the Company has complied and currently is in
compliance in all material respects with all applicable Environmental Laws. There is no pending or, to the knowledge of Seller and the Company, threatened civil or criminal litigation, notice of violation, noncompliance or penalty assessment, formal
administrative proceeding, or investigation, inquiry or information request by any Governmental Entity, relating to any Environmental Law involving the Company. Except as set forth in Section 3.23(a) of the Seller Disclosure Schedule,
the Company has not been the subject of any such litigation, proceeding, investigation, inquiry or information request, or received any such notice, within the last three (3) years. 

(b) Except as set forth in Section 3.23(b) of the Seller Disclosure Schedule, the Company has no material liabilities or
obligations arising from the release of any Materials of Environmental Concern into the environment. 
 (c) Except as set forth
in Section 3.23(c) of the Seller Disclosure Schedule, the Company is not a party to or bound by any court order, administrative order, consent order or other agreement between the Company and any Governmental Entity entered into in
connection with any legal obligation or liability arising under any Environmental Law. 
 (d) Set forth in
Section 3.23(d) of the Seller Disclosure Schedule is a list of all documents (whether in hard copy or electronic form) that contain any environmental reports, notices of noncompliance, violation or penalty assessment, investigations and
audits relating to premises currently or previously owned or operated by the Company (whether conducted by or on behalf of the Company or a third party, and whether done at the initiative of the Company or directed by a Governmental Entity or other
third party) which were received by or issued to the Company since the acquisition of the Company by Parent or Seller and of which the Company has possession or to which the Company has access. A complete and accurate copy of each such document has
been provided by Seller to Buyer. 

  
 - 23 -

 EXECUTION COPY 
  

 (e) Section 3.23(e)(1) of the Seller Disclosure Schedule sets forth a list
of all material Permits issued to or held by the Company pursuant to any Environmental Law. Except as set forth in Section 3.23(e)(2) of the Seller Disclosure Schedule, (i) the Permits listed in Section 3.23(e)(1) of the
Seller Disclosure Schedule are the only material Permits pursuant to Environmental Laws that are required for the Company to conduct its business as presently conducted, (ii) each such listed Permit is in full force and effect,
(iii) the Company is in compliance in all material respects with the terms of each Permit listed in Section 3.23(e)(1) of the Seller Disclosure Schedule, and (iv) to the knowledge of Seller and the Company, no suspension or
cancellation of any Permit listed in Section 3.23(e)(1) of the Seller Disclosure Schedule is threatened and there is no basis for believing that any such Permit listed in Section 3.23(e)(1) of the Seller Disclosure Schedule
will not be renewable upon expiration. A complete and accurate copy of each Permit listed in Section 3.23(e)(1) of the Seller Disclosure Schedule has been provided by Seller to Buyer. 

(f) Neither Seller nor the Company has any knowledge of any material environmental liability of any solid or hazardous waste transporter
or treatment, storage or disposal facility that has been used by the Company. 
 (g) The Company has installed equipment
sufficient to discharge wastewater from each of the Company’s facilities in connection with the business as presently conducted at each such facility in compliance with the conditions and limitations set forth in the current wastewater
discharge permits issued by any Governmental Entity for each such facility. 
 3.24. Legal Compliance. The Company is
currently conducting, and has at all times since the acquisition of the Company by Seller conducted, its businesses in compliance in all material respects with each applicable law (including rules and regulations thereunder) of any Governmental
Entity. The Company has not received any written or, to the knowledge of Seller and the Company, other notice or communication from any Governmental Entity or qui tam relator alleging noncompliance in any material respect with any applicable law,
rule or regulation. 
 3.25. Customers and Suppliers. Section 3.25 of the Seller Disclosure Schedule sets
forth a list of (a) each customer that accounted for more than one percent (1%) of the revenues of the Company during the last full fiscal year or the interim period through the Most Recent Net Assets Statement Date and the amount of
revenues accounted for by such customer during each such period and (b) each supplier that is the sole supplier of any significant product or service to the Company. No such customer or supplier has indicated within the past year that it will
stop, or decrease the rate of, buying products or supplying products, as applicable, to the Company in any material amount. No unfilled customer order or commitment obligating the Company or to process, manufacture or deliver products or perform
services will result in a loss to the Company upon completion of performance. No purchase order or commitment of the Company is in excess of normal requirements, nor are prices provided therein in excess of current market prices for the products or
services to be provided thereunder. 
 3.26. Permits. Section 3.26 of the Seller Disclosure Schedule sets
forth a list of all material Permits issued to or held by the Company. Such listed Permits are the only material Permits that are required for the Company to conduct its business as presently conducted. Each

  
 - 24 -

 EXECUTION COPY 
  

 
such Permit is in full force and effect; the Company is in compliance in all material respects with the terms of each such Permit; and, to the knowledge of Seller and the Company, no suspension
or cancellation of such Permit is threatened and there is no basis for believing that such Permit will not be renewable upon expiration. 
 3.27. Certain Business Relationships With Affiliates. Neither Seller nor any other Affiliate of the Company (a) owns any property or right, tangible or intangible, which is used in the
business of the Company, (b) has any claim or cause of action against the Company, or (c) owes any money to, or is owed any money by, the Company. Section 3.27 of the Seller Disclosure Schedule describes any transactions or
relationships between the Company and any Affiliate thereof which occurred or have existed since the beginning of the time period covered by the Financial Statements. 
 3.28. Books and Records. The minute books and other similar records of the Company contain complete and accurate records of all actions taken at any meetings of the Company’s stockholders,
Board of Directors or any committee thereof and of all written consents executed in lieu of the holding of any such meeting. The books and records of the Company accurately reflect in all material respects the business assets, liabilities, condition
(financial or otherwise) and results of operations of the Company and have been maintained in accordance with good business and bookkeeping practices. Section 3.28 of the Seller Disclosure Schedule contains a list of all bank accounts
and safe deposit boxes of the Company and the names of persons having signature authority with respect thereto or access thereto. 
 3.29. Projections. The projections set forth in the “SkyePharma, Inc. Business Plan 2007-2010” were prepared in good faith by the Company on the basis of assumptions believed by the
Company at the time of such preparation to be reasonable and information believed by the Company at the time of such preparation to be reliable and represented the best estimate of the Company at the time of such preparation of the matters set forth
therein. Such projections were prepared in or about summer of 2006 and were based on assumptions, information and estimates that may or may not still be operative. Buyer acknowledges and understands that neither such Business Plan nor the
projections contained therein constitute a promise, guarantee or representation of the financial, product development, sales, marketing or other performance or prospects of the Company. 

3.30. Regulation. Solely for purposes of this Section 3.30, (i) “Products” shall mean the
products that the Company (or, for and on behalf of the Company) (A) currently manufactures, markets, sells or licenses, or (B) have in clinical development, including products known as DepoCyt, DepoDur, and DepoBupivacaine, and
(ii) “Product Candidates” shall mean those products currently under pre-clinical research and development by the Company, including those products that are based on or derived from the DepoFoam or Biosphere technologies.

 (a) Compliance with Applicable Laws and Regulations. The Company is, and has been, in compliance in all material
respects with all laws, rules, regulations, guidances and orders applicable to the research and development, manufacturing, processing, distribution, labeling, storage, testing, specifications, advertising and promotion, adverse event reporting,
sale or marketing of any Product or Product Candidate by or on behalf of the Company, including the U.S. Federal Food, Drug, and Cosmetic Act (“FDCA”) and the Public Health Service Act

  
 - 25 -

 EXECUTION COPY 
  

 
(“PHSA”) and their applicable implementing regulations, all comparable state laws, and all other laws enforced by the U.S. Food and Drug Administration (“FDA”)
or Drug Enforcement Administration (“DEA”), any comparable state or local regulatory authority, the U.K. Medicines and Healthcare products Regulatory Agency (“MHPRA”), the European Medicines Evaluation Agency
(“EMEA”), Health Canada (“HC”), and other comparable governmental or regulatory authority in each jurisdiction where the Products and Product Candidates are (or are currently proposed to be) developed, processed,
tested, manufactured, labeled, stored, distributed, sold, or marketed, as applicable, by or on behalf of the Company (each, a “Relevant Regulatory Authority,” and collectively, the “Relevant Regulatory
Authorities”). 
 (b) Eligibility for Government Programs. The Company is not debarred, excluded or restricted
in any manner from participation in, any government program related to drug and biological products or any government funded health care program and, to its knowledge, does not and has not employed or obtained products or services from any debarred
or otherwise excluded or restricted individual. 
 (c) Manufacturing Operations. All manufacturing operations conducted
by the Company have been and are being conducted in compliance, in all material respects, with the FDA’s or Relevant Regulatory Authorities’ current Good Manufacturing Practices regulations, policies, and requirements for drug and
biological products. In addition, each of Seller and the Company is in material compliance with all applicable registration and listing requirements set forth in 21 U.S.C. §360 and 21 CFR Part 207 and all similar applicable laws and
regulations. Except as disclosed in Section 3.30(c)(1) of the Seller Disclosure Schedule, there are no FDA Form 483 notices or similar notices with respect to alleged violation of, or non-compliance with, any laws or regulations in
connection with the facilities where Company manufactures any Products or Product Candidates. Except as disclosed in Section 3.30(c)(2) of the Seller Disclosure Schedule, to the knowledge of Seller and the Company, no Third Party
manufacturer of Products or Product Candidates or active pharmaceutical ingredient or excipient used in any Products or Product Candidates has received an FDA Form 483 notice or similar notice with respect to alleged violation of, or non-compliance
with, any laws or regulations in connection with any facility where such Third Party manufacturer manufactures any Product or Product Candidate or active pharmaceutical ingredient or excipient used in any Product or Product Candidate. 

(d) Preclinical Tests and Clinical Trials. 
 (i) To the knowledge of Seller and the Company, all clinical investigations and trials (including any post-marketing studies), animal studies and preclinical tests and investigations conducted or
sponsored by the Company (or on behalf of the Company) (“Preclinical Tests and Clinical Trials”) relating to any Product or Product Candidate have been, and if still pending, are being, conducted in compliance in all material
respects with all applicable laws, rules, and regulations, administered or issued by the FDA or any other Relevant Regulatory Authority where the Preclinical Tests and Clinical Trials are being conducted and the requirements and approvals of the
applicable institutional review boards or similar entities, including the protocols and informed consents, as applicable, with respect to each Clinical Trial. 

  
 - 26 -

 EXECUTION COPY 
  

 (ii) Neither Seller nor the Company has received any written notice from the FDA or any
other Relevant Regulatory Authority where the Preclinical Tests or Clinical Trials are being conducted or any institutional review board or similar entity with jurisdiction over a particular Clinical Trial requiring the termination, suspension,
clinical hold, or material modification of any animal study, preclinical study or clinical trial conducted or sponsored by or on behalf of the Company. The Company has not suspended, put on hold or terminated prior to completion any Preclinical Test
or Clinical Trial due to adverse events or other safety or efficacy reasons reported during the conduct of such Preclinical Test or Clinical Trial. 
 (e) Status of Applications. Except as disclosed in Section 3.30(e) of the Seller Disclosure Schedule, the Company has not received any information from the FDA or any other Relevant
Regulatory Authority that states or would reasonably be interpreted to mean that any application or supplemental application for marketing approval of any Product or Product Candidate currently pending before the FDA or any other Relevant Regulatory
Authority may not receive approval. 
 (f) No Suspensions or Recalls. Neither Seller nor the Company nor any of their
respective representatives, nor, to the knowledge of Seller and the Company, any licensee or assignee of any Product or Product Candidate has received any notice that the FDA or any other Relevant Regulatory Authority has initiated, or threatened to
initiate, any action to suspend or otherwise restrict the manufacture, sale, or distribution of any Product or Product Candidate. Except as set forth in Section 3.30(f) of Seller Disclosure Schedule, the Company has not conducted any
recalls of any Product. There are no pending or, to the knowledge of Seller and the Company, threatened civil, criminal or administrative actions, suits, demands, claims, hearings, investigations, proceedings, complaints, voluntary or involuntary
market withdrawals, field corrective actions, safety alerts, destruction orders, seizures, injunctions, adverse letters concerning promotional materials, or other regulatory enforcement actions related to any Product. To the knowledge of Seller and
the Company, there is no act, omission, event, or circumstance that would reasonably be expected to give rise to any such action. To the knowledge of Seller and the Company, there are no known material adverse effects from the use of any marketed
Products which are not disclosed in the Products’ labeling, and there are no known material adverse effects from the use of any investigational Products which have not been disclosed to the clinical investigators. 

(g) No False Statements. Neither Seller nor the Company nor, to the knowledge of Seller and the Company, any of their respective
officers, employees or agents acting for Seller or the Company is subject to any pending or, to the knowledge of Seller and the Company, threatened, investigation by (A) the FDA pursuant to its “Fraud, Untrue Statements of Material Facts,
Bribery, and Illegal Gratuities” policy set forth in 56 Fed. Reg. 46191 (September 10, 1991) or any amendments thereto, (B) the Department of Health and Human Services Office of Inspector General, Department of Justice, or other
Governmental Entity pursuant to the Federal Anti-Kickback Statute (42 U.S.C. §1320a-7(b)), or the Federal False Claims Act, or similar state or foreign law. To the knowledge of Seller and the Company, Seller and the Company have not and none of
their respective officers, employees or agents acting for Seller or the Company has committed any act, made any statement or failed to make any statement that would reasonably be expected to provide a basis for action under any of the statutes,
regulations, 

  
 - 27 -

 EXECUTION COPY 
  

 
and policy referred to in the foregoing statement. Seller and the Company have not and none of their respective officers, employees or agents acting for Seller or the Company has been convicted
of any crime or engaged in any conduct that, to the knowledge of Seller and the Company, would reasonably be expected to result in (A) debarment under 21 U.S.C. §335a or any similar state or foreign law or (B) exclusion under 42
U.S.C. §1320a-7 or any similar state or foreign law. 
 (h) Correspondence and Reports. Seller has delivered or made
available to Buyer (by deposit into the online and physical data room maintained by Seller in connection with the transactions contemplated by this Agreement followed by written notice of such deposit to Buyer) true, correct and complete copies of:

 (i) all notices of inspectional observations, establishment inspection reports and any other documents received from the FDA
or any other Relevant Regulatory Authority, that indicate a lack of compliance with the regulatory requirements of the FDA or any other Relevant Regulatory Authority, including any regulatory or warning letters or notice under 21 U.S.C. § 335
with respect to any Product or Product Candidate; 
 (ii) all written correspondence or reports to or from the FDA and each
Relevant Regulatory Authority, all written summaries of meetings, with the FDA and each Relevant Regulatory Authority, and all other written records relating to material contacts between Seller, the Company or any of their representatives, on the
one hand, and the FDA or any other Relevant Regulatory Authority, on the other hand, relating to the Company or any Product or Product Candidate; 
 (iii) each New Drug Application (“NDA”) and each Investigational New Drug Application (“IND”), and each similar state or foreign regulatory submission made by or on
behalf of the Company, including all supplements and amendments thereto which relates to any Product or Product Candidate. 

(i) No Proceedings. To the knowledge of Seller and the Company, there are no proceedings pending with respect to any violation or
alleged violation by Seller or the Company of the FDCA, FDA regulations adopted thereunder, the Controlled Substance Act or any other legislation or regulation promulgated by any other Governmental Entity. 

(j) Certain Claims and Payments. 
 (i) To the knowledge of Seller and the Company, the Company has not (i) solicited, received, paid or offered to pay any remuneration, directly or indirectly, overtly or covertly, in cash or kind, for
the purpose of making or receiving any referral, purchase, lease, order, or recommendation of a purchase, lease, or order, which violated any applicable anti-kickback or similar law, including the Anti-Kickback Statute, or any applicable state
anti-kickback law, or (ii) submitted or caused to be submitted any claim for payment to any payment program in violation of any laws relating to false claims or fraud, including the Federal False Claims Act, 31 U.S.C. § 3729 and 18 U.S.C.
§ 287 (the “Federal False Claims Act”); the Program Fraud Civil Remedies Act, 31 U.S.C. § 3802 (the “Program Fraud Civil Remedies Act”); or any applicable state false claim or fraud law. 

  
 - 28 -

 EXECUTION COPY 
  

 (ii) The Company has complied with all applicable data security and privacy standards,
laws, and regulations regarding health information, including without limitation all applicable privacy, data security, and data security breach notification laws or regulations, and contractual obligations undertaken by the Company pursuant to such
laws or regulations. 
 (iii) Section 3.30(j) of the Seller Disclosure Schedule lists all written claims or
statements (including all material correspondence) received from Governmental Entities during the three year period prior to the Closing which alleges (i) any material violation of any applicable rule, regulation, policy or requirement of any
federal or state government funded healthcare program with respect to any activity, practice or policy of the Company, including any claim for payment or reimbursement submitted or caused to be submitted by the Company or any payment or
reimbursement paid to the Company. To the knowledge of Seller and the Company, the Company is not in material violation of any applicable rule, regulation, policy or requirement of any federal or state government funded healthcare program and there
is no reasonable basis to anticipate any investigation or inquiry, or the assertion of any claim or demand by any Governmental Entities with respect to any of the activities, practices, policies or claims of the Company, or any payments or
reimbursements claimed by the Company, in each case concerning or relating to any federal or state government funded health care program. The Company is not the subject of any outstanding audit by any Governmental Entities. To the knowledge of
Seller and the Company, there are no reasonable grounds to anticipate any such audit, except such audits in the ordinary course of review. 
 (k) Compliance with Certain Statutes and Regulations. 
 (i) To the
knowledge of Seller and the Company, the Company has not submitted or caused to be submitted any claim to any government-funded health care program in connection with any referrals that violated any applicable self-referral law, including the
Federal Ethics in Patient Referrals Act, 42 U.S.C. § 1395nn (known as the “Stark Law”), or any applicable state self-referral law. 
 (ii) Neither the Company nor, to the knowledge of Seller and the Company, any of their respective officers, directors or employees, acting in their capacities as such, is or has been involved in any
activities which are, or are alleged in writing by any qui tam relator or Governmental Entity to be, prohibited under the federal Medicare and Medicaid statutes, including 42 U.S.C. §§ 1320a-7, 1320a-7a, 1320a-7b, 1395nn, 31 U.S.C. §
3802, 18 U.S.C. §1347, § 287, §1001, and § 1035, or the federal CHAMPUS/TRICARE statute, or the regulations promulgated pursuant to such federal statutes. 
 (l) Authorizations and Permits. To the knowledge of Seller and the Company, Seller and the Company have received approval from the FDA and all other applicable Relevant Regulatory Authorities of
all registrations, applications, licenses, requests for exemptions, permits and other regulatory authorizations necessary to conduct the business of the Company as currently conducted (the “Material Permits”) and all such Material
Permits are valid and in full force and effect. To the knowledge of Seller and the Company, any third party which is a manufacturer of any Product or Product Candidate, or active pharmaceutical ingredient or excipient thereof, for the Company is in
compliance in all material respects with all 

  
 - 29 -

 EXECUTION COPY 
  

 
approvals, registrations, applications, licenses, requests for exemptions, permits and other regulatory authorizations of the FDA and other Relevant Regulatory Authorities insofar as the same
pertain to the manufacture of any Product or Product Candidate, or active pharmaceutical ingredient or excipient thereof, for the Company. To the knowledge of Seller and the Company, no Relevant Regulatory Authority is considering revoking,
withdrawing, suspending, canceling, terminating or modifying any Material Permit. 
 (m) Rights and Obligations Respecting
Other Products, Product Candidates, and Regulatory Matters. Except as set forth in Section 3.30(m) of the Seller Disclosure Schedule, there are no NDAs, ANDAs, INDs, Drug Master Files (“DMF”), regulatory agent
relationships, or other regulatory applications, dossiers, licenses, permits, or filings of any kind in any jurisdiction, for which the Company has any right, interest, ownership, obligation, or authority, other than those related to DepoCyt,
DepoDur, DepoBupivacaine and products related to the Biosphere technology. To the knowledge of Seller and the Company, the Company has complied with all legal and regulatory requirements and obligations administered or enforced by all Relevant
Regulatory Authorities in connection with the NDAs, ANDAs, INDs, DMFs, and regulatory agent relationships identified in Section 3.30(m) of the Seller Disclosure Schedule. 

3.31. Disclosure. No representation or warranty by Seller contained in this Agreement or any Ancillary Agreement, and no statement
contained in the Seller Disclosure Schedule or any other document, certificate or other instrument delivered or required to be delivered by or on behalf of Seller or the Company pursuant to this Agreement or any of the Ancillary Agreements, contains
or will contain any untrue statement of a material fact or omits or will omit to state any material fact necessary, in light of the circumstances under which it was or will be made, in order to make the statements herein or therein not misleading.
Seller and the Company have not failed to disclose to Buyer any agreement, commitment, obligation, regulatory inquiry or notice, legal claim or liability of the Company (whether absolute or contingent) that (a) is known to Seller or the Company
or would be known to Seller or the Company after reasonable inquiry by them and (b) is not within the actual knowledge of Buyer and (c) would be reasonably considered to be material to the Company. Solely for purposes of this
Section 3.31, it is agreed that Buyer shall be presumed to have actual knowledge of the following documents that Seller has delivered or made available to Buyer and its legal and accounting advisers: (i) documents included in
electronic form on the Stringer Saul LLP “Project San Diego” CD’s dated November 2006 and delivered to Buyer and its legal and accounting advisers in November 2006; (ii) documents in paper form delivered to Buyer and its legal
and accounting advisers since November 17, 2006; (iii) documents in the online and physical data rooms on November 22, 2006 that have been maintained by the Company in connection with the transactions contemplated by this Agreement
and to which Buyer and its legal and accounting advisers were provided actual access (as listed in the indexes e-mailed to Buyer on November 22, 2006); and (iv) documents e-mailed to Buyer and its legal and accounting advisers after
November 22, 2006, or deposited after November 22, 2006 into the online and physical data rooms followed by written notice (including notice by e-mail) of such deposit, listing the documents so deposited, to Buyer. 

  
 - 30 -

 EXECUTION COPY 
  

 ARTICLE IV 
 REPRESENTATIONS AND WARRANTIES OF BUYER 
 Buyer represents and warrants to
Seller that the statements contained in this Article III are true and correct as of the date of this Agreement and will be true and correct as of the Closing as though made as of the Closing, except to the extent such representations and
warranties are specifically made as of a particular date (in which case such representations and warranties will be true and correct as of such date). 
 4.1. Organization, Qualification and Corporate Power. Buyer is a corporation duly organized, validly existing and in good standing under the laws of the state of its incorporation. Buyer is duly
qualified to conduct business and is in corporate and tax good standing under the laws of each jurisdiction in which the nature of its businesses or the ownership or leasing of its properties requires such qualification, except where the failure to
be so qualified or in good standing would not have a Buyer Material Adverse Effect. Buyer has all requisite corporate power and authority to carry on the businesses in which it is engaged and to own and use the properties owned and used by it. Buyer
has furnished or made available to Seller complete and accurate copies of its Certificate of Incorporation and By-laws. 
 4.2.
Authorization of Transaction. Buyer has all requisite power and authority to execute and deliver this Agreement and the Ancillary Agreements and to perform its obligations hereunder and thereunder. The execution and delivery by Buyer of this
Agreement and the Ancillary Agreements to which Buyer is a party and the consummation by Buyer of the transactions contemplated hereby and thereby have been duly and validly authorized by all necessary corporate action on the part of Buyer. This
Agreement has been duly and validly executed and delivered by Buyer and constitutes a valid and binding obligation of Buyer, enforceable against it in accordance with its terms. 

4.3. Noncontravention. Neither the execution and delivery by Buyer of this Agreement or the Ancillary Agreements to which it is a
party, nor the consummation by Buyer of the transactions contemplated hereby or thereby, will (a) conflict with or violate any provision of the charter or By-laws of Buyer, (b) require on the part of Buyer any filing with, or permit,
authorization, consent or approval of, any Governmental Entity, (c) conflict with, result in breach of, constitute (with or without due notice or lapse of time or both) a default under, result in the acceleration of obligations under, create in
any party any right to terminate, modify or cancel, or require any notice, consent or waiver under, any contract or instrument to which Buyer is a party or by which it is bound or to which its assets are subject, except for (i) any conflict,
breach, default, acceleration, termination, modification or cancellation which would not adversely affect the consummation of the transactions contemplated hereby or (ii) any notice, consent or waiver the absence of which would not adversely
affect the consummation of the transactions contemplated hereby, or (d) violate any order, writ, injunction, decree, statute, rule or regulation applicable to Buyer or any of its properties or assets. 

4.4. Brokers’ Fees. Buyer has no liability or obligation to pay any fees or commissions to any broker, finder or agent with
respect to the transactions contemplated by this Agreement or any of the Ancillary Agreements. 

  
 - 31 -

 EXECUTION COPY 
  

 4.5. Investment Representation. Buyer is acquiring the Shares from Seller for its
own account for investment and not with a view to, or for sale in connection with, any distribution thereof, nor with any present intention of distributing or selling the same; and, except as contemplated by this Agreement and the agreements
contemplated herein, Buyer has no present or contemplated agreement, undertaking, arrangement, obligation, indebtedness or commitment providing for the disposition thereof. 
 4.6. Funding. Buyer has heretofore obtained equity commitment letters (the “Commitment Letters”) covering the funding expected to be required for the consummation of the
transactions contemplated by this Agreement and naming Parent as a third party beneficiary, copies of which have heretofore been provided to Seller. Each such Commitment Letter is in full force and effect in the form heretofore provided to Seller.
Buyer has no reason to believe that the Commitment Letters will not be fully performed in accordance with the terms thereof. 

ARTICLE V 

COVENANTS 

5.1. Closing Efforts. Each of the Parties shall use its commercially reasonable efforts to take all actions and to do all things
necessary, proper or advisable to consummate the transactions contemplated by this Agreement, including using its commercially reasonable efforts to procure that (i) its representations and warranties remain true and correct in all material
respects through the Closing Date and (ii) the conditions to the obligations of the other Parties to consummate the transactions contemplated by this Agreement are satisfied. 

5.2. Governmental and Third-Party Notices and Consents. 
 (a) Each Party shall use its commercially reasonable efforts to obtain, at its expense, all waivers, permits, consents, approvals or other authorizations from Governmental Entities, and to effect all
registrations, filings and notices with or to Governmental Entities, as may be required for such Party to consummate the transactions contemplated by this Agreement and the Ancillary Agreements and to otherwise comply with all applicable laws and
regulations in connection with the consummation of the transactions contemplated by this Agreement and the Ancillary Agreements. Without limiting the generality of the foregoing, each Party shall use its commercially reasonable efforts to make all
necessary filings, and thereafter make any other required submissions, with respect to this Agreement and the transactions contemplated hereby, required under (i) the HSR Act and any other federal, state or foreign law designed to prohibit,
restrict or regulate actions for the purpose or effect of monopolization or restraint of trade (collectively “Antitrust Laws”), and to respond to any government requests for information under any Antitrust Law. The Parties will
consult and cooperate with one another, and consider in good faith the views of one another, in connection with any analyses, appearances, presentations, memoranda, briefs, arguments, opinions and proposals made or submitted by or on behalf of any
Party hereto in connection with proceedings under or relating to any Antitrust Law. Notwithstanding anything to the contrary in this Agreement, neither Party shall be obligated (A) to institute or pursue litigation or (B) to sell or
dispose of or hold separately (through a trust or otherwise) any assets or businesses. Buyer shall pay the filing fees of the notification reports required to be filed under the HSR Act. 

  
 - 32 -

 EXECUTION COPY 
  

 (b) Seller and the Company shall, and shall procure that Parent shall, use their
respective commercially reasonable efforts to obtain, at Seller’s and Parent’s expense, all such waivers, consents or approvals from third parties, and to give all such notices to third parties, as are required to be listed in the Seller
Disclosure Schedule. 
 5.3. Parent Shareholder Approval. As promptly as practicable and (subject to
receipt of approval by the UK listing authority) in no event more than ten (10) business days following the date of this Agreement (or, if later, three (3) business days after approval by the UK listing authority), Parent shall post a
circular containing a notice calling an extraordinary general meeting of the shareholders of Parent (“EGM”) to seek the requisite approval of Parent’s shareholders (the “Circular”), such meeting to be held on a
date as soon as practicable and in no event later than the thirtieth (30th) day following the posting of the Circular. Parent shall provide Buyer with reasonable opportunity to review and comment on the Circular, and no reference to Buyer or to the rights and obligations
of the Parties under this Agreement or any of the Ancillary Agreements shall be made in the Circular without Buyer’s consent, which shall not be unreasonably withheld by Buyer. To the fullest extent permitted by applicable law, (i) Parent
and its Board of Directors shall recommend that Parent’s shareholders vote to approve this Agreement and the transactions contemplated hereby and shall include such recommendation in the Circular, and (ii) neither Parent nor its Board of
Directors nor any committee thereof shall withdraw or modify, or propose or resolve to withdraw or modify, in any manner adverse to Buyer, such recommendation; provided, that nothing in this Agreement shall prevent Parent’s Board of
Directors from withdrawing such recommendation prior to the EGM if in the exercise of their fiduciary obligations (determined in good faith by Parent’s Board of Directors following consultation with outside counsel) the failure to take such
action would result in a breach of their fiduciary obligations. Parent shall use its commercially reasonable efforts and take all action that is reasonable and lawful to solicit its shareholders to vote (or to deliver proxies) in favor of approval
of this Agreement and the transactions contemplated hereby and shall take all other reasonable and lawful action necessary or advisable to secure the required approvals of Parent’s shareholders. Without limiting the generality of the foregoing
provisions, Dr. Argeris (Jerry) Karabelas, Frank Condella, Ken Cunningham, Peter Grant, Dr. David Ebsworth, R. Stephen Harris, and Alan Bray shall confirm in the Circular their intention to vote in favor of the resolutions put at the EGM
in a form heretofore approved by Buyer and shall recommend in the Circular that Parent’s shareholders do the same. Parent shall cause the Circular to include all information required by all applicable laws, including all required information
regarding the terms of this Agreement and the transactions contemplated by this Agreement. To the extent subject thereto, the Circular will comply with applicable U.S. securities laws. 

5.4. Operation of Business. Except as contemplated by this Agreement, during the period from the date of this Agreement to the
Closing, the Company shall, and Seller shall cause the Company to, conduct its operations in the Ordinary Course of Business and in compliance with all applicable laws and regulations and, to the extent consistent therewith, use its commercially
reasonable efforts to preserve intact its current business organization, keep its physical assets in good working condition, keep available the services of its current officers and employees and preserve its relationships with customers, suppliers
and others having business dealings with it, and pay obligations incurred by it after the date of this Agreement and prior to the Closing (other than obligations disputed by the Company in good faith by appropriate

  
 - 33 -

 EXECUTION COPY 
  

 
proceedings) either when due or otherwise substantially consistently with its past practices, to the end that its goodwill and ongoing business shall not be impaired in any material respect.
Without limiting the generality of the foregoing, prior to the Closing, the Company shall not, and Seller shall cause the Company not to, take any of the following actions without the written consent of Buyer: 

(a) issue or sell any stock or other securities of the Company or any options, warrants or rights to acquire any such stock or other
securities (except pursuant to the conversion or exercise of preferred shares, options or warrants outstanding on the date hereof), or amend any of the terms of (including the vesting of) any options, warrants or restricted stock agreements, or
repurchase or redeem any stock or other securities of the Company (except from former employees, directors or consultants in accordance with agreements providing for the repurchase of shares at their original issuance price in connection with any
termination of employment with or services to the Company); 
 (b) split, combine or reclassify any shares of its capital stock;
or declare, set aside or pay any dividend or other distribution (whether in cash, stock or property or any combination thereof) in respect of its capital stock; 
 (c) create, incur or assume any indebtedness (including obligations in respect of capital leases); assume, guarantee, endorse or otherwise become liable or responsible (whether directly, contingently or
otherwise) for the obligations of any other person or entity; or make any loans, advances or capital contributions to, or investments in, any other person or entity; 
 (d) enter into, adopt or amend any Employee Benefit Plan or any employment or severance agreement or arrangement of the type described in Section 3.22(k) or (except for normal increases in the
Ordinary Course of Business for employees who are not Affiliates) increase in any manner the compensation or fringe benefits of, or materially modify the employment terms of, its directors, officers or employees, generally or individually, or pay
any bonus or other benefit to its directors, officers or employees (except for existing payment obligations listed in Section 3.22 of the Seller Disclosure Schedule) or hire any new officers or (except in the Ordinary Course of Business)
any new employees; 
 (e) acquire, sell, lease, license or dispose of any assets or property (including any shares or other
equity interests in or securities of any corporation, partnership, association or other business organization or division thereof), other than purchases and sales of assets in the Ordinary Course of Business and as otherwise required or expressly
permitted by this Agreement; 
 (f) mortgage or pledge any of its property or assets or subject any such property or assets to
any Encumbrance; 
 (g) discharge or satisfy any Encumbrance or pay any obligation or liability other than in the Ordinary
Course of Business; 
 (h) amend its charter, by-laws or other organizational documents; 

  
 - 34 -

 EXECUTION COPY 
  

 (i) change its accounting methods, principles or practices, except insofar as may be
required by a generally applicable change in IFRS, or make any new elections, or changes to any current elections, with respect to Taxes, except as required by this Agreement; 
 (j) enter into, amend, terminate, take or omit to take any action that would constitute a violation of or default under, or waive any rights under, any contract or agreement of a nature required to be
listed in Section 3.12, Section 3.13 or Section 3.15 of the Seller Disclosure Schedule; 
 (k) make or
commit to make any capital expenditure in excess of [**] dollars ($[**]) per item or [**] dollars ($[**]) in the aggregate; 

(l) institute or settle any Legal Proceeding in which the matter in controversy is more than [**] dollars ($[**]) without Buyer’s
consent (which consent shall not be unreasonably withheld); 
 (m) take any action or fail to take any action permitted by this
Agreement with the knowledge that such action or failure to take action would result in any of the representations and warranties of the Company set forth in this Agreement becoming untrue such that any of the conditions set forth in
Article VI or Article VII would not be satisfied; or 
 (n) agree in writing or otherwise to take any of the
foregoing actions. 
 5.5. Access to Information. From and after the date of this Agreement to the Closing Date:

 (a) The Company shall permit representatives of Buyer to have full access (at all reasonable times, and in a manner so as not
to interfere with the normal business operations of the Company) to all premises, properties, financial, tax and accounting records (including the work papers of the Company’s independent accountants, subject to Buyer’s entering into a
separate agreement with such accountants to permit such access), contracts, other records and documents, and personnel, of or pertaining to the Company. Notwithstanding anything to the contrary contained in this Agreement, Buyer shall not be
entitled to tax records relating to any Affiliated Group of which Seller is the common parent, other than records relating solely to the Company. 
 (b) Within fifteen (15) days after the end of each month ending prior to the Closing, beginning with the month of January 2007, the Company shall furnish to Buyer an unaudited income statement for
such month and a balance sheet as of the end of such month, prepared on a basis consistent with the Financial Statements. Such financial statements shall present fairly the financial condition and results of operations of the Company as of the dates
thereof and for the periods covered thereby (except as set forth in Section 3.6(a) of the Seller Disclosure Schedule), and shall be consistent with the books and records of the Company. 

(c) Buyer (i) shall treat and hold as confidential any Confidential Information, (ii) shall not use any of the Confidential
Information except in connection with this Agreement, and (iii) if this Agreement is terminated for any reason whatsoever, shall return to the Company all tangible embodiments (and all copies) thereof which are in its possession. 

  
 - 35 -

 EXECUTION COPY 
  

 5.6. Notice of Breaches. 

(a) From the date of this Agreement until the Closing, Seller and the Company shall promptly deliver to Buyer supplemental information
concerning events or circumstances occurring subsequent to the date hereof which would render any representation, warranty or statement in this Agreement or the Seller Disclosure Schedule inaccurate or incomplete in any material respect at any time
after the date of this Agreement until the Closing. No such supplemental information shall be deemed to avoid or cure any misrepresentation or breach of warranty or constitute an amendment of any representation, warranty or statement in this
Agreement or the Seller Disclosure Schedule. 
 (b) From the date of this Agreement until the Closing, Buyer shall promptly
deliver to the Company and Seller supplemental information concerning events or circumstances occurring subsequent to the date hereof which would render any representation or warranty in this Agreement inaccurate or incomplete in any material
respect at any time after the date of this Agreement until the Closing. No such supplemental information shall be deemed to avoid or cure any misrepresentation or breach of warranty or constitute an amendment of any representation or warranty in
this Agreement. 
 5.7. Exclusivity. Prior to the Closing: 

(a) Neither Seller nor the Company shall directly or indirectly, through Parent or any Affiliate of Parent or through any officer,
director, employee, representative, or agent of Seller, the Company, Parent or any Affiliate of Parent or otherwise, (i) initiate, solicit, encourage or otherwise facilitate any inquiry, proposal, offer or discussion with any third party (other
than Buyer) concerning any merger, reorganization, consolidation, recapitalization, business combination, liquidation, dissolution, share exchange, sale of stock, sale of material assets or similar business transaction involving the Company, any
subsidiary or any division of the Company, (ii) furnish any non-public information concerning the business, properties or assets of the Company, any subsidiary or any division of the Company to any third party (other than Buyer) or
(iii) engage in discussions or negotiations with any third party (other than Buyer) concerning any such transaction. 
 (b)
Seller and the Company shall (and represent and warrant that Parent will) immediately notify any party with which discussions or negotiations of the nature described in paragraph (a) above were pending that the Company is terminating such
discussions or negotiations. If Parent, the Company or Seller receives any inquiry, proposal or offer of the nature described in paragraph (a) above, Seller shall, within two business days after such receipt, notify Buyer of such inquiry,
proposal or offer, including the identity of the other party and the terms of such inquiry, proposal or offer. 
 5.8.
Expenses. Except as set forth in Article VIII, Section 5.2 and the Escrow Agreement, Buyer shall bear its own costs and expenses (including legal and accounting fees and expenses) incurred in connection with this Agreement
and the transactions contemplated hereby and Seller shall bear the costs and expenses (including legal and accounting fees and expenses) incurred by Seller, and/or the Company in connection with this Agreement and the transactions contemplated
hereby. 

  
 - 36 -

 EXECUTION COPY 
  

 5.9. Transition Services. Prior to the Closing, Buyer and Seller shall enter into
a transition services agreement in substantially the form of Exhibit H hereto and otherwise in form reasonably acceptable to the Parties, pursuant to which Seller shall provide (or shall procure for Parent or an appropriate Affiliate of
Parent to provide) to Buyer and Buyer shall provide to Seller the services described in Schedule 5.9 following the Closing (the “Transition Services Agreement”). 

5.10. License Agreement. Prior to the Closing, Seller shall arrange for Parent to enter into a license agreement with Buyer and
the Company in substantially the form of Exhibit I hereto. 
 5.11. Assignment; Inter-Company
Adjustments and Eliminations. After the date of this Agreement and prior to the Closing: (a) Seller shall assign or arrange to have assigned to the Company (i) the Biosphere Patents and all other patents and patent applications listed
in Schedule 5.11(a)(i) hereto and (ii) all trademarks and tradenames containing the word “Biosphere” or any variations and derivatives thereof, and all other trademarks and servicemarks listed in Schedule 5.11(a)(ii)
hereto, that have heretofore been registered in the name of Affiliates of the Company, in each case, pursuant to Assignments in substantially the forms of Exhibit G hereto (the “Biosphere Assets”); and (b) the Company
shall distribute to Seller and its Affiliates the assets identified in Schedule 5.11(b) (the “Excluded Assets”), except for the investment for GeneMedix Plc. For the avoidance of doubt, Seller represents and warrants that the
investment in GeneMedix is not owned by the Company and is not reflected in the Financial Statements, and Buyer acknowledges that such investment shall not be treated as an asset of the Company. Prior to the Closing, Seller shall take (and shall
cause the Company to take) all action required to cause the Company’s balance sheet as of the Closing to reflect the eliminations and adjustments described in Schedule 6.12, in accordance with the conditions set forth therein. After the
Closing, if any payment is received by Buyer or the Company in respect of any receivable retained by or assigned to Seller pursuant to this Agreement, Buyer and the Company shall promptly deliver such payment to Seller, and if any payment is
received by Seller or any of its Affiliates in respect of any receivable retained by or assigned to the Company or Buyer pursuant to this Agreement, Seller shall promptly deliver such payment to the Company or Buyer, as Buyer shall direct.

 5.12. [Intentionally Omitted.] 
 5.13. Change of Company Name. Promptly following the Closing, Buyer shall change the name of the Company to a name that is not related to the Names and not likely to be confused with the Names.
Buyer shall make all filings and/or notifications required by any applicable law to effect the change in name of the Company. 

5.14. Sharing of Certain Data. Seller and its professional advisers shall have the right for a period of seven (7) years
following the Closing Date to have reasonable access to such books, records and accounts, including financial and Tax information, correspondence, 

  
 - 37 -

 EXECUTION COPY 
  

 
production records, employment records and other records that are transferred to Buyer pursuant to the terms of this Agreement for the limited purposes of concluding its involvement in the
business conducted by the Company prior to the Closing Date and for complying with its obligations under applicable financial reporting, securities, Tax, environmental, employment or other laws and regulations. Buyer and its professional advisers
shall have the right for a period of seven (7) years following the Closing Date to have reasonable access to those books, records and accounts, including financial and accounting records (including the work papers of Seller’s and
Parent’s independent accountants), Tax records of the Company, correspondence, production records, employment records and other records of the Company that are or may be retained by Seller or its Affiliates (including Parent) pursuant to the
terms of this Agreement to the extent that any of the foregoing is needed by, or would be reasonably helpful to, Buyer for the purpose of conducting the business of the Company after the Closing or complying with its obligations or asserting its
rights under applicable financial reporting, securities, Tax, environmental, employment or other laws and regulations. Neither Buyer nor Seller shall destroy (and Seller shall procure for Parent not to destroy) any such books, records or accounts
retained by it without first providing the other Party with the opportunity to obtain or copy such books, records, or accounts at such other Party’s expense. Notwithstanding anything to the contrary contained in this Agreement, Buyer shall not
be entitled to Tax records relating to any Affiliated Group of which Seller is the common parent, other than records relating solely to the Company. 
 5.15. Certain Tax Matters. 
 (a) Preparation and Filing of Tax
Returns. 
 (i) To the extent not previously filed, Seller shall prepare and timely file or shall cause to be prepared and
timely filed (at its own cost and expense) (x) all Pre-Closing Tax Returns for any Income Taxes of the Company and (y) all other Pre-Closing Tax Returns of the Company required to be filed (taking into account extensions) prior to the
Closing Date. If necessary under applicable law, Buyer shall cause the Company to execute any such Pre-Closing Tax Return or provide to Seller appropriate powers of attorney. 
 (ii) To the extent not previously filed, Buyer shall prepare and timely file or cause to be prepared and timely filed (at its own cost and expense) all Pre-Closing Tax Returns of the Company that are not
described in Section 5.15(a)(i) and all Straddle Period Tax Returns of the Company. Buyer shall deliver or cause to be delivered drafts of each such Tax Return to Seller for its review at least thirty (30) days prior to the Due Date
of such Tax Return and, in the case of a Straddle Period Tax Return, shall notify Seller of Buyer’s calculation of Seller’s share of the Taxes of the Company (determined in accordance with Section 5.15(d)) for such Straddle
Period; provided, however, that such draft of such Straddle Period Tax Return or any Pre-Closing Tax Return to which this Section 5.15(a)(ii) applies, as the case may be, and, in the case of a Straddle Period Tax Return,
the calculation of Seller’s share of the Tax liability for such Straddle Period (determined in accordance with Section 5.15(d)), in each case, shall be subject to Seller’s review and approval. If Seller disputes any item on any
Tax Return to which this Section 5.15(a)(ii) applies, it shall notify Buyer of such disputed item (or items) and the basis for its objection. Buyer and Seller shall act in good faith to resolve any dispute as promptly as practicable. If
Buyer and Seller cannot resolve any disputed item, the item in question shall be resolved in accordance with Article XI. 

  
 - 38 -

 EXECUTION COPY 
  

 (iii) Transfer Taxes. Notwithstanding anything to the contrary contained in this
Agreement, Buyer and Seller shall each be responsible for the payment of 50% of any transfer, sales, use, stamp, conveyance, value added, recording, registration, documentary, filing and other similar Taxes and administrative fees (including,
without limitation, notary fees) arising in connection with the consummation of the transactions contemplated by this Agreement (“Transfer Taxes”). Buyer shall be responsible for preparing and filing all Tax Returns required to be
filed in connection with Transfer Taxes, and Seller shall cooperate with Buyer in connection with the preparation of any such Tax Return relating to Transfer Taxes. 
 (b) Tax Indemnification by Seller. Seller shall indemnify and hold harmless Buyer and the Company in respect of and against (without duplication): 

(i) all liabilities for Taxes imposed on the Company with respect to Pre-Closing Periods, and with respect to any Straddle Period, the
portion of such Straddle Period ending on the Closing Date and as determined in the manner provided in Section 5.15(d); 
 (ii) all liabilities for Taxes imposed on the Company under Section 1.1502-6 of the Treasury Regulations (and corresponding provisions of state, local and foreign law) as a result of having been a
member of any Affiliated Group for any taxable period ending on or before or that includes the Closing Date; 
 (iii) all
Transfer Taxes for which Seller is liable pursuant to Section 5.15(a)(iii); 
 (iv) any breach of a representation
set forth in Section 3.9; and 
 (v) all out-of-pocket expenses for advisors resulting from a breach of any
obligation of Seller set forth in this Section 5.15; 
 provided, however, that Seller shall not be responsible for
and shall not indemnify Buyer for (A) all Transfer Taxes for which Buyer is liable pursuant to Section 5.15(a)(iii), (B) an amount equal to the aggregate amount of Tax Reserves, (C) any and all Taxes imposed on the Company
as a result of any election under Section 338 of the Code; and (D) any and all Taxes imposed on the Company as a result of any action taken by Buyer after the Closing that is not in the Ordinary Course of Business or that result from a
breach of any of Buyer’s obligations pursuant to this Agreement (collectively, “Excluded Taxes”). 
 (c)
Tax Indemnification by Buyer. Buyer shall indemnify and hold harmless Seller in respect of and against (without duplication): 
 (i) all Excluded Taxes; 
 (ii) all liabilities for Taxes imposed on the Company
with respect to any period beginning after the Closing Date (a “Post-Closing Period”); 
 (iii) all
liabilities for Taxes imposed on the Company with respect to a Straddle Period, but only with respect to the portion of such Straddle Period beginning after the Closing Date, as determined in accordance with the principles set forth in
Section 5.15(d); 

  
 - 39 -

 EXECUTION COPY 
  

 (iv) all Taxes and out-of-pocket expenses for advisors resulting from a breach of any
obligation of Buyer set forth in this Section 5.15. 
 (d) Allocation of Certain Taxes. 

(i) Buyer and Seller agree that if the Company is permitted but not required under applicable foreign, state or local Tax laws to treat
the Closing Date as the last day of a taxable period, Buyer and Seller shall treat such day as the last day of a taxable period. Buyer and Seller agree that they will treat the Company as if it ceased to be part of the Affiliated Group of
corporations of which the Company is a member within the meaning of Section 1504 of the Code, and, to the extent applicable, any comparable or similar provision of state, local or foreign laws or regulations, as of the close of business on the
Closing Date. 
 (ii) The portion of any Taxes for a taxable period beginning before and ending after the Closing allocable to
the portion of such period ending on the Closing Date shall be deemed to equal (A) in the case of Taxes that (x) are based upon or related to income or receipts or (y) imposed in connection with any sale or other transfer or
assignment of property, other than Taxes described in Section 5.15(a)(iii), the amount which would be payable if the taxable year ended on (and included) the Closing Date, and (B) in the case of Taxes not described in
Section 5.15(d)(ii)(A) (including Taxes imposed on a periodic basis (such as real property Taxes)), the amount of such Taxes for the entire period multiplied by a fraction the numerator of which is the number of calendar days in the
period ending on (and including) the Closing Date and the denominator of which is the number of calendar days in the entire period. For purposes of this Agreement, transactions that occur on the Closing Date but after the Closing and that are not
incurred in the Ordinary Course of Business of the Company shall be considered to be attributable to the period that commences on the day following the Closing Date. For purposes of Section 5.15(d)(ii)(A), any exemption, deduction,
credit or other item that is calculated on an annual basis shall be allocated pro rata per day between the period ending on the Closing Date and the period beginning the day after the Closing Date. 

(e) Refunds. Buyer shall pay to Seller (a) all Tax refunds and credits of Taxes (including any interest in respect thereof)
received by any of Buyer or its Affiliates or the Company after the Closing Date and attributable to Taxes paid by the Company with respect to any Pre-Closing Period and (b) the portion of all refunds of Taxes or credits of Taxes (including any
interest in respect thereof) received by any of Buyer or its Affiliates or the Company after the Closing Date and attributable to Taxes paid by the Company with respect to any Straddle Period (such portion to be allocated consistent with the
principles set forth in Section 5.15(d)), Notwithstanding anything in this Section 5.15(e) to the contrary, Seller shall not be entitled to receive payment under this Section 5.15(e) to the extent such refunds or
credits are (i) attributable to items of loss, deduction or credit which arise in any Post-Closing Period and that are carried back to a Pre-Closing Period or Straddle Period, or (ii) reflected as an asset of the Company on the Final
Closing Net Assets Statement. Any such refunds or credits of Taxes required to be paid by Buyer to Seller shall be paid within five (5) business days of the receipt of such refunds or credits of Taxes by Buyer, its Affiliates or the Company.

  
 - 40 -

 EXECUTION COPY 
  

 (f) Cooperation. Buyer and Seller and their respective Affiliates shall cooperate
in the preparation of all Tax Returns of or relating to the Company and the conduct of all Tax Audits or other administrative or judicial proceedings relating to the determination of any Tax of the Company for any Tax periods for which one Party
could reasonably require the assistance of the other Party in obtaining any necessary information. Such cooperation shall include, but not be limited to, furnishing prior years’ Tax Returns of the Company or return preparation packages to the
extent related solely to the Company illustrating previous reporting practices or containing historical information relevant to the preparation of such Tax Returns of or relating to the Company, and furnishing such other information within such
Party’s possession requested by the Party filing such Tax Returns of or relating to the Company as is relevant to their preparation. Such cooperation and information also shall include without limitation provision by the Company to Seller of
powers of attorney for the purpose of signing Tax Returns and defending audits and promptly forwarding copies of appropriate notices and forms or other communications received from or sent to any Taxing Authority which relate to the Company, and
providing copies of all relevant Tax Returns to the extent related solely to the Company, together with accompanying schedules and related workpapers, documents relating to rulings received by the Company or other determinations by any Taxing
Authority with respect to the Company and records concerning the ownership and Tax basis of property of the Company, which the requested Party may possess. Buyer and Seller and their respective Affiliates shall make their respective employees and
facilities available on a mutually convenient basis to explain any documents or information provided hereunder. The obligations of Buyer and the Company under this Section 5.15(f) shall include the provision of information to Seller that
is required by Seller to enable it to file any Tax Return of an Affiliated Group of which it is the common parent and the Company is or was a member. 
 (g) Tax Audits. Buyer shall deliver a written notice to Seller in writing promptly following any demand, claim, or notice of commencement of a claim, audit, proposed adjustment, assessment,
examination or other administrative or court proceeding with respect to Taxes of the Company for which Seller may be liable pursuant to Section 5.15 (“Tax Contest”) and shall describe in reasonable detail (to the extent
known by Buyer or the Company) the facts constituting the basis for such Tax Contest, the nature of the relief sought, and the amount of the claimed Losses, if any (the “Tax Claim Notice”), provided, however, that no
delay or failure on the part of Buyer to notify Seller pursuant to this Section 5.15(g) shall relieve Seller of any liability or obligations under Section 5.15 except to the extent that Seller is adversely prejudiced as a
consequence of such failure. 
 (i) With respect to Tax Contests for Taxes of the Company for a Pre-Closing Period, Seller may
elect to assume and control the defense of such Tax Contest by written notice to that effect to Buyer within twenty (20) days after delivery by Buyer to Seller of the Tax Claim Notice. If Seller elects to assume and control the defense of such
Tax Contest, it (A) shall bear its own costs and expenses, (B) shall be entitled to engage its own counsel and (C) may (1) pursue or forego any and all administrative appeals, proceedings, hearings and conferences with any Tax
authority, (2) either pay the Tax claimed or sue for refund where applicable law permits such refund suit or (3) contest, settle or compromise the Tax Contest in any permissible manner, provided, however, that Seller shall
not enter into any settlement with respect to any such Tax Contest that relates to Taxes of the Company for a Pre-Closing Period without the prior written consent of Buyer, which consent shall not be unreasonably withheld or delayed, and Buyer shall
(and shall cause its Affiliates) to cooperate with Seller in pursuing such 

  
 - 41 -

 EXECUTION COPY 
  

 
Tax Contest (including by providing appropriate powers of attorney). If Seller elects to assume the defense of any Tax Contest, (A) Seller shall keep Buyer reasonably informed of all
material developments and events relating to such Tax Contest and (B) at its own cost and expense, Buyer shall have the right to participate in (but not control) the defense of such Tax Contest. 

(ii) In connection with any Tax Contest that relates to Taxes of the Company for a Pre-Closing Period that Seller does not elect to
control pursuant to Section 5.15(g)(i), such Tax Contest shall be controlled by Buyer and Seller agrees to cooperate with Buyer in pursing such Tax Contest, provided, however, that none of Buyer or its Affiliates (including
the Company) shall enter into any settlement with respect to any such Tax Contest that relates to Taxes of the Company for a Pre-Closing Period without the prior written consent of Seller, which consent shall not be unreasonably withheld or delayed.
In connection with any Tax Contest that is described in this Section 5.15(g)(ii) and controlled by Buyer, Buyer shall keep Seller reasonably informed of all material developments and events relating to such Tax Contest and, at its own
cost and expense, Seller shall have the right to participate in (but not control) the defense of such Tax Contest. 
 (iii)
Buyer and Seller shall jointly control (at each Party’s own cost and expense) all Tax Contests relating to Straddle Periods of the Company. The Parties agree to cooperate with each other in pursuing any such Tax Contest and neither Buyer nor
Seller shall (or shall permit any of their Affiliates) to settle a Tax Contest relating to a Straddle Period of any Company without the other Party’s prior written consent, which consent shall not be unreasonably withheld or delayed.

 (h) Termination of Tax Sharing Agreements. All Tax sharing agreements or similar arrangements between the Company, on
the one hand, and Seller or Parent, on the other hand, shall be terminated prior to the Closing Date and, after the Closing Date, Buyer and its Affiliates shall not be bound thereby or have any liability thereunder for amounts due in respect of
periods ending on or before the Closing Date. 
 (i) Exclusivity; Conflicts. Notwithstanding anything
to the contrary contained in this Agreement, (i) this Section 5.15 shall be the exclusive means by which a Party to this Agreement may seek indemnification relating or attributable to Taxes or Tax Returns, (ii) claims for
indemnification pursuant to Sections 5.15(a) and (b) may be made by a Party at any time prior to the sixtieth
(60th) day after the expiration of the statute of
limitations applicable to the Tax matter to which the claim relates and (iii) to the extent there is any inconsistency between the terms of this Section 5.15 and any other provision of this Agreement, the provisions of this
Section 5.15 shall govern and control, provided, however, that Sections 8.3(f), 8.5(c), 8.5(d) and 8.5(e) (or the principles of such Sections) shall apply to this Section 5.15. 

(j) Treatment of Indemnification Payments. Any payments made to an Indemnified Party pursuant to this Section 5.15,
Article VIII, or the Escrow Agreement shall be treated as an adjustment to the Adjusted Purchase Price for Tax purposes. 

(k) FIRPTA Certificate. Prior to the Closing, Seller shall deliver to Buyer a certification that it is not a foreign person in
accordance with the Treasury Regulations under Section 1445 of the Code. If Buyer does not receive the certification described above on or before the Closing Date, Buyer shall be permitted to withhold from the payments to be made pursuant to
this Agreement any required withholding tax under Section 1445 of the Code. 

  
 - 42 -

 EXECUTION COPY 
  

 (l) Taxes. Notwithstanding any other provision in this Agreement, except the last
sentence of this Section 5.15(l), Buyer, the Company, and the Escrow Agent shall have the right to deduct and withhold Taxes from any payments to be made hereunder (including any payments to be made under the Escrow Agreement) if such
withholding is required by law and to collect any necessary Tax forms, including Forms W-8 or W-9, as applicable, or any similar information, from Seller and any other recipients of payments hereunder. To the extent that amounts are so withheld,
such withheld amounts shall be treated for all purposes of this Agreement as having been delivered and paid to Seller or any other recipient of payments in respect of which such deduction and withholding were made. Unless otherwise required by a
change in law after the date hereof, Buyer shall not withhold any Taxes in respect of payments to be made to Seller for the covenants not to compete set forth in Section 9.3(a), as determined in accordance with Section 1.9
and Schedule 1.9. 
 (m) No Section 338 Election. None of Buyer or its Affiliates shall make any election
pursuant to Section 338 of the Code (or any comparable provision of state, local or other Tax law) with respect to the Company. 
 (n) No Amendment. Neither Buyer nor the Company shall amend any Tax Return of the Company relating to a Pre-Closing Period or Straddle Period without the consent of Seller; provided,
however, that Buyer or the Company shall be permitted to amend any such Tax return without the consent of Seller if Seller will not be adversely affected thereby, taking into account Seller’s obligations under this Agreement. 

(o) Certain Limitations. Notwithstanding anything to the contrary contained in this Agreement, neither Parent nor Seller (or any
of their Affiliates) shall be required to indemnify or hold harmless Buyer and its subsidiaries (including after the Closing, the Company) and each Indemnified Buyer Party in respect of or against any and all Losses resulting from, relating or
attributable to (i) Taxes or Tax Returns other than as set forth in Sections 5.15(b)(i), 5.15(b)(ii), 5.15(b)(iii), 5.15(b)(iv) (solely to the extent of Taxes of the Company for Pre-Closing Periods and Straddle
Periods (determined in accordance with Section 5.15(d)) and 5.15(b)(v); provided, however, that the limitations imposed by this Section 5.15(o)(i) shall not apply to Losses resulting from a breach of Sections
3.9(a)(v), 3.9(a)(xii), 3.9(a)(xvi), 3.9(c), 3.22(h), 3.22(k), and 3.22(m) and (ii) any Tax attribute of the Company (other than resulting from a breach of Section 3.9(c)), including any net operating loss carryover or credit
carryover, or the determination that any such carryover is subject to any limitation on its use under applicable law. 
 (p)
Limitation on Actions. Subject to Section 5.15(g), neither Buyer nor any of its Affiliates (including after the Closing, the Company) shall take any action after the Closing relating or attributable to (or that would reasonably be
expected to affect Taxes with respect to) a Pre-Closing Period or Straddle Period of the Company that would reasonably be expected to result in any increased Tax liability (or a reduction in a Tax refund or credit) in respect of a Pre-Closing Period
of the Company or the portion of a Straddle Period of the Company ending on the Closing Date (determined in accordance with the principles of Section 5.15(d)). Subject to 

  
 - 43 -

 EXECUTION COPY 
  

 
Section 5.15(g), neither Seller nor any of its Affiliates shall take any action after the Closing relating or attributable to (or that would reasonably be expected to affect Taxes
with respect to) a Post-Closing Period or Straddle Period of the Company that would reasonably be expected to result in any increased Tax liability (or a reduction in a Tax refund or credit) in respect of a Post-Closing Period of the Company or the
portion of a Straddle Period of the Company beginning after the Closing Date (determined in accordance with the principles of Section 5.15(d)), provided, however, that all Pre-Closing Period Tax attributes of the Company
(and any Tax attributes relating to the portion of any Straddle Period ending on the Closing Date determined in accordance with the principles of Section 5.15(d)), other than to the extent of the tax basis represented in
Section 3.9(c), shall be ignored. 
 (q) Transfer of Biosphere Assets. Unless otherwise required by a Final
Determination, the Parties shall (i) treat the transfer of the Biosphere Assets to the Company pursuant to Section 5.11(a) as a taxable transaction (and not as a transaction to which section 351 of the Code (or any comparable
provision of any state, local or foreign tax jurisdiction) applies), and (ii) report such transfer as a taxable transaction for all Tax purposes and in a manner consistent with such assets having a fair market value as of the Closing Date equal
to approximately [**] dollars ($[**]). 
 (r) Unless otherwise required by a Final Determination or change in law after the date
hereof, Seller shall not include in gross income on the Seller’s 2007 U.S. consolidated Tax Return for Income Taxes and any comparable 2007 Tax Return for state or local Income Taxes (taking into account Section 108 of the Code and
Section 1.1502-28 of the Treasury regulations promulgated under the Code, and any comparable provisions of state or local Tax law), any material amount of cancellation of indebtedness income that may result from Seller’s assumption of the
net debt owed by the Company to Parent and/or to any of its Affiliates (the “Company Debt”) and Parent’s and/or any of its Affiliates’ novation of the Company liability under the Company Debt to Seller. The adjustments to
the assets and liabilities of the Company set forth in Schedule 6.12 shall be effected in a manner that does not result, in any material respect, in any adverse Tax effect on the Company, other than the possible reduction of Tax attributes of
the Company other than the tax basis represented in Section 3.9(c). 
 5.16. Employee Retention Arrangements.
Seller shall pay (on behalf of the Company, when due), or shall reimburse the Company (promptly following payment by the Company and notice by the Company to Seller) for, all amounts due to be paid by the Company after the Most Recent Net Assets
Statement Date to Company employees pursuant to the Company’s Stay Incentive Plan and related Stay Incentive Agreements to the extent that such employees do not accept stock (or options to acquire stock) of Buyer or the Company (as determined
by Buyer) in lieu of such cash amounts under the Stay Incentive Plan and Stay Incentive Agreements. 
 5.17. Transfer of
Rights and Obligations Respecting Other Products, Product Candidates, and Regulatory Matters. Prior to the Closing, the Company will transfer to a third party(ies) acceptable to Buyer all rights, interest, ownership, obligations, and authority
with respect to all NDAs, INDs, DMFs, regulatory agent relationships, and other regulatory applications, dossiers, licenses, permits, or filings other than those related to DepoCyt, DepoDur, DepoBupivacaine, and products related to the Biosphere
technology. 

  
 - 44 -

 EXECUTION COPY 
  

 ARTICLE VI 
 CONDITIONS TO OBLIGATIONS OF BUYER 
 The obligations of Buyer under this
Agreement are subject to the fulfillment, at the Closing Date, of the following conditions precedent, each of which may be waived (to the extent legally waivable) in writing in the sole discretion of Buyer: 

6.1. Parent Shareholder Approval and Other Consents and Approvals. The requisite approval of Parent’s shareholders as set
forth in Sections 2.2, 3.3 and 5.3 shall have been obtained, and Parent, Seller and the Company shall have obtained at their own expense (and shall have provided copies thereof to Buyer) the consents and approvals described in Schedule
6.1 and all of the waivers, permits, consents, approvals or other authorizations, and effected all of the registrations, filings and notices, referred to in Section 5.2(a) which are required on the part of Seller, Holder and the
Company. 
 6.2. Continued Accuracy of Representations and Warranties of Seller and the Company. The representations and
warranties of Seller set forth in Article II, the first sentence of Section 3.1 and in Section 3.3 and any representations and warranties of Seller set forth in this Agreement that are qualified as to materiality shall
be true and correct in all respects, and all other representations and warranties of Seller set forth in this Agreement shall be true and correct in all material respects, in each case as of the date of this Agreement and as of the Closing as though
made as of the Closing, except to the extent such representations and warranties are specifically made as of a particular date (in which case such representations and warranties shall be true and correct as of such date); 

6.3. Compliance with Covenants and Obligations. Seller and the Company shall have performed or complied with in all material
respects their respective agreements and covenants required to be performed or complied with under this Agreement and Parent shall have performed or complied with in all material respects its agreements and covenants required to be performed or
complied with in the Parent Guaranty as of or prior to the Closing Date. 
 6.4. Adverse Proceedings. No Legal Proceeding
shall be pending or threatened against Parent, Seller or the Company or any of their Affiliates (a) seeking to prevent the consummation of any of the transactions contemplated by this Agreement or any of the Ancillary Agreements,
(b) seeking to cause any of the transactions contemplated by this Agreement or any of the Ancillary Agreements to be rescinded, (c) wherein an adverse judgment would have, individually or in the aggregate, a Company Material Adverse
Effect, and no such judgment, order, decree, stipulation or injunction shall be in effect. 
 6.5. Seller Compliance
Certificate. Seller shall have delivered to Buyer the Seller Compliance Certificate. 
 6.6. Resignations. Buyer
shall have received copies of the resignations, effective as of the Closing, of each director and officer of the Company (other than any such resignations which Buyer designates, by written notice to the Company, and other than the individual named
in Section 6.10(j)). 

  
 - 45 -

 EXECUTION COPY 
  

 6.7. Opinion of Counsel. Buyer shall have received from counsel to Parent, Seller
and the Company an opinion with respect to the matters set forth in Exhibit C attached hereto, addressed to Buyer and dated as of the Closing Date. 
 6.8. Additional Closing Deliveries. Buyer shall have received such other certificates and instruments (including certificates of good standing of the Company in their jurisdiction of organization
and the various foreign jurisdictions in which they are qualified, certified charter documents, certificates as to the incumbency of officers and the adoption of authorizing resolutions) as it shall reasonably request in connection with the Closing.

 6.9. HSR Act. The waiting period applicable to the consummation of the transactions contemplated by this Agreement
under the HSR Act shall have expired or been terminated. 
 6.10. Certain Agreements. 

(a) Paul Capital. The Paul Capital Agreements shall have been amended as set forth in the Paul Capital Term Sheet annexed as
Exhibit E hereto, and no other consent or waiver of Paul Capital shall be required for the execution or delivery of this Agreement or any of the Ancillary Agreement or the consummation of any of the transactions contemplated hereby or thereby
(other than consents and waivers that shall heretofore have been obtained and delivered to Buyer and be in full force and effect). 
 (b) Endo. The Development and Marketing Strategic Alliance Agreement dated December 31, 2002 among Endo Pharmaceuticals, Inc., SkyePharma, Inc. and SkyePharma Canada Inc. shall have been
terminated in accordance with the Termination Agreement with respect thereto substantially in the form of Exhibit F hereto and on the terms set forth Schedule 6.10(b) hereto. 

(c) Parent Guaranty. Parent shall have executed and delivered to Buyer the Parent Guaranty, and the Parent Guaranty shall be in
full force and effect. 
 (d) Release of Encumbrances, Upstream and Sister-Company Guarantees. The Company and its assets
and properties shall have been fully, absolutely and unconditionally released from (i) all guarantees and obligations in respect of liabilities and obligations of Parent, Seller and their Affiliates and (ii) all Encumbrances (including
liens in favor of General Electric Capital Corporation) other than liens in favor of equipment lessors with respect to equipment that is leased to the Company and will remain in the possession of the Company following the Closing. 

(e) License Agreement. Seller shall have executed and delivered (and shall have procured for Parent and its Affiliates to execute
and deliver) to Buyer a License Agreement in substantially the form of Exhibit I hereto with Buyer and the Company in form reasonably acceptable to Buyer and such License Agreement shall be in full force and effect. 

  
 - 46 -

 EXECUTION COPY 
  

 (f) Patent and Trademark Assignments. Seller shall have executed and delivered
(and shall have procured for Parent and its Affiliates, as applicable, to execute and deliver) to the Company a patent assignment with respect to the Biosphere Patents and all other patents and patent applications listed in Schedule
5.11(a)(i) hereto and a trademark assignment with respect to the name “Biosphere” and all trademarks and tradenames containing the word “Biosphere” or any variations and derivatives thereof, and all other trademarks and
servicemarks listed in Schedule 5.11(a)(ii) hereto, in each case substantially in the forms of Exhibit G hereto, and each such assignment shall be in full force and effect. 

(g) [Intentionally Omitted]. 
 (h) Transition Service Agreement. Seller shall have executed and delivered (and shall have procured for Parent and its Affiliates to execute and deliver) to Buyer the Transition Services Agreement,
and such agreement shall be in full force and effect. 
 (i) Escrow Agreement. The Escrow Agreement shall have been
executed and delivered by all parties thereto and shall be in full force and effect. 
 6.11. No Material Adverse Effect.
No Company Material Adverse Effect shall have occurred, and no circumstance shall exist and no event or occurrence shall have occurred, that would be reasonably likely to result in a Company Material Adverse Effect. 

6.12. Balance Sheet. Seller and the Company shall have taken all action required to cause the Company’s balance sheet as of
the Closing to reflect the eliminations and adjustments described in Schedule 6.12. 
 6.13. 401(k) Contribution.
Parent or Seller shall have paid in full (or shall have caused the Company to pay, out of funds provided by Parent or Seller, to the extent necessary) the 401(k) contribution to be made by the Company for 2006, in a total amount of $[**].

 ARTICLE VII 
 CONDITIONS TO OBLIGATIONS OF SELLER 
 The obligations of Seller under this
Agreement are subject to the fulfillment, at the Closing Date, of the following conditions precedent, each of which may be waived in writing (to the extent legally waivable) in the sole discretion of Seller: 

7.1. Parent Shareholder Approval. The requisite approval of Parent’s shareholders as set forth in Section 5.3
shall have been obtained. 
 7.2. Continued Accuracy of Representations and Warranties of Buyer. The representations and
warranties of Buyer set forth in the first sentence of Section 4.1 and in Section 4.2 and any representations and warranties of Buyer set forth in this Agreement that are qualified as to materiality shall be true and correct
in all respects, and all other representations and warranties of Buyer set forth in this Agreement shall be true and correct in all material respects, in each case as of the date of this Agreement and as of the Closing as though made as of the
Closing, except to the extent such representations and warranties are specifically made as of a particular date (in which case such representations and warranties shall be true and correct as of such date). 

  
 - 47 -

 EXECUTION COPY 
  

 7.3. Compliance with Covenants and Obligations. Buyer shall have performed or
complied with in all material respects its agreements and covenants required to be performed or complied with under this Agreement as of or prior to the Closing Date. 
 7.4. Adverse Proceedings. No Legal Proceeding shall be pending or threatened in writing wherein an unfavorable judgment, order, decree, stipulation or injunction would (a) prevent consummation
of any of the transactions contemplated by this Agreement, (b) cause any of the transactions contemplated by this Agreement to be rescinded following consummation or (c) have, individually or in the aggregate, a Buyer Material Adverse
Effect, and no such judgment, order, decree, stipulation or injunction shall be in effect. 
 7.5. Buyer Compliance
Certificate. Buyer shall have delivered to Seller the Buyer Compliance Certificate. 
 7.6. Opinion of Counsel.
Seller shall have received from counsel to Buyer an opinion with respect to the matters set forth in Exhibit D attached hereto, addressed to Seller and dated as of the Closing Date. 

7.7. Additional Closing Deliveries. Seller shall have received such other certificates and instruments (including certificates of
good standing of Buyer in its jurisdiction of organization, certified charter documents, certificates as to the incumbency of officers and the adoption of authorizing resolutions) as Seller shall reasonably request in connection with the Closing.

 7.8. HSR Act. The waiting period applicable to the consummation of the transactions contemplated by this Agreement
under the HSR Act shall have expired or been terminated. 
 7.9. Transition Service Agreement. Buyer shall have executed
and delivered to Seller the Transition Services Agreement, and such agreement shall be in full force and effect. 
 ARTICLE
VIII 
 INDEMNIFICATION 
 8.1. Indemnification by Seller. Seller shall indemnify Buyer and its subsidiaries (including, after the Closing, the Company) and their respective directors, offices, employees, agents and
representatives (each an “Indemnified Buyer Party” and collectively the “Indemnified Buyer Parties”) in respect of, and hold harmless each of the Indemnified Buyer Parties against, any and all Losses incurred or
suffered by the Indemnified Buyer Parties resulting from, relating to or constituting: 
 (a) any breach of or inaccuracy in, as
of the date of this Agreement or as of the Closing Date, of any representation or warranty of Seller or the Company contained in this Agreement, any of the Ancillary Agreements or any other agreement or instrument furnished by Seller or the Company
to Buyer expressly pursuant to this Agreement, or any Third Party Claim alleging matters that would, if true, constitute such a breach or inaccuracy; 

  
 - 48 -

 EXECUTION COPY 
  

 (b) any failure to perform any covenant or agreement of Seller or the Company contained
in this Agreement, any of the Ancillary Agreements or any agreement or instrument furnished by Seller or the Company to Buyer expressly pursuant to this Agreement, or any Third Party Claim alleging matters that would, if true, constitute such a
failure; 
 (c) any claim by Endo relating to DepoDur for any act or omission occurring or any circumstance existing prior to
the Closing; 
 (d) any Losses arising out of conditions or events involving noncompliance with or violation of, prior to the
Closing, any Permit or Environmental Law relating to wastewater discharge; 
 (e) any claim by Paul Capital Partners or any of
its Affiliates for any breach after the Closing Date of any obligation of Parent, Seller or any of their Affiliates pursuant to any agreement between Parent, Seller or any of their Affiliates, on one hand, and Paul Capital Partners or any of its
Affiliates, on the other hand; 
 (f) any of the claims identified in Schedule 8.1(f); 

(g) the 401(k) contribution to be made by the Company for 2006, in a total amount of $[**], to the extent (if any) that such amount is
not paid by Parent or Seller at or prior to the Closing; and/or 
 (h) any of the Designated Amounts; provided, that the
indemnifiable Losses with respect to Designated Amounts shall be limited to the actual out-of-pocket amounts paid by Buyer and/or the Company (up to the actual amount invoiced (in the case of invoiced amounts) and up to the invoiced amount (or the
portion thereof) that relates to the amount accrued on Schedule 12.1 (in the case of amounts listed on Schedule 12.1 as accruals and not yet invoiced as of the date hereof), plus any interest, late fee or similar charge for late
payment, collection costs, and legal fees for which the Company is responsible or which the Company is obligated to bear, plus the actual reasonable legal fees and expenses incurred by Buyer and/or the Company in defending or responding to claims
with respect to the designated Amounts). 
 8.2. Indemnification by Buyer. Buyer shall indemnify Seller and its
subsidiaries and their respective directors, offices, employees, agents and representatives (each an “Indemnified Seller Party” and collectively the “Indemnified Seller Parties”) in respect of, and hold each of the
Indemnified Seller Parties harmless against, any and all Losses incurred or suffered by them resulting from, relating to or constituting: 
 (a) any breach, as of the date of this Agreement or as of the Closing Date, of any representation or warranty of Buyer contained in this Agreement or any other agreement or instrument furnished by Buyer
to Seller expressly pursuant to this Agreement; 
 (b) any failure to perform any covenant or agreement of Buyer contained in
this Agreement or any agreement or instrument furnished by Buyer to Seller expressly pursuant to this Agreement, or any Third Party Claim alleging matters that would, if true, constitute such a failure; and/or 

  
 - 49 -

 EXECUTION COPY 
  

 (c) any claim by Paul Capital Partners or any of its Affiliates for any breach after the
Closing Date of any post-Closing obligation of the Company pursuant to the agreement contemplated by the Paul Capital Term Sheet annexed hereto as Exhibit E to be entered into between Paul Capital Partners and the Company effective as of the
Closing Date in connection with the transactions contemplated by this Agreement. 
 8.3. Indemnification Claims.

 (a) An Indemnified Party shall give written notification to the Indemnifying Party of the service or receipt by the
Indemnified Party of any Third Party Claim. Such notification shall be given within twenty (20) days after receipt by the Indemnified Party of the summons, complaint or other notice in writing of such Third Party Claim, and shall describe in
reasonable detail (to the extent known by the Indemnified Party) the facts constituting the basis for such Third Party Claim, the nature of the relief sought, and the amount of the claimed damages (if any); provided, however, that no
delay or failure on the part of the Indemnified Party in so notifying the Indemnifying Party shall relieve the Indemnifying Party of any liability or obligation hereunder except to the extent of any damage or liability caused by or arising out of
such failure. Within twenty (20) days after delivery of such notification, the Indemnifying Party may, upon written notice thereof to the Indemnified Party, assume control of the defense of such Third Party Claim with counsel reasonably
satisfactory to the Indemnified Party; provided that (i) the Indemnifying Party may only assume control of such defense if (A) it acknowledges in writing to the Indemnified Party that any Losses that the Indemnified Party may incur
or sustain in connection with such Third Party Claim constitute Losses for which the Indemnified Party shall be indemnified pursuant to this Article VIII and (B) the ad damnum (when added to the total amount of all other
claims for indemnification theretofore paid or then pending) is less than or equal to the amount of Losses for which the Indemnifying Party is liable under this Article VIII and (ii) the Indemnifying Party may not assume control of
the defense of any Third Party Claim involving criminal liability or in which equitable relief or specific performance is sought against the Indemnified Party. If the Indemnifying Party does not, or is not permitted under the terms hereof to, so
assume control of the defense of a Third Party Claim, the Indemnified Party shall control such defense. The Non-controlling Party may participate in such defense at its own expense. The Controlling Party shall keep the Non-controlling Party advised
of the status of such Third Party Claim and the defense thereof and shall consider in good faith recommendations made by the Non-controlling Party with respect thereto. The Non-controlling Party shall furnish the Controlling Party with such
information as it may have with respect to such Third Party Claim (including copies of any summons, complaint or other pleading which may have been served on such party and any written claim, demand, invoice, billing or other document evidencing or
asserting the same) and shall otherwise cooperate with and assist the Controlling Party in the defense of such Third Party Claim. The fees and expenses of counsel to the Indemnified Party with respect to a Third Party Claim shall be considered
Losses for purposes of this Agreement if (i) the Indemnified Party controls the defense of such Third Party Claim pursuant to the terms of this Section 8.3(a) or (ii) the Indemnifying Party assumes control of such defense and
the Indemnified Party reasonably concludes that the Indemnifying Party and the Indemnified Party have conflicting interests or different defenses available with respect to such Third Party Claim. The Indemnifying Party shall not agree to any
settlement of, or the entry of any judgment arising from, any Third Party Claim without the prior written consent of 

  
 - 50 -

 EXECUTION COPY 
  

 
the Indemnified Party, which shall not be unreasonably withheld, conditioned or delayed; provided that the consent of the Indemnified Party shall not be required if the Indemnifying Party
unconditionally and absolutely agrees in writing to pay any amounts payable pursuant to such settlement or judgment and such settlement or judgment includes a complete release of the Indemnified Party from further liability and has no other adverse
effect on the Indemnified Party. The Indemnified Party shall not agree to any settlement of, or the entry of any judgment arising from, any such Third Party Claim without the prior written consent of the Indemnifying Party, which shall not be
unreasonably withheld, conditioned or delayed. 
 (b) In order to seek indemnification under this Article VIII, an
Indemnified Party shall deliver a Claim Notice to the Indemnifying Party. If the Indemnified Party is Buyer and is seeking to enforce such claim pursuant to the Escrow Agreement, the Indemnifying Party shall deliver a copy of the Claim Notice to the
Escrow Agent. 
 (c) Within twenty (20) days after delivery of a Claim Notice, the Indemnifying Party shall deliver to the
Indemnified Party and the Escrow Agent a Response, in which the Indemnifying Party shall: (i) agree that the Indemnified Party is entitled to receive all of the Claimed Amount (in which case the Response shall be accompanied by a payment by the
Indemnifying Party to the Indemnified Party of the Claimed Amount, by check or by wire transfer or, if the Indemnified Party is Buyer and is seeking to enforce such claim pursuant to the Escrow Agreement, a written authorization executed by Seller
instructing the Escrow Agent to pay to Buyer an amount out of the Escrow Fund equal to the Claimed Amount); (ii) agree that the Indemnified Party is entitled to receive the Agreed Amount (in which case the Response shall be accompanied by a
payment by the Indemnifying Party to the Indemnified Party of the Agreed Amount, by check or by wire transfer, or, if the Indemnified Party is Buyer and is seeking to enforce such claim pursuant to the Escrow Agreement, a written authorization
executed by Seller instructing the Escrow Agent to pay to Buyer an amount out of the Escrow Fund equal to the Agreed Amount); or (iii) dispute that the Indemnified Party is entitled to receive any of the Claimed Amount. 

(d) During the 30-day period following the delivery of a Response that reflects a Dispute, the Indemnifying Party and the Indemnified
Party shall use good faith efforts to resolve the Dispute. If the Dispute is not resolved within such 30-day period, the Indemnifying Party and the Indemnified Party shall submit the Dispute to binding arbitration in accordance with the provisions
of Section 8.3(e). If the Indemnified Party is Buyer and is seeking to enforce the claim that is the subject of the Dispute pursuant to the Escrow Agreement, the Indemnifying Party and the Indemnified Party shall deliver to the Escrow
Agent, promptly following the resolution of the Dispute (whether by mutual agreement, arbitration, judicial decision or otherwise), a written notice executed by Buyer and Seller instructing the Escrow Agent as to what (if any) amount out of the
Escrow Fund shall be paid to Buyer (which notice shall be consistent with the terms of the resolution of the Dispute). 
 (e)
If, as set forth in Section 8.3(d), the Indemnified Party and the Indemnifying Party submit any Dispute to binding arbitration, the arbitration shall be conducted by a single arbitrator (the “Arbitrator”) in accordance
with the Commercial Rules in effect from time to time and the following provisions: 
 (i) In the event of any conflict between
the Commercial Rules in effect from time to time and the provisions of this Agreement, the provisions of this Agreement shall prevail and be controlling. 

  
 - 51 -

 EXECUTION COPY 
  

 (ii) The applicable Parties shall commence the arbitration by jointly filing a written
submission with the New York, New York office of the AAA in accordance with Commercial Rule 5 (or any successor provision). 

(iii) No depositions or other discovery shall be conducted in connection with the arbitration. 

(iv) Not more than thirty (30) days after the conclusion of the arbitration hearing, the Arbitrator shall prepare and distribute to
the Parties a writing setting forth the arbitral award and the Arbitrator’s reasons therefor. Any award rendered by the Arbitrator shall be final, conclusive and binding upon the Parties, and judgment thereon may be entered and enforced in any
court of competent jurisdiction; provided, that the Arbitrator shall have no power or authority to grant injunctive or equitable relief or specific performance. 
 (v) The Arbitrator shall have no power or authority, under the Commercial Rules or otherwise, to (x) modify or disregard any provision of this Agreement, including the provisions of this
Section 8.3(e), or (y) address or resolve any issue not submitted by the Parties. 
 (vi) In connection with
any arbitration proceeding pursuant to this Agreement, each party to such proceeding shall bear its own costs and expenses, except that the fees and costs of the AAA and the Arbitrator, the costs and expenses of obtaining the facility where the
arbitration hearing is held, and such other costs and expenses as the Arbitrator may determine to be directly related to the conduct of the arbitration and appropriately borne equally by Buyer and Seller (which shall not include any Party’s
attorneys’ fees or costs, witness fees (if any), costs of investigation and similar expenses) shall be shared equally by the Indemnified Party and the Indemnifying Party. 
 (f) If an Indemnified Buyer Party is entitled to indemnification from Seller, Buyer shall be entitled (but not required) to satisfy the amount of any indemnification entitlement by deduction from and
offset and set-off against the amounts (if any) that Buyer would obligated be to pay to Seller pursuant to Section 1.7. 
 8.4. Survival. All representations and warranties, and all covenants and agreements (other than covenants and agreements that by their terms involve continuing or post-Closing obligations), that
are covered by the indemnification provisions of Section 8.1(a) and (b) and Section 8.2 shall, except as provided in Section 5.15, (a) survive the Closing and (b) shall expire at 11:59 p.m. Pacific
time on the date that is eighteen (18) months after the Closing Date (subject to extension as provided below, the “Expiration Date”), except that (i) the representations and warranties set forth in Sections 2.1, 2.2.
and 2.5, Sections 3.1, 3.2, and 3.3 and Sections 4.1 and 4.2 shall survive the Closing without limitation and (ii) the representations and warranties set forth in Sections 3.13, 3.22, 3.23 and 3.30 shall
survive until ninety (90) days following the date that would otherwise be the expiration of all statutes of limitation applicable to the matters 

  
 - 52 -

 EXECUTION COPY 
  

 
referred to therein. If an Indemnified Party delivers to an Indemnifying Party, before expiration of a representation or warranty, either a Claim Notice based upon a breach of or inaccuracy in
such representation or warranty, or an Expected Claim Notice involving a breach or alleged breach of or inaccuracy or alleged inaccuracy in such representation or warranty, then the applicable representation or warranty shall survive, and the
Expiration Date shall be extended, for purposes of the resolution of any claims arising from or related to the matter covered by such notice, until such resolution. If the legal proceeding or written claim with respect to which an Expected Claim
Notice has been given is definitively withdrawn or resolved in favor of the Indemnified Party, the Indemnified Party shall promptly so notify the Indemnifying Party; and if the Indemnified Party has delivered a copy of the Expected Claim Notice to
the Escrow Agent and a portion of the Escrow Fund has been retained in escrow after the Termination Date (as defined in the Escrow Agreement) with respect to such Expected Claim Notice, the Indemnifying Party and the Indemnified Party shall promptly
deliver to the Escrow Agent a written notice executed by both Buyer and Seller instructing the Escrow Agent to distribute such retained portion of the Escrow Fund to Seller in accordance with the terms of the Escrow Agreement. If the legal
proceeding or claim with respect to which an Expected Claim Notice has been given is resolved against an Indemnified Party, the Indemnified Party shall promptly so notify the Indemnifying Party and the Expected Claim Notice shall thereupon
automatically be converted into and shall thenceforth be treated as a Claim Notice. The rights to indemnification set forth in this Article VIII shall not be affected by (i) any investigation conducted by or on behalf of an Indemnified
Party or any knowledge acquired (or capable of being acquired) by an Indemnified Party, whether before or after the date of this Agreement or the Closing Date, with respect to the inaccuracy or noncompliance with any representation, warranty,
covenant or obligation which is the subject of indemnification hereunder or (ii) any waiver by an Indemnified Party of any closing condition relating to the accuracy of representations and warranties or the performance of or compliance with
agreements and covenants. 
 8.5. Limitations. 
 (a) Except as otherwise expressly set forth herein, Seller shall not be liable under this Article VIII unless and until the aggregate Losses for which Seller would otherwise be liable under
this Article VIII exceed [**] dollars ($[**]) (the “Threshold Amount”) (at which point Seller shall become liable for all aggregate Losses subject to indemnification under this Article VIII, and not just
amounts in excess of the Threshold Amount; provided that the limitation set forth in this sentence shall not apply to a claim pursuant to Section 8.1(a) relating to a breach of the representations and warranties set forth in
Sections 2.1, 2.2 or 2.5 or Sections 3.1, 3.2, 3.3, 3.13, 3.23(g), or 3.30 or pursuant to Section 8.1(f) (as to which the Threshold Amount shall not apply), or to a claim pursuant to Section 8.1(d) with
respect to matters disclosed in Schedule 8.1(d) (as to which the Threshold Amount shall be deemed to be [**] dollars ($[**])). For purposes solely of this Article VIII, all representations and warranties of Seller in Article
II and Article III (other than Section 3.7 (Absence of Certain Changes) and Section 3.31 (Disclosure)) shall be construed without respect to any materiality limitation, materiality qualification or materiality
basket, as if the term “material” and any reference to “Company Material Adverse Effect” (and variations thereof) were omitted from such representations and warranties. 

  
 - 53 -

 EXECUTION COPY 
  

 (b) Notwithstanding anything to the contrary herein, Buyer shall not be liable under
this Article VIII unless and until the aggregate Losses for which Buyer would otherwise be liable under this Article VIII exceed the Threshold Amount (at which point Buyer shall become liable for all aggregate Losses subject
to indemnification under this Article VIII, and not just amounts in excess of the Threshold Amount); provided that the limitation set forth in this sentence shall not apply to a claim pursuant to Section 8.1(a)
relating to a breach of the representations and warranties set forth in Sections 4.1, 4.2, 4.3, 4.4 or 4.6 or a claim for payment of any amount due pursuant to Article I. For purposes solely of this Article VIII, all
representations and warranties (if any) of Buyer in Article IV with materiality limitations, qualifications or baskets shall be construed without respect to any materiality limitation, materiality qualification or materiality basket, as
if the term “material” and any reference to “Buyer Material Adverse Effect” (and variations thereof) were omitted from such representations and warranties. 
 (c) The Escrow Agreement is intended to secure the indemnification obligations of Seller under Article VIII and Section 5.15, the adjustment obligations of Seller under
Section 1.5, and the obligations of Parent under the Parent Guaranty. However, the rights of Buyer under this Article VIII, Section 5.15, and Section 1.5 shall not be limited to the Escrow Fund nor shall the
Escrow Agreement be the exclusive means for Buyer to enforce such rights; provided that, except as otherwise expressly permitted by this Agreement, Buyer shall not attempt to collect any Losses directly from Seller pursuant to this Article
VIII or Section 5.15 unless no remaining portion of the Escrow Fund is held in escrow pursuant to the Escrow Agreement and no portion of the Earn-Out is available to satisfy such Losses; and provided further that,
notwithstanding anything to the contrary herein, in no event shall the aggregate liability of Seller pursuant to this Article VIII and Section 5.15 (and the aggregate liability of Parent pursuant to the Parent Guaranty insofar as
such guaranty relates to the liabilities of Seller pursuant to this Article VIII), taken together, exceed the Cap. 
 (d)
Except with respect to claims based on fraud or willful misrepresentation, after the Closing, the rights of the Indemnified Parties under this Article VIII, Section 5.15 and the Escrow Agreement, shall be the exclusive remedy
of the Indemnified Parties with respect to claims resulting from or relating to any breach of or inaccuracy in any representation or warranty in this Agreement. For the avoidance of doubt, nothing in this Section 8.5(d) is intended to
limit the Partiers’ rights to recover purchase price adjustments pursuant to Section 1.5 or any rights of offset and set-off pursuant to Section 1.4 (b). 

(e) Neither Seller nor any of its subsidiaries shall have any right of contribution against the Company with respect to any breach of or
inaccuracy in any representation and warranty of the Company or any breach by the Company of any of its covenants or agreements. 
 (f) In the event that adjustment has been made pursuant to Section 1.5 for any item that also constitutes an indemnifiable Loss pursuant to this Article VIII arising out of a breach of
Seller’s representations and warranties in Section 3.14 or Section 3.16, Buyer shall not be entitled to recover indemnification under this Article VIII for any amount that Buyer has theretofore recovered as an
adjustment to the Base Purchase Price pursuant to Section 1.5. 

  
 - 54 -

 EXECUTION COPY 
  

 ARTICLE IX 
 CERTAIN POST-CLOSING AGREEMENTS 
 Seller agrees that from and after the
Closing Date: 
 9.1. Proprietary Information. 
 (a) Seller shall (and shall cause each of its Affiliates to) hold in confidence and shall use its (and their) commercially reasonable efforts to have all officers, directors and personnel who continue
after the Closing to be employed by Seller or any Affiliate of Seller to hold in confidence all knowledge and information of a secret or confidential nature with respect to the business of the Company and not to disclose, publish or make use of the
same without the consent of Buyer, except as required by law (in which case Seller shall provide reasonable advance notice of such proposed disclosure and shall cooperate with Buyer and the Company, at their expense, in seeking an appropriate
protective order or other confidentiality assurances) and except to the extent that such information shall have become public knowledge other than by breach of this Agreement by Seller. 

(b) If (i) the employment of an officer, director or other employee of Seller or any Affiliate thereof, to whom secret or
confidential knowledge or information concerning the business of the Company has been disclosed, is terminated and (ii) such individual is subject to an obligation to maintain such knowledge or information in confidence after such termination,
Seller shall, upon request by Buyer, take all reasonable steps at their expense to enforce such confidentiality obligation in the event of an actual or threatened breach thereof. Any legal counsel retained by Seller in connection with any such
enforcement or attempted enforcement shall be selected by Seller, but shall be subject to the approval of Buyer, which approval shall not be unreasonably withheld. 
 (c) Seller agrees that the remedy at law for any breach of this Section 9.1 would be inadequate and that Buyer shall be entitled to injunctive relief in addition to any other remedy it may
have upon breach of any provision of this Section 9.1. 
 9.2. No Solicitation of Former Employees. Except as
provided by law, for a period of [**] ([**]) years after the Closing Date, Seller shall not (and shall cause its subsidiaries and Affiliates not to) directly or indirectly solicit, induce or encourage any person who was an employee (other than
secretarial and clerical staff) of either the Company on the date hereof or the Closing Date to terminate his employment with Buyer (or the Company, as the case may be) or to become an employee of Seller or any of its subsidiaries or Affiliates;
provided, that nothing in this Section 9.2 shall be construed to prohibit Seller from placing advertisements in publications of general circulation that are not directly specifically at employees of Buyer or the Company.

 9.3. Non-Competition Agreement. 
 (a) For a period of [**] ([**]) years after the Closing Date (the “Restricted Period”), neither Seller nor any of its subsidiaries or Affiliates shall (and Seller shall procure that
Parent shall not), either directly or indirectly through any subsidiary or Affiliate, develop, 

  
 - 55 -

 EXECUTION COPY 
  

 
manufacture, market or sell, anywhere in the world (including anywhere in the United States or any country in North America, Japan or any country in Asia, Australia, New Zealand, England or any
country in Europe), (i) any sustained-release bupivacaine-based product for use in pain management, or (ii) any sustained-release opioid-based product for use in pain management (other than the non-injectable sustained-release
naproxen-hydrocodone combination products currently under development at the Company), or (iii) any sustained-release cytarabine-based product, or (iv) any sustained-release Biologics Product (as defined in Schedule 1.7). For
purposes of this provision, “sustained-release” shall mean release such that the intended dosing or use is for more than twelve (12) hours. For a period of [**] ([**]) years after the Closing Date, Seller shall not, and shall procure
that Parent and its Affiliates shall not, solicit any drug development business with respect to any of the substances listed in Column A of Schedule 9.3(a) from any of the entities named or otherwise identified opposite such substance in
Column B thereof. 
 (b) Seller and Buyer agree that the market for the Company’s products is worldwide, that development
cycles for products such as the Company’s products are lengthy, and that duration and geographic scope of the non-competition provision set forth in this Section 9.3 are reasonable. In the event that any court of competent
jurisdiction determines that the duration or the geographic scope, or both, are unreasonable and that such provision is to that extent unenforceable, Seller and Buyer agree that the provision shall remain in full force and effect for the greatest
time period and in the greatest area that would not render it unenforceable. Seller and Buyer intend that this non-competition provision shall be deemed to be a series of separate covenants, one for each and every county of each and every state of
the United States of America and each and every country and political subdivision of each and every country outside the United States of America where this provision is intended to be effective. Seller agrees that damages are an inadequate remedy
for any breach of this provision and that Buyer shall, whether or not it is pursuing any potential remedies at law, be entitled to equitable relief in the form of preliminary and permanent injunctions without bond or other security upon any actual
or threatened breach of this non-competition provision. 
 (c) Notwithstanding the foregoing provisions: (i) nothing herein
shall be construed to prevent or prohibit the acquisition of Parent as a whole by any unaffiliated acquiror or to subject the other operations of any such acquiror to the restrictions of this Section 9.3 (it being understood and agreed
that the provisions of this Section 9.3 shall continue to apply to the operations of Seller and the entities that prior to the consummation of such an acquisition are Affiliates of Seller (including Parent and its Affiliates)); and
(ii) in the event that Parent acquires a company whose assets and operations would violate the provisions of this Section 9.3, neither Parent nor Seller shall be deemed to be in violation of this Section 9.3 as long as
Parent shall have divested, spun off or otherwise ceased to own or operate such assets and operations within one hundred eighty (180) days after the consummation of such acquisition. 

9.4. Further Assurances. If at any time before the Closing or during the three (3) year period following the Closing any
Omitted IP is discovered, Seller shall (and shall procure that Parent and its Affiliates shall), at Seller’s sole expense, (a) assign, transfer and deliver all right, title and interest held by Seller (or by Parent or any of its
Affiliates) in, to and under such Omitted IP to the Company at the Closing or as soon as reasonably practicable after the Closing, 

  
 - 56 -

 EXECUTION COPY 
  

 
but in any case, within thirty (30) days after such Omitted IP is discovered, and (b) take such further action reasonably requested by the Company or Buyer in order to more fully vest
and record title in and to such Omitted IP the name of the Company. Subject to Seller’s compliance with this Section 9.4, and provided that the omission of such Omitted IP is inadvertent, Buyer agrees and acknowledges that
Buyer’s rights under this Section 9.4 shall be its sole and exclusive remedy for a breach of the representations and warranties set forth in Section 3.13(g), where such breach arises solely from the failure of the
Company to own such Omitted IP as of the Closing. Effective upon (and subject to) the assignment to the Company of any Licensed-Back Omitted IP in accordance with this Section 9.4, the Company hereby grants to Seller and its Affiliates a
non-exclusive, royalty-free, perpetual, irrevocable, worldwide license, with the right to sublicense, under any and all such Licensed-Back Omitted IP for use by Seller and its Affiliates subject to the provisions of Section 9.3.

 ARTICLE X 
 TERMINATION OF AGREEMENT 
 10.1. Termination by Lapse of Time. This
Agreement shall terminate at 5:00 p.m. Pacific Standard Time, on April 30, 2007, if the transactions contemplated hereby have not been consummated, unless such date is extended by the written consent of the Company, Buyer and Seller.

 10.2. Termination by Agreement of the Parties. This Agreement may be terminated by the mutual written agreement of the
Parties hereto. In the event of such termination by agreement, Buyer shall have no further obligation or liability to Seller or the Company under this Agreement, and Seller shall have no further obligation or liability to Buyer under this Agreement.

 10.3. Termination by Reason of Breach. 
 (a) This Agreement may be terminated by Seller by giving written notice to Buyer in the event Buyer is in breach of any representation, warranty or covenant contained in this Agreement, and such
breach, individually or in combination with any other such breach, (i) would cause the conditions set forth in Sections 7.2 or 7.3 not to be satisfied and (ii) is not cured within twenty (20) days following delivery by Seller
to Buyer of written notice of such breach. 
 (b) This Agreement may be terminated by Buyer by giving written notice to Seller
and the Company in the event that Seller or the Company are in breach of any representation, warranty or covenant contained in this Agreement, and such breach, individually or in combination with any other such breach, (i) would cause the
conditions set forth in Sections 6.11 not to be satisfied and (ii) is not cured within twenty (20) days following delivery by Buyer of written notice of such breach. 

10.4. Termination For Failure to Obtain Shareholder Approval. This Agreement may be terminated by either Party if the requisite
approval of Seller’s shareholders as set forth in Section 5.3 shall not have been obtained at the EGM (including adjournments thereof); provided, however, that no Party shall have the right to terminate this Agreement
pursuant to this Section 10.4 if the failure to obtain the requisite approval of Seller’s shareholders is attributable to a breach of that Party’s obligations under this Agreement. 

  
 - 57 -

 EXECUTION COPY 
  

 10.5. Effect of Termination. If any Party terminates this Agreement pursuant to
Section 10.1 or 10.2, all obligations of the Parties hereunder shall terminate without any liability of any Party to any other Party and shall be null and void (except in each case for any liability of any Party for bad faith breaches of
this Agreement). Notwithstanding the foregoing, (a) if this Agreement is terminated by any Party pursuant to Section 10.4, Seller shall promptly pay to Buyer the out-of-pocket expenses actually incurred by Buyer and its shareholders
in connection with the negotiation of this Agreement and the Ancillary Agreements and the pursuit of the transactions contemplated hereby and thereby (the amount of which shall be disclosed by Buyer to Seller promptly following delivery by Seller to
Buyer of a notice of intended termination requesting the same), up to a maximum of [**] dollars ($[**]); and (b) if this Agreement is terminated (i) by Seller pursuant to Section 10.1 or Section 10.4, or
(ii) by Buyer pursuant to Section 10.1 for breach by Seller of any of its obligations under Section 5.7, or (iii) by Buyer pursuant to Section 10.1 or 10.4, and if, in each case within the scope of the
immediately preceding clauses (i), (ii) and (iii), after the date hereof and prior to such termination a competing offer, bid or indication or expression of interest (an “Acquisition Proposal”) shall have been made to acquire
the Company or any material asset of the Company and such offer, bid or indication or expression of interest shall not have been definitively and unconditionally withdrawn a reasonable time before the EGM, and Seller, Seller, the Company or any of
their subsidiaries enter into a definitive agreement with respect to an Acquisition Proposal within twelve (12) months after the date of such termination, then Seller shall, prior to and as a condition precedent to the effectiveness of any such
termination and prior to or concurrently with the signing of such definitive agreement, pay to Buyer, by wire transfer of immediately available funds to an account to be designated by Buyer, the sum in cash of [**] dollars ($[**]) plus the
out-of-pocket expenses actually incurred by Buyer in connection with the negotiation of this Agreement and the Ancillary Agreements and the pursuit of the transactions contemplated hereby and thereby (the amount of which shall be disclosed by Buyer
to Seller promptly following delivery by Seller to Buyer of a notice of intended termination requesting the same), which in no event shall be more than [**] dollars ($[**]) in total (the “Termination Fee”). In the event that a
payment is made pursuant to Section 10.5(b), no payment shall be made pursuant to Section 10.5(a), and in the event that a payment is made pursuant to Section 10.5(a), any subsequent payment pursuant to
Section 10.5(b) shall be net of any amount paid pursuant to Section 10.5(a). 
 10.6. Election of
Remedies; Liquidated Damages. If Seller wrongfully fails to close and complete the purchase and sale of the Shares contemplated by this Agreement, Buyer shall be entitled, at its election and in its sole discretion, to one (but not both) of the
following remedies: (a) specific performance or other equitable relief to compel the consummation of the transactions contemplated by this Agreement or (b) payment by Buyer of liquidated damages in the amount of the Termination Fee, which
(if paid by Seller within two (2) business days after receipt of notice of Buyer’s election of remedy) shall constitute full satisfaction of any and all claims that Buyer may have against Seller for breach of this Agreement;
provided, that if Buyer elects the remedy provided by clause (a) of this Section 10.6, then the maximum amount of 

  
 - 58 -

 EXECUTION COPY 
  

 
damages recoverable by Seller against Buyer in respect of any claim or counterclaim of breach by Buyer of this Agreement shall be reciprocally limited to the amount of the Termination Fee, and if
Buyer elects the remedy provided by clause (b) of this Section 10.6, then the damage remedies available to Seller against Buyer in respect of any claim or counterclaim of breach by Buyer of this Agreement shall not be limited to the
amount of the Termination Fee. 
 ARTICLE XI 
 DISPUTE RESOLUTION 
 11.1. General. In the event that any dispute
should arise between Buyer and Seller after the Closing with respect to any matter covered by this Agreement (other than a dispute within the scope of Section 8.3(d) and 8.3(e)), including the Adjusted Purchase Price, Buyer and Seller
shall resolve such dispute in accordance with the procedures set forth in this Article XI. 
 11.2. Consent of the
Parties. Buyer and Seller shall first use their commercially reasonable efforts to resolve such dispute among themselves. If Buyer and Seller are unable to resolve the dispute within thirty (30) calendar days after the commencement of
efforts to resolve the dispute, either Buyer or Seller may either (i) commence an action with respect to the matter in dispute in an appropriate court of competent jurisdiction in accordance with the provisions of Section 13.8, or
(ii) submit the matter in dispute to arbitration in accordance with Section 11.3; provided, that if the other Party objects or is seeking relief that the arbitrator is not authorized or empowered to award, the matter in
dispute shall not be submitted to arbitration but shall instead be determined in court in accordance with the provisions of Section 13.8. 
 11.3. Arbitration. 
 (a) Either Buyer or Seller may submit any matter
referred to in Section 11.2 to arbitration by notifying the other Party (and, if the matter involves the Escrow Fund, the Escrow Agent), in writing, of such dispute. Within ten (10) days after receipt of such notice, Buyer and
Seller shall designate in writing one arbitrator to resolve the dispute; provided, that if Buyer and Seller cannot agree on an arbitrator within such 10-day period, the arbitrator shall be selected by the AAA. The arbitrator so designated
shall not be an employee, consultant, officer, director or stockholder of any Party hereto or any Affiliate of any Party to this Agreement. 
 (b) Within fifteen (15) days after the designation of the arbitrator, the arbitrator, Buyer and Seller shall meet, at which time Buyer and Seller shall be required to set forth in writing all
disputed issues and a proposed ruling on each such issue. 
 (c) The arbitrator shall set a date for a hearing, which shall be
no later than thirty (30) days after the submission of written proposals pursuant to paragraph (b) above, to discuss each of the issues identified by Buyer and Seller. Buyer and Seller shall each have the right to be represented by
counsel. The arbitration shall be governed by the rules of the AAA; provided, that the arbitrator shall have sole discretion with regard to the admissibility of evidence. 

(d) The arbitrator shall use his best efforts to rule on each disputed issue within thirty (30) days after the completion of the
hearings described in paragraph (c) above. 

  
 - 59 -

 EXECUTION COPY 
  

 
The determination of the arbitrator as to the resolution of any dispute shall be binding and conclusive upon all Parties hereto. All rulings of the arbitrator shall be in writing and shall be
delivered to the Parties hereto and, to the extent they involve the Escrow Fund, the Escrow Agent. 
 (e) The prevailing party
in any arbitration shall be entitled to an award of reasonable attorneys’ fees incurred in connection with the arbitration. The non-prevailing party shall pay such fees, together with the fees of the arbitrator and the costs and expenses of the
arbitration. 
 (f) Any arbitration pursuant to this Section 11.3 shall be conducted in New York, New York.

 (g) Notwithstanding any provision of this Article XI to the contrary, disputes that are within the scope of
Section 8.3(d) and 8.3(e) shall be resolved in accordance with the provisions of Article VIII and not this Article XI. 
 ARTICLE XII 
 DEFINITIONS 

12.1. Certain Definitions. For purposes of this Agreement, each of the following terms shall have the meaning set forth below.

 “AAA” shall mean the American Arbitration Association. 

“Adjusted Purchase Price” shall mean the Base Purchase Price as adjusted in accordance with Section 1.5(c).

 “Affiliate” shall mean any affiliate, as defined in Rule 12b-2 under the Securities Exchange Act of 1934.

 “Affiliated Group” shall mean a group of corporations with which the Company has filed (or was required to
file) consolidated, combined, unitary or similar Tax Returns. 
 “Affiliate Owned Intellectual Property” shall
have the meaning set forth in Section 3.13(a). 
 “Affiliated Period” shall mean any period in which
the Company was a member of an Affiliated Group. 
 “Agreed Amount” shall mean part, but not all, of the Claimed
Amount. 
 “Agreement” shall have the meaning set forth in the first paragraph. 

“Ancillary Agreements” means the Parent Guaranty, the Escrow Agreement, the License Agreement, the Transition Services
Agreement, the Assignment of Patents, and the Assignment of Trademarks. 

  
 - 60 -

 EXECUTION COPY 
  

 “Anti-Kickback Statute” shall mean 42 U.S.C. § 1320a-7b(b).

 “Antitrust Laws” shall have the meaning set forth in Section 5.2. 

“Arbitrator” shall have the meaning set forth in Section 8.3(e). 

“Base Purchase Price” shall mean the portion of the purchase price to be paid by Buyer at the Closing, as set forth in
Section 1.3, subject to adjustment pursuant to Section 1.5. 
 “Biosphere Assets” shall
have the meaning set forth in Section 5.11. 
 “Buyer” shall have the meaning set forth in the first
paragraph of this Agreement. 
 “Buyer Compliance Certificate” shall mean a certificate to the effect that each
of the conditions specified in Article VII is satisfied in all respects. 
 “Buyer Material Adverse
Effect” shall mean any material adverse change, event, circumstance or development with respect to, or material adverse effect on, the business, assets, liabilities, capitalization, prospects, condition (financial or other), or results of
operations of Buyer. For the avoidance of doubt, the Parties agree that the terms “material”, “materially” or “materiality” as used in this Agreement with an initial lower case “m” shall have their respective
customary and ordinary meanings, without regard to the meaning ascribed to Buyer Material Adverse Effect. 

“Cap” shall mean [**] dollars ($[**]). 
 “CERCLA” shall mean the federal Comprehensive Environmental Response, Compensation and Liability Act of 1980, as amended. 

“Circular” shall have the meaning set forth in Section 5.3. 

“Claim Notice” shall mean written notification which contains (i) a description of the Losses incurred or reasonably
expected to be incurred by the Indemnified Party and the Claimed Amount of such Losses, to the extent then known, (ii) a statement that the Indemnified Party is entitled to indemnification under Article VIII for such Losses and a
reasonable explanation of the basis therefor, and (iii) a demand for payment in the amount of such Losses. 

“Claimed Amount” shall mean the amount of any Losses incurred by the Indemnified Party or, in the case of Third-Party
Claims, incurred or reasonably expected to be incurred by the Indemnified Party. 
 “Closing” shall mean the
closing of the transactions contemplated by this Agreement. 
 “Closing Date” shall mean the date on which the
actually closing occurs. 
 “Code” and “Internal Revenue Code” shall mean the Internal Revenue
Code of 1986, as amended. 

  
 - 61 -

 EXECUTION COPY 
  

 “Commercial Rules” shall mean the Commercial Arbitration Rules of the
AAA. 
 “Commitment Letters” shall have the meaning set forth in Section 4.6. 

“Common Stock” shall mean the shares of common stock, no par value per share, of the Company. 

“Company” shall have the meaning set forth in the first paragraph of this Agreement. 

“Company Debt” shall have the meaning set forth in Section 5.15(r). 

“Company Intellectual Property” shall have the meaning set forth in Section 3.13(a). 

“Company Material Adverse Effect” shall mean any material adverse change, event, circumstance or development with respect
to, or material adverse effect on, the business, assets, liabilities, capitalization, employees, condition (financial or other), or results of operations of the Company. For the avoidance of doubt, the Parties agree that the terms
“material,” “materially” or “materiality” as used in this Agreement with an initial lower case “m” shall have their respective customary and ordinary meanings, without regard to the meaning ascribed to Company
Material Adverse Effect, and that the departure from the Company of material members of senior management (or the departure from the Company of a number of employees that is material to the operation of the business of the Company after the Closing
and the transactions contemplated by this Agreement) may constitute a Company Material Adverse Effect. 
 “Company Owned
Intellectual Property” shall have the meaning set forth in Section 3.13(a). 
 “Company
Patents” shall have the meaning set forth in Section 3.13(a). 
 “Company Plan” shall mean
any Employee Benefit Plan maintained, or contributed to, by the Company or any ERISA Affiliate for the benefit of any current or former employees of the Company. 
 “Confidential Information” shall mean any confidential or proprietary information of the Company that is furnished in writing to Buyer by the Company in connection with this Agreement and
is labeled confidential or proprietary; provided, however, that it shall not include any information (A) which, at the time of disclosure, is available publicly, (B) which, after disclosure, becomes available publicly through
no fault of Buyer, (C) which Buyer knew or to which Buyer had access prior to disclosure or (D) which Buyer rightfully obtains from a source other than the Company. 
 “Controlling Party” shall mean the party controlling the defense of any Third Party Claim. 
 “Copyrights” shall have the meaning set forth in Section 3.13(a). 
 “DEA” shall have the meaning set forth in Section 3.30. 

  
 - 62 -

 EXECUTION COPY 
  

 “Designated Amounts” shall mean the items listed in Schedule
12.1. 
 “Dispute” shall mean the dispute resulting if the Indemnifying Party in a Response disputes its
liability for all or part of the Claimed Amount. 
 “DMF” shall have the meaning set forth in
Section 3.30(m). 
 “Draft Closing Net Assets Statement” shall have the meaning set forth in
Section 1.5(a). 
 “Due Date” shall mean, with respect to any Tax Return, the date such Tax Return
is required to be filed (taking into account all valid extensions). 
 “EGM” shall have the meaning set forth in
Section 5.3. 
 “EMEA” shall have the meaning set forth in Section 3.30. 

“Employee Benefit Plan” shall mean any “employee pension benefit plan” (as defined in Section 3(2) of
ERISA), any “employee welfare benefit plan” (as defined in Section 3(1) of ERISA), and any other written or oral plan, agreement or arrangement involving direct or indirect compensation, including insurance coverage, severance
benefits, disability benefits, deferred compensation, bonuses, stock options, stock purchase, phantom stock, stock appreciation or other forms of incentive compensation or post-retirement compensation. 

“Encumbrance” means any and all Security Interests, covenants, conditions, restrictions, voting trust arrangements,
liens, charges, encumbrances, rights of first offer or first refusal, options and adverse claims or rights whatsoever, provided, however, that Encumbrance shall not include a lien for Taxes (i) not yet due and payable, or (ii) being
contested in good faith in appropriate proceedings and with respect to which adequate reserves have been established on the Most Recent Balance sheet in accordance with IFRS. 
 “Endo Agreement” means the Development and Marketing Strategic Alliance Agreement dated December 31, 2002 among Endo Pharmaceuticals, Inc., SkyePharma, Inc. and SkyePharma Canada
Inc. 
 “Environmental Law” shall mean any federal, state or local law, statute, rule, order, directive,
judgment, Permit or regulation or the common law relating to the environment, occupational health and safety, or exposure of persons or property to Materials of Environmental Concern, including any statute, regulation, administrative decision or
order pertaining to: (i) the presence of or the treatment, storage, disposal, generation, transportation, handling, distribution, manufacture, processing, use, import, export, labeling, recycling, registration, investigation or remediation of
Materials of Environmental Concern or documentation related to the foregoing; (ii) air, water and noise pollution; (iii) groundwater and soil contamination; (iv) the release, threatened release, or accidental release into the
environment, the workplace or other areas of Materials of Environmental Concern, including emissions, discharges, injections, spills, 

  
 - 63 -

 EXECUTION COPY 
  

 
escapes or dumping of Materials of Environmental Concern; (v) transfer of interests in or control of real property which may be contaminated; (vi) community or worker right-to-know
disclosures with respect to Materials of Environmental Concern; (vii) the protection of wild life, marine life and wetlands, and endangered and threatened species; (viii) storage tanks, vessels, containers, abandoned or discarded barrels
and other closed receptacles; and (ix) health and safety of employees and other persons. As used above, the term “release” shall have the meaning set forth in CERCLA. 

“ERISA” shall mean the Employee Retirement Income Security Act of 1974, as amended. 

“ERISA Affiliate” shall mean any entity which is, or at any applicable time was, a member of (1) a controlled group
of corporations (as defined in Section 414(b) of the Code), (2) a group of trades or businesses under common control (as defined in Section 414(c) of the Code), or (3) an affiliated service group (as defined under
Section 414(m) of the Code or the regulations under Section 414(o) of the Code), any of which includes or included the Company. 
 “Escrow Agent” shall mean Boston Trust & Investment Management Company (or another escrow or depositary agent designated by Buyer and reasonably acceptable Seller). 

“Escrow Agreement” shall mean an escrow agreement in substantially the form attached hereto as Exhibit B.

 “Escrow Amount” shall mean two million dollars ($2,000,000). 

“Escrow Fund” shall have the meaning set forth in Section 1.6. 

“Excluded Assets” shall have the meaning set forth in Section 5.11. 

“Excluded Taxes” shall have the meaning set forth in Section 5.15(b). 

“Expected Claim Notice” shall mean a notice that, as a result of a legal proceeding instituted by or written claim made
by a third party, an Indemnified Party reasonably expects to incur Losses for which it is entitled to indemnification under Article VIII. 
 “Expiration Date” shall have the meaning set forth in Section 8.4. 
 “FDA” shall have the meaning set forth in Section 3.30. 
 “FDCA” shall have the meaning set forth in Section 3.30. 
 “Federal False Claims Act” shall have the meaning set forth in Section 3.30. 
 “Final Closing Net Assets Statement” shall have the meaning set forth in Section 1.5(b). 

  
 - 64 -

 EXECUTION COPY 
  

 “Final Determination” shall mean (i) a decision by a court of
competent jurisdiction that is not subject to further judicial review, (ii) a closing agreement or other final resolution with the relevant Taxing Authority, or (iii) any other event that is a final and irrevocable determination of
liability for Tax. 
 “Financial Statements” shall mean the balance sheet of the Company on a stand-alone basis
as of October 27, 2006 and the Most Recent Net Assets Statement, each of which shall be prepared by Seller on a going-concern basis. 
 “Governmental Entity” shall mean (a) any nation (including but not limited to the United States of America), state, province, canton, county, city, district or other jurisdiction or
political subdivision or unit of any nature; (b) any national, federal, state, provincial, cantonal, county, city, local, municipal or other government; (c) any branch or instrumentality of any government whether executive, legislative,
judicial, administrative or other; (d) any administrative agency, administration or commission; (e) any court or tribunal; any quasi-governmental authority or body exercising or entitled to exercise any administrative, executive, judicial,
legislative, police, regulatory, or taxing authority or power of any nature; and (f) any multi-national or supranational organization or body. 
 “Group Owned Intellectual Property” shall have the meaning set forth in Section 3.13(a). 
 “HC” shall have the meaning set forth in Section 3.30. 

“HSR Act” shall mean the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended. 

“IFRS” shall mean International Financial Reporting Standards. 

“Income Tax(es)” shall mean any Tax(es) imposed upon or measured by net income and any franchise Tax(es). 

“IND” shall have the meaning set forth in Section 3.30(h). 

“Indemnified Buyer Party” shall have the meaning set forth in Section 8.1. 

“Indemnified Party” shall mean a Person entitled, or seeking to assert rights, to indemnification under
Article VIII. 
 “Indemnified Seller Party” shall have the meaning set forth in
Section 8.2. 
 “Indemnifying Party” shall mean the party from whom indemnification is sought by the
Indemnified Party. 
 “Intellectual Property” shall have the meaning set forth in Section 3.13(a).

 “IP Contracts” shall have the meaning set forth in Section 3.13(a). 

  
 - 65 -

 EXECUTION COPY 
  

 “Lease” shall mean any lease or sublease pursuant to which the Company
leases or subleases from another party any real property. 
 “Legal Proceeding” shall mean any action, suit,
proceeding, claim, arbitration or investigation before any Governmental Entity or before any arbitrator, except that the foregoing shall not apply to proceedings before the United States Patent and Trademark Office or similar entities in other
jurisdiction with respect to patent prosecution conducted in the ordinary course of business. 
 “Licensed-Back Omitted
IP” means Omitted IP that is (a) assigned by Seller or its Affiliates to the Company in accordance with Section 9.4, and (b) used by Seller or its Affiliates as of the Closing Date, other than in the business of the
Company; provided, however, that “Licensed-Back Omitted IP” shall exclude any Product Intellectual Property and Intellectual Property solely comprising, claiming or covering the DepoFoam or Biosphere technologies. 

“Losses” shall mean any and all debts, obligations and other liabilities (whether absolute, accrued, contingent, fixed or
otherwise, or whether known or unknown, or due or to become due or otherwise), diminution in value, monetary damages, fines, fees, penalties, interest obligations, deficiencies, losses and expenses (including amounts paid in settlement, interest,
court costs, costs of investigators, fees and expenses of attorneys, accountants, financial advisors and other experts, and other expenses of litigation), other than those costs and expenses of arbitration of a Dispute which are to be shared equally
by the Indemnified Party and the Indemnifying Party as set forth in Section 8.3(e)(vi). The Losses recoverable by an Indemnified Party pursuant to Article VIII shall be net of any insurance proceeds actually received by the
Indemnified Party without adverse impact on the continuation or increase in the cost of such insurance (it being understood and agreed that nothing herein shall be construed to impose any obligation to procure or maintain any insurance or to make or
pursue any claim against any insurance that the Indemnified Party may possess). 
 “Material Contract” shall
have the meaning set forth in Section 3.15. 
 “Material Permits” shall have the meaning set forth
in Section 3.30. 
 “Materials of Environmental Concern” shall mean any: pollutants, contaminants or
hazardous substances (as such terms are defined under CERCLA), pesticides (as such term is defined under the Federal Insecticide, Fungicide and Rodenticide Act), solid wastes and hazardous wastes (as such terms are defined under the Resource
Conservation and Recovery Act), chemicals, other hazardous, radioactive or toxic materials, oil, petroleum and petroleum products (and fractions thereof), or any other material (or article containing such material) listed or subject to regulation
under any law, statute, rule, regulation, order, Permit, or directive due to its potential, directly or indirectly, to harm the environment or the health of humans or other living beings. 

“MHPRA” shall have the meaning set forth in Section 3.30. 

  
 - 66 -

 EXECUTION COPY 
  

 “Most Recent Net Assets Statement” shall mean the unaudited asset and
liability accounts of the Company as of the Most Recent Net Assets Statement Date, in the form set forth in Column D of the spreadsheet attached in Schedule 1.5(a)(i). 
 “Most Recent Net Assets Statement Date” shall mean November 24, 2006. 
 “Names” shall have the meaning set forth in Section 1.1. 
 “Net Assets Target” shall have the meaning set forth in Section 1.5(a). 
 “NDA” shall have the meaning set forth in Section 3.30(h). 
 “Non-controlling Party” shall mean the party not controlling the defense of any Third Party Claim. 
 “Objection Deadline Date” shall mean the date twenty (20) days after delivery by Seller to Buyer of the Draft Closing Net Assets Statement. 

“Objection Statement” shall have the meaning set forth in Section 1.5(b). 

“Omitted IP” means any Intellectual Property that is (i) owned by the Parent or any of its Affiliates (other than
the Company) on the Closing Date, (ii) used by the Company as of the Closing Date or necessary for the conduct of its business in the manner conducted as of the Closing Date or intended to be conducted (as such phrase is defined in
Section 3.13(a)(ix)) as of the Closing Date, and (iii) primarily used in the business of the Company (and not primarily being used in the business of the Parent or any of its Affiliates (other than the Company)) as of the Closing
Date, including, without limitation, all such Intellectual Property satisfying subsections (i), (ii) and (iii) above and relating to, claiming or covering the development, making, using, selling or otherwise commercializing any Product or
Product Candidate. 
 “Ordinary Course of Business” shall mean the ordinary course of business consistent with
past custom and practice (including with respect to frequency and amount). 
 “Owned Real Property” shall mean
each item of real property owned by the Company. 
 “Parent” shall have the meaning set forth in the second
recital. 
 “Parent Guaranty” shall have the meaning set forth in the second recital. 

“Parties” shall mean Buyer, Seller and the Company, and “Party” shall mean each of any of them, as
appropriate in the context. 
 “Patents” shall have the meaning set forth in Section 3.13(a).

 “Patent Office” shall have the meaning set forth in Section 3.13(f). 

  
 - 67 -

 EXECUTION COPY 
  

 “Paul Capital Agreements” means (a) Royalty Interest Assignment
Agreement, dated as of December 29, 2000, among SKPI, as seller, Jagotec, as seller, SKPP, as parent, and Paul Capital Royalty Acquisition Fund, L.P. (now known as Paul Royalty Fund, L.P., as purchaser, as transferred, conveyed and assigned by
Paul Royalty Fund, L.P. to Royalty Financial Company LLC pursuant to Sale and Contribution Agreement dated as of December 9, 2004, between Paul Royalty Fund, L.P., as originator, and Royalty Financial Company LLC, as purchaser, as further
transferred and assigned by Royalty Financial Company LLC to the Purchaser pursuant to Transfer and Servicing Agreement, dated as of December 9, 2004, among Royalty Financial Company LLC, as transferor, Paul Capital Advisors, L.L.C., as
servicer, and the Purchaser, as issuer; (b) Security Agreement, dated as of December 29, 2000, among SKPI., as grantor, Jagotec, as grantor, and Paul Capital Royalty Acquisition Fund, L.P., as purchaser, as transferred, conveyed and
assigned by Paul Royalty Fund, L.P. to Royalty Financial Company LLC pursuant to Sale and Contribution Agreement dated as of December 9, 2004, between Paul Royalty Fund, L.P., as originator, and Royalty Financial Company LLC, as purchaser, as
further transferred and assigned by Royalty Financial Company LLC to the Purchaser pursuant to Transfer and Servicing Agreement, dated as of December 9, 2004, among Royalty Financial Company LLC, as transferor, Paul Capital Advisors, L.L.C., as
servicer, and the Purchaser, as issuer; and (c) Lockbox Agreement, dated as of December 3, 2004, by and among SKPP, Jagotec, SKPI, Paul Royalty Fund, L.P. and JPMorgan Chase Bank, National Association, as assigned by Paul Royalty Fund,
L.P. to Deutsche Bank Trust Company Americas, as Custodian, pursuant to Amended and Restated Custody Agreement dated as of December 9, 2004, between Paul Royalty Fund, L.P. and Deutsche Bank Trust Company Americas, as Custodian. 

“Permits” shall mean all permits, licenses, registrations, certificates, orders, approvals, franchises, variances and
similar rights issued by or obtained from any Governmental Entity (including those issued or required under Environmental Laws and those relating to the occupancy or use of owned or leased real property). 

“Permitted Encumbrance” shall mean (i) mechanic’s, materialmen’s, and similar liens, (ii) liens
arising under worker’s compensation, unemployment insurance, social security, retirement, and similar legislation and (iii) liens on goods in transit incurred pursuant to documentary letters of credit, in each case arising in the Ordinary
Course of Business of the Company and not material to the Company. 
 “Person” means a natural person or entity,
including a corporation, partnership, limited liability company, trust, or other entity. 
 “PHSA” shall have
the meaning set forth in Section 3.30. 
 “Preclinical Tests and Clinical Trials” shall have the
meaning set forth in Section 3.30. 
 “Pre-Closing Period” shall mean any taxable period ending on
or before the Closing Date. 
 “Pre-Closing Tax Return” shall mean any Tax Return relating to a Pre-Closing
Period. 

  
 - 68 -

 EXECUTION COPY 
  

 “Products,” solely for purposes of Section 3.30, shall have
the meaning set forth in Section 3.30, and, for all other purposes of this Agreement, shall have the meaning set forth in Section 3.13(a)(v). 
 “Product Candidates,” solely for purposes of Section 3.30, shall have the meaning set forth in Section 3.30, and, for all other purposes of this Agreement, shall
have the meaning set forth in Section 3.13(a)(vi). 
 “Product Intellectual Property” shall have the
meaning set forth in Section 3.13(a). 
 “Program Fraud Civil Remedies Act” shall have the meaning
set forth in Section 3.30. 
 “Registered Intellectual Property” shall have the meaning set forth in
Section 3.13(a). 
 “Relevant Regulatory Authority” shall have the meaning set forth in
Section 3.30. 
 “Response” shall mean a written response containing the information provided for in
Section 8.3(c). 
 “Restricted Period” shall have the meaning set forth in
Section 9.3(a). 
 “Security Interest” shall mean any mortgage, pledge, security interest,
encumbrance, charge or other lien (whether arising by contract or by operation of law). 
 “Seller” shall have
the meaning set forth in the first paragraph. 
 “Seller Compliance Certificate” shall mean a certificate to the
effect that each of the conditions specified in Article VI is satisfied in all respects. 
 “Seller Disclosure
Schedule” shall mean the disclosure schedule provided by Seller and the Company to Buyer on the date hereof. 

“Shares” shall have the meaning set forth in the first recital. 

“Straddle Period” shall mean any taxable period beginning on or before and ending after the Closing Date. 

“Straddle Period Tax Return” shall mean any Tax Return relating to a Straddle Period. 

“Subsidiary” shall mean any corporation, partnership, trust, limited liability company or other non-corporate business
enterprise in which the Company (or another Subsidiary) holds stock or other ownership interests representing (a) more than fifty percent (50%) of the voting power of all outstanding stock or ownership interests of such entity or
(b) the right to receive more than fifty percent (50%) of the net assets of such entity available for distribution to the holders of outstanding stock or ownership interests upon a liquidation or dissolution of such entity. 

“Target Net Assets Statement” shall have the meaning set forth in Section 1.5(a). 

  
 - 69 -

 EXECUTION COPY 
  

 “Taxes” shall mean all taxes, charges, fees, levies or other similar
assessments or liabilities in the nature of a tax, including income, gross receipts, ad valorem, premium, value-added, net-worth, capital stock, capital gains, documentary, recapture, alternative or add-on minimum, disability, estimated,
registration, recording, excise, real property, personal property, sales, use, license, lease, service, service use, transfer, withholding, employment, unemployment, insurance, social security, business license, business organization, environmental,
workers compensation, payroll, profits, severance, stamp, occupation, windfall profits, customs, duties, franchise and other taxes imposed by the United States of America or any state, local or foreign government, or any agency thereof, or other
political subdivision of the United States of America or any such government, and any interest, fines, penalties, assessments or additions to tax resulting from, attributable to or incurred in connection with any tax or any contest or dispute
thereof. 
 “Tax Claim Notice” shall have the meaning set forth in Section 5.15(g). 

“Tax Contest” shall have the meaning set forth in Section 5.15(g). 

“Tax Reserves” shall mean any reserves for Taxes reflected on the Final Closing Net Assets Statement. 

“Tax Returns” shall mean all reports, returns, declarations, statements or other information required to be supplied to a
taxing authority in connection with Taxes. 
 “Taxing Authority” shall mean a Governmental Entity responsible
for the imposition or collection of Taxes. 
 “Transfer Taxes” shall have the meaning set forth in
Section 5.15(a)(iii). 
 “Third Party Claim” shall mean any claim, suit or proceeding (including
claims for or constituting Designated Amounts and suits and proceedings to collect Designated Amounts) by a person or entity other than a Party for which indemnification may be sought by a Party under Article VIII. 

“Third Party Intellectual Property” shall have the meaning set forth in Section 3.13(a). 

“Trademarks” shall have the meaning set forth in Section 3.13(a). 

“Transition Services Agreement” shall have the meaning set forth in Section 5.9. 

“Trade Secrets” shall have the meaning set forth in Section 3.13(a). 

“Unresolved Objections” shall mean any objections set forth in an Objection Statement that remain unresolved thirty
(30) days after delivery of such Objection Statement. 

  
 - 70 -

 EXECUTION COPY 
  

 12.2. Certain Rules of Construction. 

(a) The terms “law” and “laws” refer to each and every applicable U.S. and non-U.S. federal, national, state,
provincial, local and municipal law, statute, rule, regulation and directive and each judgment, order, decree, permit, or order of each court and other Governmental Entity or Relevant Regulatory Authority of competent jurisdiction. Any reference to
any federal, state, national provincial, local, municipal, foreign or other law shall be deemed also to refer to all rules and regulations promulgated thereunder (including rules and regulations of the Securities and Exchange Commission, state
securities regulators, the NASD and its affiliates, and the FDA and other Relevant Regulatory Authorities), unless the context requires otherwise. 
 (b) Unless the context of this Agreement otherwise requires, (i) words of either gender or the neuter include the other gender and the neuter, (ii) words using the singular number also include
the plural number and words using the plural number also include the singular number, (iii) the terms “hereof”, “herein”, “hereby” and derivative or similar words refer to this entire Agreement as a whole and not
to any particular Article, Section or other subdivision, (iv) the terms “Article” or “Section” or other subdivision refer to the specified Article, Section or other subdivision of the body of this Agreement, (v) the
word “include” shall be deemed to be followed by the phrase “but are not limited to”, the word “includes” shall be deemed to be followed by the phrase “but is not limited to”, and the word
“including” shall be deemed to be followed by the phrase “but not limited to”, (vi) the phrase “materiality limitation”, with respect to a Party’s representations, warranties, covenants and agreements,
includes all qualifications, limitations, thresholds and exceptions based on the concept of materiality, whether expressed by the word “material”, “materially”, “materiality”, “material adverse change”, or
“material adverse effect”, (vii) when a reference is made in this Agreement to Exhibits, such reference shall be to an Exhibit to this Agreement unless otherwise indicated, (viii) when a statement herein with respect to a
particular matter is qualified by the phrase “in all material respects”, materiality shall be determined solely by reference to, and solely within the context of, the specified matter and not with respect to the entirety of this Agreement
or the entirety of the transactions contemplated hereby, and (ix) the terms “third party” or “third parties” refers to Persons other than Buyer, Seller, Parent, and the Company. 

(c) When used herein, the phrases “to the knowledge of” any Person, “to the best knowledge of” any Person,
“known to” any Person or any similar phrase, means (i) with respect to any Person who is an individual, the actual knowledge of such Person, (ii) with respect to any other Person (other than the Company), the actual knowledge of
the directors and officers of such Person, and (iii) with respect to Seller and/or the Company, the directors and officers of Parent, Seller, and the Company and the individuals listed on Schedule 12.2(c), as well as any other knowledge
which such executive directors, officers and individuals would have possessed had they made reasonable inquiry of appropriate employees and agents of the Company with respect to the matter in question. 

(d) The language used in this Agreement shall be deemed to be the language chosen by the Parties to express their mutual intent, and no
rule of strict construction shall be applied against any Party. The drafting and negotiation of the representations, warranties, covenants and conditions to the obligations of Buyer, Seller and the Company herein reflect compromises, and certain
provisions may overlap with other provisions or may address the same 

  
 - 71 -

 EXECUTION COPY 
  

 
or similar subject matters in different ways or for different purposes. It is the intention of the Parties that, to the greatest extent possible, unless provisions are mutually exclusive and
effect cannot be given to both or all such provisions, (i) the provisions of in this Agreement shall be construed to be cumulative; (ii) each provision of this Agreement shall be given full separate and independent effect; and
(iii) no provision shall be limited by any other provision unless such limitation is expressly set forth. 
 ARTICLE XIII

 MISCELLANEOUS 
 13.1. Press Releases and Announcements. No Party shall issue any press release or public announcement relating to the subject matter of this Agreement without the prior written approval of the
other Parties or referring to any other Party (or any stockholder of the Company or Buyer) without the prior written approval of the Party to whom reference is proposed to be made; provided, however, that any Party may make any public
disclosure it believes in good faith is required by applicable law, regulation or stock market rule (in which case the disclosing Party shall use reasonable efforts to advise the other Parties and provide them with a copy of the proposed disclosure
prior to making the disclosure). 
 13.2. Notices. Any notices or other communications required or permitted hereunder
shall be sufficiently given if delivered personally or sent by telex, federal express, registered or certified mail, postage prepaid, addressed as follows or to such other address of which the Parties may have given notice: 

 

			
	To Buyer:	  	 Blue Acquisition Corp.
 c/o
Wilmer Cutler Pickering Hale and Dorr LLP
 1117 California Avenue
 Palo Alto, CA 94304
 Fax: 650-858-6100
 Attention: Rod J. Howard, Esq.
  

	With a copy to:	  	 Wilmer Cutler Pickering Hale and Dorr LLP
 1117 California Avenue
 Palo Alto, CA 94304
 Fax: 650-858-6100
 Attention: Rod J. Howard, Esq.

 

	To Seller, or the Company:	  	 SkyePharma PLC
 105
Piccadilly
 London W1J 7NJ
 United
Kingdom
 Fax: 011 44 (0) 207-491-3338

Attention: Frank Condella, CEO
 and

Fax: 011 44 (0) 207-491-3338
 Attention: John
Murphy, General Counsel

  
 - 72 -

 EXECUTION COPY 
  

  

			
	With a copy to:	  	 Reed Smith LLP
 599
Lexington Avenue, 29th Floor
 New York, NY 10022
 Fax: 212-521-5450
 Attention: Herbert F. Kozlov, Esq.

Unless otherwise specified herein, such notices or other communications shall be deemed received (a) on the date delivered, if delivered personally,
or (b) three (3) business days after being sent, if sent by registered or certified mail. 
 13.3. Successors and
Assigns. This Agreement shall be binding upon and inure to the benefit of the Parties hereto and their respective successors and assigns, except that Buyer, on the one hand, and Seller and the Company, on the other hand, may not assign their
respective obligations hereunder without the prior written consent of the other Party; provided, however, that Buyer may assign this Agreement, and its rights and obligations hereunder, to a subsidiary or Affiliate of Buyer. Any
assignment in contravention of this provision shall be void. No assignment shall release Buyer, Seller or the Company from any obligation or liability under this Agreement. 
 13.4. Entire Agreement; Amendments; Attachments. This Agreement, all Schedules and Exhibits hereto, and all agreements and instruments to be delivered by the Parties pursuant hereto represent the
entire understanding and agreement between the Parties hereto with respect to the subject matter hereof and supersede all prior oral and written and all contemporaneous oral negotiations, commitments and understandings between such Parties. Buyer,
by the consent of its Board of Directors or officers authorized by such Board, and Seller may amend or modify this Agreement, in such manner as may be agreed upon, by a written instrument executed by Buyer and Seller. If the provisions of any
Schedule or Exhibit to this Agreement are inconsistent with the provisions of this Agreement, the provisions of the Agreement shall prevail. The Exhibits and Schedules attached hereto or to be attached hereafter are hereby incorporated as integral
parts of this Agreement. 
 13.5. Severability. Any provision of this Agreement which is invalid, illegal or
unenforceable in any jurisdiction shall, as to that jurisdiction, be ineffective to the extent of such invalidity, illegality or unenforceability, without affecting in any way the remaining provisions hereof in such jurisdiction or rendering that or
any other provision of this Agreement invalid, illegal or unenforceable in any other jurisdiction. 
 13.6. No Third Party
Beneficiaries. This Agreement shall not confer any rights or remedies upon any person other than the Parties and their respective successors and permitted assigns, the Indemnified Seller Parties, and the Indemnified Buyer Parties. 

13.7. Governing Law. This Agreement (including the validity and applicability of the arbitration provisions of this Agreement, the
conduct of any arbitration of a Dispute, the enforcement of any arbitral award made hereunder and any other questions of arbitration law or 

  
 - 73 -

 EXECUTION COPY 
  

 
procedure arising hereunder) shall be governed by and construed in accordance with the internal laws of the State of New York without giving effect to any choice or conflict of law provision or
rule (whether of the State of New York or any other jurisdiction) that would cause the application of laws of any jurisdictions other than those of the State of New York. 
 13.8. Submission to Jurisdiction. Each Party (a) submits to the exclusive jurisdiction of U.S. District Court for the Southern District of New York (and the federal appellate courts with
reviewing jurisdiction thereover) and, if such courts do not have subject matter jurisdiction of such matter, either the Supreme Court (Commercial Division) of the State of New York sitting in the City and County of New York (and the state appellate
courts of the State of New York with reviewing jurisdiction thereover) or, at the election of Buyer, arbitration before a single arbitrator in accordance with the provisions of Article XI, in any action or proceeding arising out of or
relating to this Agreement (including any action or proceeding for the enforcement of any arbitral award made in connection with any arbitration of a Dispute hereunder), (b) agrees that all claims in respect of such action or proceeding may be
heard and determined in any such court, (c) waives any claim of inconvenient forum or other challenge to venue in such court, (d) agrees not to bring any action or proceeding arising out of or relating to this Agreement in any other court,
and (e) waives any right it may have to a trial by jury with respect to any action or proceeding arising out of or relating to this Agreement; provided in each case that, solely with respect to any arbitration of a Dispute, the
Arbitrator shall resolve all threshold issues relating to the validity and applicability of the arbitration provisions of this Agreement, contract validity, applicability of statutes of limitations and issue preclusion, and such threshold issues
shall not be heard or determined by such court. Each Party agrees to accept service of any summons, complaint or other initial pleading made in the manner provided for the giving of notices in Section 13.2, provided that nothing
in this Section 13.8 shall affect the right of any Party to serve such summons, complaint or other initial pleading in any other manner permitted by law. 
 13.9. Section Headings. The Article, Section and sub-Section headings are for the convenience of the Parties and in no way alter, modify, amend, limit, or restrict the contractual obligations
of the Parties. 
 13.10. Counterparts and Facsimile Signature. This Agreement may be executed in two or more
counterparts, each of which shall be deemed an original but all of which together shall constitute one and the same instrument. This Agreement may be executed by facsimile signature. 

  
 - 74 -

 EXECUTION COPY 
  

 IN WITNESS WHEREOF, this Agreement has been duly executed by the Parties hereto as of
and on the date first above written. 
  

			
	BLUE ACQUISITION CORP.
		
	By:	 	 /s/ Luke Evnin

	Name:	 	Luke Evnin
	Title:	 	Director
		
	By:	 	 /s/ Carl L. Gordon

	Name:	 	Carl L. Gordon
	Title:	 	Director
		
	By:	 	 /s/ Fred A. Middleton

	Name:	 	Fred A. Middleton
	Title:	 	Director
		
	By:	 	 /s/ Andreas Wicki

	Name:	 	Andreas Wicki
	Title:	 	Director

  
 - 75 -

 EXECUTION COPY 
  

 IN WITNESS WHEREOF, this Agreement has been duly executed by the Parties hereto as of
and on the date first above written. 
  

			
	SKYEPHARMA HOLDING, INC.
		
	By:	 	 /s/ Steven Thornton

	Name:	 	Steven Thornton
	Title:	 	President
	
	SKYEPHARMA, INC.
		
	By:	 	 /s/ Steven Thornton

	Name:	 	Steven Thornton
	Title:	 	President

  
 - 76 -

 EXECUTION COPY 
  

 Schedule 1.5(a)(ii) 

Further Eliminations to be Applied in Preparing the Target Net Assets Statement, the  

Draft Closing Net Assets Statement and the Final Closing Net Assets Statement  

The following assets and liabilities (“Exclusions”) will be temporarily adjusted and will not be included in the Target Net Assets
Statement, the Draft Closing Net Assets Statement and the Final Closing Net Assets Statement: 
  

	 	a.	Eliminate Paul Capital accounts 

  

	 	b.	Eliminate all intangible assets (including IP, software, goodwill etc) 

  

	 	c.	Eliminate cash held on trust in respect of employee medical obligations and the related liabilities 

 

	 	d.	Eliminate liabilities for management stay incentives 

  

	 	e.	Eliminate accounts receivable for sales of DepoCyt and DepoDur after December 31, 2006 

 

	 	f.	Eliminate all accumulated depreciation recorded from November 24, 2006 to the Closing Date 

 

	 	g.	Eliminate all prepaid amortization recorded from November 24, 2006 to the Closing Date 

 

	 	h.	Eliminate all deferred rent amortization recorded from November 24, 2006 to the Closing Date 

 

	 	i.	Eliminate all deferred revenue amortization recorded from November 24, 2006 to the Closing Date for sales recorded prior to November 25, 2006

  

	 	j.	Eliminate the Designated Amounts 

  

	 	k.	Eliminate the Company’s liability for Company (employer) 401(k) contributions for 2006 

  
 - 77 -

 EXECUTION COPY 
  

 Schedule 1.7 

 

			
	 DepoBupivacaine
 Milestone
Payments
	  	 1)      One time payment of $10,000,000 upon First Commercial
Sale in the United States.
  

2)      One time payment of $4,000,000 upon First Commercial Sale in a Major EU
Country.
  

3)      $8,000,000 when annual Net Sales in the Territory reach
$100,000,000.
  

4)      $8,000,000 when annual Net Sales in the Territory reach
$250,000,000.
  

5)      $32,000,000 when annual Net Sales in the Territory reach
$500,000,000.

		
	 DepoBupivacaine
 Percentage
Payments
	  	The Company will pay Seller a payment of 3% of Net Sales of DepoBupivacaine in the Territory
		
	Biologics Products Percentage Payments	  	The Company will pay Seller a payment of 3% of Net Sales of Biologics Products (not to exceed 20% of royalty income to the Company) in the Territory

1.1 Certain Definitions. Solely for purposes of this Schedule 1.7, the following terms shall have the meanings set forth below. All other
capitalized terms used in this Schedule 1.7 (other than names and proper nouns) shall have the meanings ascribed to such terms in the Stock Purchase Agreement to which this Schedule 1.7 is attached. 

(a) “Biologics Products” means a pharmaceutical composition having one or more of the following active ingredients:
follicle stimulating hormone, Biosphere-encapsulated human growth hormone, interferon-alpha, erythropoietin, and granulocyte colony stimulating factor. 
 (b) “DepoBupivacaine” means a pharmaceutical composition having bupivacaine as an active ingredient encapsulated with the Company’s multivesicular liposomes technology to provide
sustained release. 
 (c) “First Commercial Sale” means, with respect to a Product in a country in the
Territory, the first day after the Closing Date when the Company (or any person or entity that after the Closing is an Affiliate or licensee of the Company) first sells or otherwise commercially disposes of such Product for use or consumption by the
general public in a country in the Territory after receipt of Marketing Authorization for such country. 
 (d) “Force
Majeure” means causes beyond the control of the Party asserting such causes as grounds for nonperformance, including, without limitation, acts of God; acts, regulations, or laws of any government adopted after the date of this Schedule
1.7 or subject to a new interpretation after the date of this Schedule 1.7 that render impossible or illegal performance by a Party of its obligations under this Schedule 1.7; war; civil commotion; destruction of production
facilities or materials by fire, flood, earthquake, explosion or storm; epidemic; and failure of public utilities or common carriers. 

  

 EXECUTION COPY 
  

 (e) “Major EU Country” means United Kingdom, France, Germany, Italy and
Spain or any of them. 
 (f) “Marketing Authorization” means, with respect to a country, all approvals,
licenses, registrations and regulatory authorizations required to market and sell a Product in such country as granted by the Relevant Regulatory Authority. For countries where the Relevant Regulatory Authority approval is required for pricing or
reimbursement for Product prior to undertaking sales or marketing, “Marketing Authorization” shall not be deemed to occur until such pricing or reimbursement approval is obtained. 

(g) “Net Sales” means total gross sales of each Product invoiced and actually collected by the Company, its Affiliates
or any licensee of the Company (or a further sublicense of such licensee) to unaffiliated third parties, less the following amounts actually deducted or allowed: (i) transport, freight and insurance costs; (ii) sales and excise taxes and
duties; (iii) normal and customary trade, quantity and cash discounts and rebates; (iv) refunds and chargebacks; (v) actual rebates and credits or allowances allowed to customers in respect thereof; and (vi) amounts repaid or
credited for actually returned or recalled Products. Notwithstanding anything else in Section 1.7 or this Schedule 1.7, the supply or other disposition of Products at no cost or charge to the recipient (x) as reasonable
quantities of samples consistent with industry practices, (y) for use in non-clinical or clinical studies, or (z) for use in any tests or studies reasonably necessary to comply with any law, regulation or request by a regulatory or
Relevant Governmental Authority, shall not be included within the computation of Net Sales. In the event a Product is sold in combination with, or contains, one or more other active ingredients which are not the subject of this Agreement (as used in
this definition of Net Sales, a “Combination”), then the gross amount invoiced for that product shall be calculated by multiplying the gross amount invoiced for such Combination by the fraction A/(A+B), where “A” is the
gross amount invoiced for the Product sold separately and “B” is the gross amount invoiced for the other active ingredient(s) sold separately; provided, however, for the avoidance of doubt, in the case of DepoBupivacaine, a
Product will not qualify as a “Combination” under this provision due to the use or inclusion of bupivacaine as another active ingredient in such product, regardless of the form or formulation that such bupivacaine may be included or
otherwise found within DepoBupivacaine. In the event that the other active ingredient is not sold separately, then the gross amount invoiced for that product shall be calculated by multiplying the gross amount invoiced for the Combination by the
fraction A/C, where “A” is the gross invoice amount for the Product, if sold separately, and “C” is the gross invoice amount for the Combination. In the event that no such separate sales are made, Net Sales for royalty
determination shall be determined by the Parties in good faith. 
 (h) “Payment Period” has the meaning set
forth for such term in Section 1.3 of this Schedule 1.7. 
 (i) “Product” means
DepoBupivacaine or any of the Biologics Products. 
 (j) “Territory” means the United States of America, Japan
and each Major EU Country. 

  
 - 79 -

 EXECUTION COPY 
  

 (j) “Valid Claim” means a claim of any unexpired Patent of the Company
existing as of the date of this Agreement (that will remain with the Company after the Closing) and issued in the Territory that shall not have been donated to the public, disclaimed, or held invalid or unenforceable against the other Party by a
court of competent jurisdiction in an unappealed or unappealable decision. 
 1.2 Diligence; Non-Circumvention; Periodic Reports.

 (a) During the Restricted Period, Buyer will cause the Company to use good faith efforts toward the development and
commercialization of DepoBupivacaine in the United States and a Major EU Market Country; provided, however, that in all decisions related to such development and commercialization efforts the Company may take into account the
factors of safety and efficacy, risk profile, profitability, product profile, competitive landscape, difficulty in developing or manufacturing the Product, competitiveness of alternative products, the patent or other proprietary position of the
Product and/or third party products, the regulatory structure involved and the potential, and current corporate goals and priorities; and provided further that the Company may cease or reduce such development and commercialization
efforts and funding for any reason other than for the sole or primary purpose of depriving Seller of payments it would otherwise be entitled to received under this Schedule 1.7 if the Board of Directors of the Company, in
the exercise of its good faith business judgment, determines that it is in the best interests of the Company and its stockholders to do so. 
 (b) [**] times each year until the end the Payment Period, as long as any of the DepoBupivacaine Milestone Payments remains unpaid and there is a reasonable expectation that such payment will become
payable in the future, not later than the last day of the months of [**], Buyer shall cause the Company to furnish Seller with a report summarizing the development status of DepoBupivacaine and the Biologics Products. 

1.3 Payments. 
 (a)
Beginning with the calendar quarter in which the First Commercial Sale of a Product is made in a country in the Territory and for each calendar quarter thereafter, on a country-by-country basis, until the expiration of the last Valid Claim covering
the sale of such Product in such country (the “Payment Period”), the Company shall make the DepoBupivacaine Percentage Payments and Biologics Products Percentage Payments with respect to Net Sales of such Product in such country, as
set forth in the table above (collectively, the “Percentage Payments”), as applicable, to Seller within ninety (90) days following the end of each calendar quarter. Each Percentage Payment shall be accompanied by a report,
summarizing the total gross sales and total Net Sales (including an itemization of the deductions applied to the gross sales to derive such Net Sales), the number of units of Product sold (less damaged, rejected, returned or recalled Product) during
the relevant calendar quarter and the calculation of the Percentage Payment, if any, due. Each such statement shall be accompanied by the payment of the Percentage Payment due to Seller. No invoice shall be required from Seller in this respect.

  
 - 80 -

 EXECUTION COPY 
  

 (b) All payments under this Schedule 1.7 shall, for sales made in the United
States, be made in U.S. dollars, and shall, for all other sales worldwide, be made in Euros, in each case via wire transfer of immediately available funds or check as directed by Seller from time to time. Payments shall be without deduction of
exchange, collection, transfer or other charges. Conversion into U.S. dollars and Euros, as appropriate, shall be made at the exchange rate on the applicable payment date as reported in The Wall Street Journal (East Coast edition) for the
immediately preceding business day. Seller shall be entitled to interest on all late payments. Such interest shall be calculated from the date such amount was due until the date such amount is actually paid, at the prime rate of interest reported in
The Wall Street Journal (East Coast Edition) for the date such amount was due plus [**]%. 
 (c) The DepoBupivacaine Percentage
Payments shall be made in consideration for the covenant not to compete set forth in Section 9.3(a)(i) and the Biologics Products Percentage Payments shall be made in consideration for the covenant not to compete set forth in
Section 9.3(a)(iv). 
 (d) If after the expiration of the Restricted Period, Parent or any of its Affiliates engages
in the development, manufacture, marketing or sale of any product within the scope of Section 9.3(a)(i), (ii) or (iii) anywhere in the world, the obligation to make payments under Section 1.7 and this Schedule
1.7 shall automatically and immediately cease. If after the expiration of the Restricted Period, Parent or any of its Affiliates engages in the development, manufacture, marketing or sale of any product within the scope of
Section 9.3(a)(iv) anywhere in the world, and the Company is then selling or thereafter sells a Biologics Product, the obligation to make payments under Section 1.7 and this Schedule 1.7 shall automatically and
immediately cease. 
 (e) Notwithstanding the foregoing, if during the Restricted Period the Company markets and sells a product
as a substitute for DepoBupivacaine, the obligation to make DepoBupivacaine Percentage Payments under Section 1.7 and this Schedule 1.7 shall automatically and immediately cease and terminate and, in lieu thereof, the aggregate
sales of such substitute product shall be counted toward the achievement of the thresholds for the DepoBupivacaine Milestone Payments. 
 (f) Until the end of the Payment Period, as long as there is a reasonable expectation that a payment pursuant to this Schedule 1.7 will become payable in the future, if the Company or any
subsidiary or majority owner of the Company proposes to sell, assign or transfer substantially all rights to any of the Products to a third party, the Company shall, as a condition of such sale, assignment or transfer, require such third party to
assume the obligations of the Company pursuant to this Schedule 1.7 with respect to such Product. 
 1.4 Records Retention.
Commencing with the First Commercial Sale of a Product, Buyer shall keep, and shall require its relevant Affiliates to keep, and shall use commercially reasonable efforts to include terms in its licenses with licensees requiring its licensees to
keep, complete and accurate records pertaining to the sale of Product for a period of three (3) calendar years after the year in which such sales occurred and in sufficient detail to permit Seller to confirm the accuracy of the Percentage
Payments paid by Buyer pursuant to this Schedule 1.7. 

  
 - 81 -

 EXECUTION COPY 
  

 1.5 Audits. 
 (a) At the request and expense of Seller, Buyer (and its Affiliates, if applicable) shall permit an independent, certified public accountant appointed by Seller and reasonably acceptable to Buyer, at
reasonable times and upon reasonable written notice not more than once in each calendar year, to examine such records as may be necessary for the sole purpose of verifying the calculation and reporting of Net Sales and the correctness of any
Percentage Payment or other payment made under this Schedule 1.7 for any period within the preceding [**] ([**]) calendar years. Said accountant shall not disclose to Seller or any other person any information, except that such accountant may
disclose to Seller the fact of a deficiency, the lack of a deficiency or any overpayment, and the degree thereof, including the dollar amount. All results of any such examination shall be made available to Buyer. 

(b) In the event that any audit reveals an overpayment or an underpayment in the amount of any payments that should have been paid by
Buyer to Seller, then the overpayment or underpayment amount, as the case may be, shall be paid within thirty (30) days after receipt of the final audit report, plus interest thereon. Such interest shall be calculated in accordance with
Section 1.3(b) of this Schedule 1.7. In addition, if the underpayment is in excess of [**] percent ([**]%) of the amount that actually should have been paid, then Buyer shall reimburse Seller for the reasonable cost of such audit.
This Section 1.5(b) of this Schedule 1.7 sets forth the Parties’ sole and exclusive liability for any such overpayment or underpayment. 
 (c) Except in the case of circumstances which would have prevented an error or anomaly from being disclosed during an audit performed under this Section 1.5 of this Schedule 1.7 such as
fraud, misrepresentation or other willful misconduct or gross negligence to provide accurate information, upon the expiration of three (3) years following the end of any calendar year, the calculation of Percentage Payments payable with respect
to such year will be binding and conclusive upon each Party and Buyer will be released from any liability or accountability with respect to Percentage Payments for such calendar year. 
 1.6 Force Majeure. Other than with respect to obligations for the payment of money, neither Party shall be held liable or responsible to the other Party nor be deemed to be in default under, or in
breach of any provision of, this Schedule 1.7 for failure or delay in fulfilling or performing any obligation of this Schedule 1.7 when such failure or delay is due to Force Majeure. In such event, Seller or Buyer, as the case may be,
shall immediately notify the other Party, with written notice to follow, of such inability and of the period for which such inability is expected to continue. The Party giving such notice shall thereupon be excused from such of its obligations under
this Schedule 1.7 as it is thereby disabled from performing for so long as it is so disabled. Upon termination of a Force Majeure event, the performance of any suspended obligation or duty shall promptly recommence. To the extent possible,
each Party shall use reasonable efforts to minimize the duration of any Force Majeure. 

  
 - 82 -

 Schedule 1.9 

 

											
	 Portion of —
	 	 Allocated to
 Shares
	 	 Allocated to
 Section 9.3(a)(i)
 Covenant Not to
Compete
	 	 Allocated to
 Section 9.3(a)(ii)
 Covenant Not to
Compete
	 	 Allocated to
 Section 9.3(a)(iii)
 Covenant Not to
Compete
	 	 Allocated to
 Section 9.3(a)(iv)
 Covenant Not to
Compete

						
	 Adjusted Purchase Price
	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]
						
	 “Milestone Payments” pursuant to Section 1.7 and Schedule 1.7
	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]
						
	 DepoBupivacaine Percentage Payments pursuant to Section 1.7 and Schedule 1.7
	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]
						
	 “Biologics Products Percentage Payments” pursuant to Section 1.7 and
Schedule 1.7
	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]

 EXECUTION COPY 
  

 Schedule 3.10(a) 

Certain Assets 
  

	1)	All physical assets of the Company (see attached print-out) 

  

	2)	DepoDur and DepoCyt product rights and manufacturing/supply arrangements; 

  

	3)	DepoBupivacaine product and development rights; 

  

	4)	RDF licenses; 

  

	5)	Biologics Products development programs and associated agreements; 

  

	6)	Building and equipment leases; 

  

	7)	Licenses related to the site and manufacturing of above products; 

  

	8)	Employees; and 

  

	9)	All other projects/third party feasibility agreements 

  
 - 84 -

 EXECUTION COPY 
  

 Schedule 5.9 

Transition Services 
 1. In respect of services that Seller or Parent (or an Affiliate of Seller) needs to provide to Company: 
  

	 	•	 	 customs clearance for DepoCyt in France (to the extent permitted by law); 

 

	 	•	 	 assistance with VAT returns in France (to the extent permitted by law); 

 

	 	•	 	 transitional insurance cover; 

  

	 	•	 	 packaging, labeling and release of DepoCyt for EU; 

  

	 	•	 	 transition, administration and wind-down (as requested by and at no cost to Buyer) of employee benefit plans maintained for Company employees by Parent
or an Affiliate (Buyer to be responsible for any unpaid withholding taxes); and 

  

	 	•	 	 others to be discussed. 

2. In respect of services that the Company needs to provide to Seller and/or its Affiliates: 

 

	 	•	 	 accounting and HR for Skye US Inc.; 

  

	 	•	 	 assistance with preparation and interface with PWC for 2006 Tax Return; 

 

	 	•	 	 access to records and data not physically transferred or removed; 

 

	 	•	 	 consultancy services regarding representation at FDA; 

 

	 	•	 	 transition, administration and wind-down (as requested by and at no cost to Seller) of employee benefit plans that heretofore have been administered by
the Company for employees of other U.S. subsidiaries of Parent (Parent, Seller or such other U.S. subsidiary to be responsible for any unpaid withholding taxes); and 

 

	 	•	 	 others to be discussed. 

  

 EXECUTION COPY 
  

 Schedule 5.11 

(a)(i) Assigned Patents 
 All patents and patent applications related to the “Biosphere” drug delivery system and technology of Parent and its Affiliates. 
 To the extent not already owned by the Company, all patents and patent applications set forth in Section 3.13(b) of the Seller Disclosure Schedule. 

(a)(ii) Assigned Trademarks 
  

																			
	 Mark
	 	 Case Ref.
	 	 Status
	 	 Country
	 	 Application
No.
	 	 Filing Date
	 	 Registration
No.
	 	 Grant Date
	 	 Owner
	 	 International
Classes

	 [**]        
	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]
	 [**]
	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]
	 [**]
	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]
	 [**]
	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]
	 [**]
	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]
	 [**]
	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]

 All other trademarks and tradenames
containing the word “Biosphere” or any variations and derivatives thereof, and other trademark registrations and applications used or held for use in the business of SkyePharma, Inc. but not held by SkyePharma, Inc. 

  

 EXECUTION COPY 
  

 Schedule 5.11 

(cont’d) 
 (b) Excluded Assets 
 All right, title and interest in and to the outstanding
promissory note and capital stock of GeneMedix, PLC pursuant to that certain August 2006 Deed of Waiver and Modification from the Company to GeneMedix, PLC 
 The other eliminations in items “c,” “d,” “e,” “f,” “g,” and “h” of Schedule 6.12 

  
 - 87 -

 EXECUTION COPY 
  

 Schedule 6.1 
 Term Loan Agreement, dated December 22, 2003, by and between Parent and General Electric Capital Corporation. 
 Industrial Real Estate Lease, dated December 8, 1994, by and between Company, as successor to Depotech Corporation, and Lankford & Associates, Inc. for property located at 10450 Science
Center Drive, San Diego, California. 
 Industrial Real Estate Triple Net Lease, dated August 17, 1993 by and between Company, as successor
to Depotech Corporation, and Slough TPSP, LLC, as successor to Equitable Life Assurance Society of the United States, for property located at 11011 N. Torrey Pines Road, La Jolla, California. 
 Supply Agreement, dated May 27, 2004, by and between Company and Sandoz GmbH/SkyePharma Inc. 

Collaboration Agreement dated March 31, 1994 by and between Company, as successor to Depotech Corporation, and Chiron Corporation. 

Master Technology Service Agreement dated January 30, 2006 between the Company and Medidata Solutions, Inc. 

  

 EXECUTION COPY 
  

 Schedule 6.10(b) 
 Endo Pharmaceuticals, Inc. (“Endo”) shall have returned all rights with respect to DepoDur, DepoBupivacaine and DepoFoam technology to the Company, at no current or future cost to the
Company (except as otherwise expressly set forth in the Agreement to terminate the Development and Strategic Alliance Agreement dated January __, 2007 by and among Endo Pharmaceuticals, Inc., SkyePharma, Inc. and Jagotec AG (the “Termination
Agreement”) with respect to payments in consideration of services rendered by Endo after March 31, 2007 at the option and request of SkyePharma, Inc. after the Closing Date, and otherwise on terms consistent with the terms set forth
below, and the Company shall be the sole holder of all such rights; and the Endo Agreement, shall have been terminated and such termination shall be in full force and effect; and the Company shall have no liability or obligation to Endo
Pharmaceuticals, Inc., except as expressly set forth above with respect to the Termination Agreement. 

  
 - 89 -

 EXECUTION COPY 
  

 Schedule 6.12 
 The following adjustments to the assets and liabilities of the Company will be effected by Parent, Seller and the Company prior to the Closing; the eliminated assets and liabilities will not be included
in the assets and liabilities of the Company at the Closing; and the added assets will be included in the assets of the Company at the Closing. On a pro forma basis, had the adjustments described below taken place as at November 24, 2006, the
assets and liabilities of the Company would have been substantially as set forth in Column Q of the spreadsheet attached in Schedule 1.5(a)(i). 
 a. Transfer Biosphere IP to the Company from Jagotec in accordance with Section 5.11. 

b. Adjust for Paul Capital lock box receipts to allocate relevant cash received against specific receivables of the Company. 

c. Eliminate accounts receivable for sales and royalties receivable in respect of sales prior to January 1, 2007, of DepoCyt and DepoDur.

 d. Eliminate liabilities to Paul Capital for products (other than DepoDur and DepoCyt) pursuant to the amended agreement with Paul Capital.

 e. Eliminate all intra-group accounts with Parent and its Subsidiaries. Seller shall assume the Company Debt, and Parent and/or any of its
Affiliates shall effect a novation of the Company liability under the Company Debt to Seller. 
 f. Eliminate share based payment liabilities in
respect of SkyePharma PLC and equity reserves by adjustment within equity. 
 g. Eliminate FX equity reserves by adjustment within equity.

 h. Eliminate cash balance (except cash in account related to the employee 125S plan). 

  

 EXECUTION COPY 
  

 Schedule 8.1(f) 
 Claims by [**] or [**] for services provided or alleged to be provided to the Company. 
 The class
action lawsuits and claims filed by the Action Alliance of Senior Citizens of Greater Philadelphia against Elan Corporation PLC and the Company under the Sherman Antitrust Act and various state statutes alleging, among other things, a contract in
restraint of trade as well as an attempt to monopolize the market for Naprelan in violation of those laws[, as identified in Section 3.8 of the Seller Disclosure Schedule]. 

  

 EXECUTION COPY 
  

 Section 9.3(a) 

 

			
	 Column A
	  	 Column B

		
	[**]	  	[**]
	[**]	  	[**]
	[**]	  	[**]
	[**]	  	[**]
	[**]	  	[**]
	[**]	  	[**]

  
 - 92 -

 EXECUTION COPY 
  

 Schedule 12.1 

 

																	
	DESIGNATED AMOUNTS	 		 		 		 		 	
						
	ACCOUNTS PAYABLE 20000	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]
									
	 Supplier
	 	 	 	 	 	 Invoice
	 	 Date
	 	 	 	 	 	 	 	 Amount

									
	[**]	 		 		 	[**]	 	[**]	 		 		 		 	[**]
	[**]	 		 		 	[**]	 	[**]	 		 		 		 	[**]
	[**]	 		 		 	[**]	 	[**]	 		 		 		 	[**]
	[**]	 		 		 	[**]	 	[**]	 		 		 		 	[**]
		 		 		 		 		 		 		 		 	 
		 		 		 		 		 		 		 		 	[**]
		 		 		 		 		 		 		 		 	 
		 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]
					
	ACCRUED AMOUNTS PAYABLE 20100	 	[**]	 	[**]	 	[**]	 	[**]
									
	 CO
	 	 Dept
	 	 Acct
	 	 Journal ID
	 	 Batch
	 	 Reference
	 	 Txn Note
	 	 Comment
	 	 Amount

									
	00	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]
	00	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]
	00	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]
	00	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]
	00	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]
	00	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]
	00	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]
	00	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]
	00	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]
	00	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]
	00	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]
	00	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]
	00	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]
	00	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]
	00	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]
	00	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]

  

 EXECUTION COPY 
  

																	
	 [**]
	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]
	 [**]
	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]
	 [**]
	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]
	 [**]
	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]
	 [**]
	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]
	 [**]
	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]
	 [**]
	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]
	 [**]
	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]
	 [**]
	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]
	 [**]
	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]
	 [**]
	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]
	 [**]
	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]
	 [**]
	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]
	 [**]
	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]
	 [**]
	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]
	 [**]
	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]
	 [**]
	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]
	 [**]
	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]
	 [**]
	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]
	 [**]
	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]
	 [**]
	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]
	 [**]
	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]
	 [**]
	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]
	 [**]
	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]
	 [**]
	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]	 	[**]
		 		 		 		 		 		 		 		 	 
	 [**]
	 		 		 		 		 		 		 		 	[**]
		 		 		 		 		 		 		 		 	 
	  
 CURRENT ACCRUED LIABILITIES
22900
	 		 		 		 		 	
	[**]	 		 		 		 		 		 	[**]
	[**]	 		 		 		 		 		 		 	[**]
		 		 		 		 		 		 		 		 	 
	[**]	 		 		 		 		 		 		 		 	[**]
		 		 		 		 		 		 		 		 	 
	TOTAL	 		 		 		 		 		 		 	[**]
		 		 		 		 		 		 		 		 	 

  
 - 94 -

 EXECUTION COPY 
  

 Schedule 12.2(c) 
 [**]

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00181-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00181-of-00352.parquet"}]]